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Abstract 
Costimulation is required for the generation of an effective T cell based immune 
response. The presentation of tumour associated antigens may occur in the absence of 
effective costimulation, inducing tolerance. Conversely effective costimulation can 
overcome immunosuppressive mechanisms present within the tumour. Costimulation 
may therefore hold significant potential for cancer immunotherapy. Using 
recombinant adenoviral vectors encoding the costimulatory molecules CD80 and 4-
1BBL (CD137L) and the cytokine IL-12 tumour cell lines were transduced to express 
these molecules individually or in combination in vitro. Using PBMC from healthy 
donors the effect of costimulation in response to pan-T cell stimulation with the anti-
CD3 antibody OKT-3 were initially studied. The combination of CD80+4-1BBL 
supported the proliferation of CD8
+
 T cells and was superior to either molecule alone. 
Proliferation was further enhanced by the addition of IL-12 to the combination of 
CD80+4-1BBL. Unexpectedly in the absence of OKT-3 costimulation with 4-1BBL 
or IL-12 was observed to predominantly induced the proliferation of natural killer 
(NK) cells. The effects of 4-1BBL on human NK cells are not clearly defined in the 
literature. Further experiments were therefore conducted to investigate the ability of 
4-1BBL and IL-12 to stimulate NK cells. The combination of 4-1BBL+IL-12 was 
superior to either stimulation alone for the activation, proliferation and function of 
NK cells from healthy lab donors. 4-1BBL was also shown to promote the long term 
expansion of NK cells. Importantly renal cell carcinoma patient NK cells were shown 
to require a combination of 4-1BBL+IL-12 for short and long term expansion; 
stimulated NK cells were also shown to be functional. These data highlight the need 
for understanding of the pleiotropic effects of costimulatory molecules and the 
necessity to choose optimal combinations for the activation of not only the adaptive 
 III 
but also the innate immune response. The combined intratumoural delivery of 4-
1BBL and IL-12 via adenoviral vectors could potentially stimulate beneficial T cell 
and NK cell responses, and therefore warrant further investigation as a potential 
immunotherapy. 
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1 Introduction 
 2 
1.1 The immune system 
1.1.1 Overview 
The immune system contains many cell types which are derived from an or
i
ginal 
hematopoietic stem cell population, which produces all cells of myeloid and 
origin as shown in figure  
Figure 1-1. The immune system can be viewed as a series of sub-divisions based on 
function and origin, firstly the division of the innate and the adaptive immune 
response. In humans the innate immune system is commonly erroneously thought of 
as a simple system. It is able to respond immediately to generic danger signals by the 
recognition of conserved microbial products by germline-encoded pattern recognition 
receptors (PRR) such as Toll-like receptors (TLR). In contrast the adaptive immune 
system is considered to be superior, only being possessed by higher animals. Through 
the generation of diverse antigen binding receptors the adaptive immune response is 
able to respond to and recognise almost any antigen. Most remarkably the adaptive 
immune response also possesses the ability to form memory and life long immunity. 
 
The view of the immune system as functionally separate subdivisions with their own 
roles however is flawed. The immune system possessed by humans began to evolve 
around 500 million years ago with the development of the ability to rearrange antigen 
binding receptors, facilitated by the formation of recombination-activating genes 
(RAG); the hallmark of the adaptive immune system. As such all jawed vertebrates 
(cartilaginous fish to humans) possess lymphocytes, and are able to rearrange antigen 
binding receptors. Over the following millions of years the immune system evolved, 
and not in isolation, the adaptive and innate immune systems have developed in 
 3 
parallel, and therefore have evolved to function together (Flajnik and Du Pasquier, 
2004; Litman et al., 2005). 
 
 
 
Figure 1-1 Haematopoiesis. A schematic diagram showing the origin and common 
progenitors of all terminally differentiated hematopoietic cell lineages. Dotted lines 
represent un-shown intermediaries during differentiation. Adapted from Abbas and 
Lithcman, (2000). 
 
The innate immune system includes many cell types, such as monocytes, 
macrophages, neutrophils and eosinophils, however two cell types within the innate 
immune system are of particular interest firstly the natural killer (NK) cell which have 
important anti-viral and anti-tumour functions and the dendritic cell (DC) which is the 
most efficient of professional antigen presenting cells (APC), able to provide signals 
to promote the strongest of adaptive immune responses or alternately provide signals 
to dampen down an overactive immune response. The adaptive immune system on the 
other hand contains two cell types, the B cell and the T cell. The B cell is responsible 
for the production of antibodies and thus the humoral immune response, which is 
linked into the innate immune system for example by opsonization mediated by 
 4 
complement and antibody dependent cellular cytoxicity (ADCC) mediated by NK 
cells. While the T cell in its many subsets plays a defining role in the B cell led 
humoural immune response but is also responsible for the generation of the cellular 
immune response, where NK cells and APC also have important roles. Thus our 
immune system is interconnected. There is significant crosstalk; the innate immune 
system is required to activate and alert the adaptive immune response to potential 
dangers, and likewise the adaptive immune response is capable of fuelling the innate 
immune response. 
 
Besides the immune systems role in protection from pathogens, the immune system 
has also been shown to prevent the formation of cancer through a process of 
immunosurveillance and can also actively impact on the growth of a tumour.  
 
Ultimately the immune system protects us from harm whether from pathogenic 
viruses, bacteria, fungi or parasites, or from threats within in the form of neoplastic 
changes. Utilising the immune system as a novel therapy for cancer is a growing area 
of development of great importance. 
1.1.2 T cells 
There are two dominant types of T cells in the periphery, those which express the 
CD8 co-receptor and those which express the CD4 co-receptor. In a textbook model 
of the immune system these two subsets of T cells can be thought to have two distinct 
roles, the CD8
+
 T cell being responsible for cytotoxicity, while the CD4
+
 T cell is able 
to provide ‘help’ for the immune response interacting with antigen presenting cells 
 5 
and producing cytokines, however in reality the division and functions of these cells 
are far more diverse. 
 
T cell antigen recognition is restricted to specific peptide epitopes presented in a 
complex with MHC molecules on the surface of target cells or APC; the MHC-
peptide complex is recognised by the T cell receptor (TCR). The recognition of the 
plethora of epitopes generated from the many pathogens encountered is dependent on 
the diverse repertoire of TCRs which is generated during T cell development.  
 
Peptide antigen can either be presented via MHC class I to CD8
+
 T cells, or via MHC 
class II molecules to CD4
+
 T cells. This in itself restricts the function of the CD4 T 
cell since, in contrast to HLA class I which is ubiquitously expressed on all cell types, 
expression of class II is restricted to specific cell types. However, the recognition of 
antigen alone is not capable of inducing activation and proliferation of T cells and 
requires further stimulus, as is discussed in section 1.1.2.3. 
1.1.2.1 T cell receptor rearrangement 
TCR diversity is generated by the rearrangement of the four T cell receptor genes 
(Tcra, Tcrb, Tcrg, Tcrd) by V(D)J recombination during intrathymic T cell 
development. The site-specific recombination process directed by recombinase 
(RAG1 and RAG2) (Bassing et al., 2002), which create double-strand breaks at 
specific recombination signal sequences (RSSs) flanking the TCR variable (V), 
diversity (D) and joining (J) gene segments. The subsequent rejoining of these 
double-stranded breaks creates unique Tcr gene sequences (Krangel, 2009). 
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Along with TCR rearrangement the development of T cells is a series of fate 
decisions, between B, NK and T cell lineage and subsequently between CD4
+
 or 
CD8
+
 T cell. These choices are controlled at the molecular level by transcription 
factors. There are also cell fate decisions between αβ-TCR and γδ-TCR usage, both of 
which arise from a common double negative (DN) precursor, with progression to the 
CD4
+
CD8
+
 double positive (DP) stage marking the point of irreversible commitment 
to the αβ lineage, however the control of this process is not understood (Narayan and 
Kang, 2007). The TCR rearrangement of γδ-T cells is similar to that of αβ-T cells 
however the selection pressures on these cells during development vary considerably. 
Unlike αβ-T cells there is no known antigen-presentation mechanism for γδ-T cell 
ligands nor do antigens require to be peptide–MHC complexes. Interestingly γδ-T 
cells also do not require prior stimulation to produce cytokines (Jensen and Chine, 
2009; Konigshofer and Chine et al, 2006). As these cells are distinct and their exact 
roles in the immune response are not fully defined the discussion of T cells will focus 
primarily upon αβ-T cells. 
 
Within the thymus as αβ-T cells develop they progress through a series of defined 
steps allowing the generation and release of naïve but mature T cells into the 
periphery. As the naïve T cell develops it moves from the bone marrow to the 
subcapsular sinus and outer cortical regions within the thymus. Within the thymus 
appropriate developmental signals are delivered to allow T cell development. 
Thymocytes first express TCRs within the cortex and begin to mature into CD4
+
 or 
CD8
+
 T cells, followed by the final stages of T cell development in the medulla and 
release into the periphery (Abbas and Lichtman, 2005; Hayday and Pennington, 
2007).  
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Following production in the bone marrow and migration to the thymus the initial 
stages of T cell development begin with the pro-T cell stage, during which the double-
negative thymocytes lack CD4 or CD8 expression and TCR, CD3 or δ chain 
expression. At this stage RAG-1 and RAG-2 genes are expressed allowing receptor 
rearrangement to take place. The first rearrangement events to occur are Dβ-to-Jβ 
involving joining of either the Dβ1 or Dβ2 gene segment to one of six Jβ1 or Jβ2 gene 
fragments respectively (Abbas and Lichtman, 2005; Hayday and Pennington, 2007).  
 
Following Dβ-to-Jβ rearrangement the pro-T cell is considered to have become a pre-T 
cell, which can now undergo Vβ-to-DJβ rearrangements. The DNA sequences between 
the rearranging elements are deleted during this stage, and the TCR-β chain is 
transcribed and expressed on the cell surface which along with the invariant pre-Tα 
chain, CD3 and δ chain forms the pre-T cell receptor. Signals from the pre-TCR allow 
transition to the double positive stage of T cell development and down regulation of 
the RAG genes inhibiting further TCR-β rearrangement (Abbas and Lichtman, 2005; 
Krangel, 2009). 
 
A second phase of RAG gene expression occurs late in pre-T cell development 
facilitating the rearrangement of the TCR α-chain; as no D segment is present in the α 
locus, rearrangement consists of V and J rearrangements. Productive rearrangements 
may occur on both chromosomes, which may result in a single T cell expressing two 
TCR-α chains but one β-chain; up to 30% of mature peripheral T cells express two 
different TCRs however the functional consequences of this are not understood. If no 
productive TCR α rearrangements occur the thymocyte will undergo apoptosis at this 
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stage. Following expression of αβ-TCR the thymocyte will enter the medulla prior to 
release into the periphery (Abbas and Lichtman, 2005; Krangel, 2009).  
 
Following expression of the final αβ-TCR the T cell will also undergo positive and 
negative selection on the basis of binding self peptide and self HLA, helping to ensure 
tolerance, the mechanisms by which tolerance is achieved are subsequently discussed. 
1.1.2.2 Tolerance 
Due to the remarkable ability of the TCR to recognise virtually any antigen there will 
inevitably be TCRs generated during TCR rearrangement which will be reactive to 
peptides derived from self proteins. If T cells possessing these self reactive TCRs 
were allowed into the circulation and were allowed to become activated considerable 
pathology could result. Therefore there are a number of safeguards to ensure tolerance 
to self. 
1.1.2.2.1 Central tolerance 
Central tolerance is the initial mechanism facilitating tolerance by deletion of T cells 
possessing TCR which recognise self with high affinity (Mathis and Benoist, 2004). 
 
Positive selection is the first step in the process of central tolerance, resulting in the 
selection of thymocytes with self-MHC restricted TCRs. Within the thymic cortex 
double positive thymocytes encounter epithelial cells expressing MHC class I and 
class II, presenting self peptides. If the TCR possessed by a double positive cell can 
recognise self-MHC with interactions from either CD8
+
 or CD4
+
 the cell will receive 
survival signals and continue to develop into a CD8
+
 or CD4
+
 T cell, dependent upon 
whether Class I or Class II is bound. If no interaction takes place the cell will die 
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through neglect, therefore producing self-MHC restricted single positive immature T 
cells. However this process also enriches T cells with TCR which are self reactive 
(Hogquist et al., 2005). 
If a TCR is able to recognise self-MHC loaded with self peptide with high affinity 
there is a requirement to remove this TCR from the repertoire. To achieve this 
negative selection functions in the thymic medulla subsequent to the process of 
positive selection. While the majority of thymocytes are removed through positive 
selection the remaining population (~10% of the original thymocytes) are subject to 
negative selection, of these approximately half are deleted (Palmer, 2003).  
 
The process of negative selection is dependent on the expression of the transcription 
factor known as autoimmune regulator (AIRE) by medullary thymic epithelial cells 
and DC within the thymus. AIRE allows the promiscuous expression of tissue specific 
genes within the thymus. Mutation of the AIRE gene results in autoimmune 
polyendocrine syndrome type 1, a multi-organ form of autoimmunity. During 
negative selection it is believed that a developing T cell will interact with a number of 
different cells presenting varying combinations of self peptides. T cells possessing 
TCRs which recognise self peptide with high affinity undergo deletion (Palmer, 2003; 
Hogquist et al., 2005). However the mechanisms by which the varied avidity of TCR 
binding can be translated into a decision of cell fate have yet to be defined 
(McCaughtry
 and 
Hogquist, 2008). Alternatively some cells may not undergo deletion 
instead being converted to suppressor T cells which are discussed further in section 
1.1.2.4.3 (Jordan et al., 2001; Apostolou et al., 2002).  
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Interestingly ligation of TCR alone has been shown to be insufficient to promote 
deletion. Counter to its requirement in the activation of peripheral T cells (as 
discussed in section 1.1.2.3.2) interaction of CD28 on the T cell with the 
costimulatory molecules CD80/CD86 has been shown to be required to promote 
deletion of a self reactive clone (Kishimoto and Sprent, 1999; Gao et al., 2002). 
Although a consensus on the mechanisms by which deletion is mediated has not been 
reached (Palmer, 2003; Hogquist et al., 2005), the orphan nuclear steroid receptor 
Nur77 which is induced following strong TCR stimulation has been implicated to 
have a role as has the pro-apoptotic Bcl-2 family member Bim (McCaughtry
 and 
Hogquist, 2008). 
1.1.2.2.2 Peripheral tolerance 
While central tolerance is able to remove a significant proportion of potentially 
pathogenic self reactive T cells it is impossible to ensure complete tolerance to all self 
epitopes and still retain sufficient TCR diversity, therefore potentially self reactive T 
cells still remain in the periphery. These T cells therefore must be controlled in order 
to prevent autoimmune pathology (Caspi, 2006; Mathis and Benoist, 2004). 
 
The mechanisms by which peripheral tolerance is achieved is diverse, firstly some 
organs such as the testis, central nervous system and the eye are so called ‘immune-
privileged’ sites. Tolerance within these sites may be achieved by a number of 
differing passive and active strategies, including the prevention of access to specific 
sites, e.g. blood-ocular barrier. The organ itself may also actively produce an 
immunosuppressive environment through the production of immunosuppressive 
cytokines, e.g. TGF-β, and the expression of inhibitory ligands, e.g. FasL and PDL-1, 
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inducing apoptosis and anergy. Privileged sites may also show a paucity of APC 
while promoting the development of regulatory T cells (Stein-Streilein, 2008). 
 
Although these mechanisms can protect a select population of organs which are 
highly sensitive to the detrimental effects of inflammatory immune responses, 
whether the immune response is valid or otherwise, peripheral tolerance must also be 
able to control auto-reactive T cells in the wider environment. As will be discussed 
further in section 1.1.2.3 the encounter of antigen alone by a T cell, such as a self 
antigen, without further stimulation generally results in the production of a state 
anergy (hypo-responsiveness), this is particularly relevant to self reactive T cells; 
having been through the process of central tolerance self reactive T cells should 
recognise their cognate antigen with low affinity, this process is known as ignorance 
(Redmond and Sherman, 2005). Repeated exposure to antigen without further 
costimulation can also lead to activation-induced cell death (AICD) (Walker and 
Abbas, 2002). However, ignorance of self-antigen is far from complete, under 
appropriate inflammatory conditions low avidity T cells can be activated (Sacher et 
al., 2002; O’Sullivan et al., 2006). 
 
 A number of further models exist to account for the control of self reactive T cells 
such as the ‘danger’ signal hypothesis in which APC require danger signals provided 
by cell death or microbial products, in order to become activated; APC which have 
not been activated, such as immature DCs, present antigen in a tolerogenic manner 
(Dhodapkar et al., 2001; Levings et al., 2001). Likewise there are subsets of APC 
which actively induce anergy or convert T cells to regulatory T cells; therefore self 
antigen presented under such conditions will also induce anergy or generate 
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regulatory T cells. As naïve T cells leaving the thymus circulate between secondary 
lymphoid tissue and the blood a self-reactive T cell could be most likely to see 
antigen presented by immature DC, i.e. in a tolerogenic manner, rather than expressed 
in tissue (Redmond and Sherman, 2005; Walker and Abbas, 2002). Interestingly there 
is also a growing body of work suggesting that AIRE may be expressed, all be it at 
low levels, in the secondary lymphoid tissue, however the functional consequences of 
such expression are not yet understood (Gardner et al., 2009). 
 
The final mechanism by which peripheral tolerance is maintained is through the 
action of regulatory T cells, in particular CD4
+
FoxP3
+
 T cells, without which severe 
autoimmune pathology results. Regulatory T cells will be discussed separately in 
section 1.1.2.4.3. The stringent requirement for this cell population suggests 
regulatory T cells play a major role in maintaining tolerance to self in the periphery 
(Sakaguchi, 2004; Walker and Abbas, 2002). 
 
As will also be discussed in later chapters many of these mechanisms of tolerance are 
subverted in the course of tumour development and are therefore particularly pertinent 
to understanding immune responses within a tumour. 
1.1.2.3 Antigen presentation and activation of T cells 
As stated all cells possess MHC class I and are therefore capable of presenting antigen 
to CD8
+
 T cells, however only a restricted population also express class II allowing 
presentation to CD4
+
 T cells. The presentation of antigen alone however will 
ultimately result in the production of anergy or in AICD unless antigen is presented in 
an appropriate manner. This is achieved by the provision of an additional signal 
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(signal two) i.e. costimulation, by professional antigen presenting cells, allowing the 
activation, proliferation and acquisition of effector functions by T cells (Sharp and 
Freeman, 2002). 
 
Over the last 15 years the number of receptor:ligand pairs which are known to have 
costimulatory functions has risen drastically. The majority of costimulatory molecules 
fall into one of two families. Either the immunoglobulin superfamily including 
CD28:CD80/CD86 (1.1.2.3.2) or the tumour necrosis factor receptor (TNFR) 
superfamily including 4-1BB:4-1BBL (1.1.2.3.3). It can also be argued that a number 
of cytokine:receptor pairs could also be considered to have costimulatory action, such 
as IL-2R, IL-7R and IL-12R. There is also a suggestion that an additional signal in the 
form of cytokines may be required (signal three) for the full acquisition of effector 
functions; cytokines such as IL-12 can provide this additional signal (1.1.2.3.4) 
(Schmidt and Mescher 2002; Croft, 2003; Curtsinger et al., 2003). 
 
As there is a diverse range of costimulatory molecules and receptors the expression 
patterns of which vary from constitutive to tightly regulated it is not surprising that 
the different costimulatory molecules have been shown to have some redundant 
functions but also to act separately to enhance or generate distinct immune responses 
in a temporal manner (Bertram et al., 2002; Croft, 2003; Watts, 2005). Therefore 
investigation of the optimal costimulatory combinations is important to allow a better 
understanding of their influences within an immune response; ultimately with the aim 
of allowing the enhancement or inhibition of immune responses for clinical 
applications. 
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1.1.2.3.1 Antigen processing 
The majority of peptides to be loaded on to MHC class I molecules are generated 
proteasome degradation of newly synthesised ubiquitinated proteins. Two 
proteins within the proteasome, LMP-2 and LMP-7, are up-regulated by IFNγ, 
increasing the generation of 6-30 residue peptides containing carboxyl terminal 
or hydrophobic amino acids, which are suited to presentation by MHC class I. 
Peptides which are capable of binding to MHC class I molecules are actively 
transported from the cytosol to the endoplasmic reticulum by two ATP-binding 
cassette (ABC) proteins called TAP-1 and TAP-2 (transporters associated with 
antigen processing-1 and -2). Peptides are then loaded onto newly synthesised 
class I molecules by a complex of several ER resident chaperons such as tapasin 
calreticulin (Wright et al., 2004; Cresswell et al., 1999). The loaded MHC-peptide 
complex is then presented on the cell surface via the Golgi apparatus (see  
Figure 1-2).  
 
Breakdown of endogenously synthesised proteins and presentation on MHC class I is 
an important process in surveillance of viral infection or malignant transformation by 
CD8
+
 T cells. As there is also a requirement for costimulation in order to generate a 
CD8
+
 T cell response there is a necessity for APC to be able to present antigen from 
virus infected or tumour cells in order to provide costimulation to a specific T cell. In 
order to do this a process of cross presentation or cross dressing is undertaken by the 
DC. Cross presentation involves the uptake of cell debris in phagosomes resulting in 
processing and presentation of antigen via MHC class I. Alternatively DC can also 
acquire MHC-peptide complexes from the surface of dead cells, termed cross 
dressing, allowing presentation by the DC (Dolan et al., 2006). 
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Presentation of peptides by MHC class II molecules occurs through a distinct 
pathway. Most Class II peptides are generated from proteins internalised by 
endocytosis, and degraded by proteases, e.g. cathepsins, within the acidic endosome. 
Class II molecules are synthesised in the ER, αβMHC class II dimers form with the 
help of ER-chaperones e.g. calnexin, and associate with a trimer of invariant (Ii) 
chain, forming a nonamer complex which exits from the ER and passes through the 
Golgi apparatus and enter the endocytic pathway. Within the acidic compartment of 
the endosome Ii chains are degraded and MHC class II molecules are loaded with 
antigenic peptides (generated from endocytosed proteins) under the control of HLA-
DM and HLA-DO. The class II-peptide complexes subsequently traffic to the surface 
of the plasma membrane (see  
Figure 1-2) (Abbas and Lichtman, 2005; Banchereau and Steinman, 1998). 
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Figure 1-2 Processing of MHC class I and Class II antigens. 
Adapted from Abbas and Lichtman, (2005). 
 
1.1.2.3.2 Costimulation: Immunoglobulin superfamily 
The immunoglobulin (Ig) superfamily is a diverse selection of proteins in the immune 
system ranging from immunoglobulin itself to MHC; all contain conserved constant 
or variable domains. The costimulatory receptor:ligand pairs present in the Ig 
superfamily include CD27:CD70 and ICOS:ICOSL. The Ig superfamily also includes 
the coinhibitory receptor PD-1 and its ligands PD-1L and PD-2L. However the most 
widely studied of all costimulatory receptor or molecules are CD28 and its ligands 
CD80 or CD86 (that are also members of the Ig superfamily) (Carreno and Collins, 
2002; Greenwald et al., 2005).  
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1.1.2.3.2.1 CD28 
CD28 is characterised by a single extracellular Ig variable-like (IgV) domain followed 
by a short cytoplasmic tail (Aruffo and Seed, 1987). Its ligands CD80 and CD86 also 
have an IgV and a Ig constant-like (IgC) domain present in the extracellular portion 
(Freeman et al., 1989; Freeman et al., 1993). CD28 expressed by 90% of CD4
+
 T cells 
and 50% of CD8
+
 T cells in human peripheral blood (Peggs and Allison, 2005). 
 
CD28 lacks inherent signalling capacity, requiring interaction with the SH2 and SH3 
domains of a number of intracellular signalling proteins, including 
phosphatidylinositide 3-kinase (PI3K) and Grb2, via proline and tyrosine-motifs. 
Ligation of CD28 results in activation of diverse signalling pathways. Briefly, 
increased tyrosine phosphorylation by src-family kinases (p56lck and p59fyn), PIK3 
mediates the activation of phosphoinositide-dependent protein kinase 1 (PDK1) via 
pleckstrin homology (PH) domains, which in turn activates protein kinase B 
(PKB/AKT). Phosphorylation of PDK1 and PKB modulate the activity of multiple 
pathways linked to protein synthesis, cellular metabolism, and cell survival including 
Bcl-2 and Bcl-XL. CD28 ligation can also activate NF-κB through phosphorylation 
and subsequent degradation of IκB by serine/threonine kinases and the IκB kinases 
(IKKs) (Rudd et al., 2009). 
 
Signalling activated by CD28 engagement induces the expression of cytokines such as 
IL-2 and chemokines such as MIP-1α by the T cell (Freeman et al., 1989; Herold et 
al., 1997) and also accelerate entry into and progression through the cell cycle, in a 
partly IL-2 independent manner including the activation of cyclin-dependent kinases, 
phosphorylation of retinoblastoma protein (pRb) and degradation of cyclin-dependent 
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kinase inhibitor (KIP)-1 and PI3K-AKT (Mittnacht, 1998; Appleman et al., 2000; 
Bonnevier and Mueller, 2002). Ligation of CD28 is also able to increase the survival 
of T cells, partially through the extrinsic survival effects of IL-2 signalling but also 
through the increased expression of the anti-apoptotic protein Bcl-2 and Bcl-XL 
(Boise et al., 1995). 
 
CD28 signalling can also facilitate further costimulation by promoting the expression 
of the inducible TNF superfamily costimulatory receptors OX40 and 4-1BB which 
will be discussed in section 1.1.2.3.3 (Diehl et al., 2002; Walker et al., 1999). 
1.1.2.3.2.2 CTLA-4 
CTLA-4 was initially identified by Burnet et al. (1987) during cDNA screening as a 
member of the Ig superfamily and shown to be expressed by activated T cells. An 
interesting feature in the complexity of costimulation is the inducible expression of 
CTLA-4 following activation. CTLA-4 is expressed following initial TCR and CD28 
engagement, while CD28 is down regulated. CTLA-4 also binds CD80/CD86 with a 
higher affinity than CD28 (Kd values of approximately 12nM compared with 200nM 
respectively) (Greenwald et al., 2005; Rudd et al., 2009). Subsequent ligation of 
CTLA-4 results in negative signals being delivered to the T cell, antagonising the 
initial stimulatory effects of CD28 ligation , and may also act to out-compete CD28 
for the binding of CD80/CD86 (Peggs and Allison, 2005), or reduce the contact time 
with APC thus reducing the strength of other signals, including TCR (Rudd et al., 
2009). CTLA-4 therefore acts as a regulatory mechanism to prevent over zealous T 
cell activation in the presence of the ubiquitous expression of CD80/CD86 by APC. It 
is likely that other costimulatory molecules are then required to allow the continuation 
of an immune response (Bertram et al., 2002; Bertram et al., 2004).  
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Knockout of CTLA-4 in mouse results in a lethal polyclonal CD4-dependent lympho-
proliferation within the first few weeks after birth (Chambers et al., 1997). Likewise a 
number of autoimmune diseases including insulin-dependent diabetes mellitus, 
Grave's disease and rheumatoid arthritis have been implicated to have a genetic 
linkage to the CTLA-4 locus (Ueda et al., 2003). 
 
In contrast to the inducible expression of CTLA-4 on CD8
+
 and CD4 Th cells, Tregs 
express CTLA-4 in a constitutive manner. The function of this is not clearly defined, 
however blocking of CTLA-4 has been shown in a number of studies to antagonise 
the generation and suppressive functions of Tregs (Horwitz et al., 2008; Read et al., 
2006; Tang et al., 2004). As discussed later in section 1.2.6.8 CTLA-4 blocking 
antibodies are currently being trialled for the treatment of solid tumours with some 
interesting and encouraging results.  
1.1.2.3.2.3 CD80/CD86 
The CD28/CTLA-4 ligands CD80 and CD86 are structurally homologous and through 
knockout studies in mice are known to have similar signalling pathways with very 
closely overlapping functions (Sharp and Freeman, 2002). The identification of CD86 
by Lenschow et al. (1993) was facilitated by the inability of anti-CD80 to inhibit a 
mixed lymphocyte response while hCTLA-4-Ig inhibited the response. 
Both ligands can be expressed by monocytes, B cells and DC, while T cells can also 
express these ligands (Greenwald et al., 2005). The expression patterns of CD80 and 
CD86 however vary; CD86 is constitutively expressed at low levels and up-regulated 
within 6h of stimulation, with maximal levels of expression occurring between 18 and 
24h. CD80 is expressed later than CD86 by activated APC; expression is not 
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detectable until 24h after initial stimulation and does not reach maximal levels until 
48 to 72h (Lenschow et al., 1993). 
1.1.2.3.3 TNF superfamily 
CD40 and its ligand, CD40L (CD154), were the first costimulatory molecules to be 
identified as members of the TNFR/TNF superfamily of which 19 ligands and 30 
receptors have now been identified, including CD27/CD70, CD30/CD30L, 
OX40/OX40L, 4-1BB/4-1BBL, and glucocorticoid-induced TNF receptor 
(GITR)/GITR ligand. The TNF super family are separated into three groups; the death 
domain (DD)–containing receptors, the decoy receptors, and TNF receptor-associated 
factor (TRAF) binding receptors. The DD containing receptors, e.g. Fas and TRAIL, 
activate caspases leading to apoptosis. A number of decoy receptors have also been 
identified, i.e. DcR1, 2 and3, which lack portions of the cytoplasm domain preventing 
activation of caspases; these receptors therefore compete for DD receptor ligands 
antagonising their function. In contrast the TRAF binding receptors e.g. 4-1BB, OX40 
and CD27 recruit TRAF through a 4-6 amino acid motif. Subsequent signalling 
following ligation of the receptor, provided by TRAF activation, promotes cellular 
activation, differentiation, and survival (Ashkenazi, 2002; Croft, 2009; Watts, 2005).  
Currently six TRAFs have been identified (Dempsey et al., 2005). All TRAF 
associated receptors bind TRAF2, while the other TRAFs are differentially 
to various receptors, as shown in  
Figure 1-3. Interestingly although all receptors bind TRAF2, the TRAF2 binding 
domain of each receptor is divergent; therefore different receptors bind TRAF2 with 
differing affinities (Ye and Wu, 2000).  
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Figure 1-3 TNFR family members and association with TRAFs. Shown are the 
most prominent TNF receptor:ligand pairs and the variable association with TRAFs 
(Adapted from Watts, 2005). 
 
The expression of these receptors on naïve T cells is activation induced (with the 
exception of CD27 which is expressed but up-regulated following T cell activation). 
In contrast memory T cells and Tregs constitutively express certain family members 
such as HVEM and GITR respectively, however the expression of OX-40 and 4-1BB 
remains activation induced, in humans (Pollock et al., 1993; Croft, 2009). The 
expression of ligands by APC is also regulated; expression can be induced by signals 
including TLR signalling. Curiously, while CD4
+
 and CD8
+
 T cells express receptors, 
both are also capable of expressing ligands; possibly resulting in T cell:T cell 
interactions (Croft, 2009; Stephan et al., 2007). 
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1.1.2.3.3.1 4-1BB Receptor 
As a member of the TNFR family 4-1BB (CD137) is a type I membrane protein, the 
extracellular portion of which is characterized by multiple cysteine-rich pseudo-
repeats (Won et al., 2009).  
 
As stated above the expression of 4-1BB is inducible on T cells in response to antigen 
and/or cytokine stimulation. 4-1BB is also expressed on a number of other cell types 
including NK cells, NKT cells, mast cells and neutrophils (Wang et al., 2009). 
 
Both CD4
+
 and CD8
+
 T cells are capable of expressing 4-1BB following stimulation, 
likewise Th1 and Th2 cells can both express 4-1BB. In vitro T cell antigen 
stimulation induces 4-1BB expression on the cell surface reaching a maximal level of 
expression 48hr after initial stimulation, expression then diminishes 4-5 days after 
initial stimulation (Watts, 2005). However the expression of 4-1BB in vivo may vary 
from that seen in vitro, with more rapid and transient expression (Takahashi et al., 
1999).  
 
4-1BB associates with TRAF2 and TRAF1 (Watts, 2005), TRAFs associated with 4-
1BB complex with inhibitor of NF-κB-α subunit (IκBα), IκB kinase-β (IKKβ) and 
NF-κB-inducing kinase (NIK), allowing activation of both canonical and non-
canonical NF-κB signalling pathways, resulting in decreased cell death through 
increased expression of the anti-apoptotic proteins Bcl-2, Bcl-XL and BFL1. In 
addition 4-1BB signalling down regulates pro-apoptotic Bim and activates PIK3 and 
PKB and can influence the expression of cyclins. Ligation of 4-1BB also synergizes 
with TCR-induced signals to induce cell cycle progression and cytokine production. 
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4-1BB signalling activates JUN N-terminal kinase (JNK) and activator protein 1 
(AP1), mitogen-activated protein kinases p38 and ERK, and promotes the nuclear 
accumulation of nuclear factor of activated T cells (NFAT). These factors promote the 
production of cytokines, including IL-2, IL-4, IL-5 and IFN and up-regulation of 
cytokine receptor expression, such as CD25 and IL-12Rβ2 (Croft, 2009; Wang et al., 
2009). Additionally 4-1BB stimulation has also been shown not only to prevent but to 
also break established anergy of T cells (Wilcox et al., 2004). 
1.1.2.3.3.2 4-1BB Ligand 
4-1BBL (CD137L) is a type II membrane protein. Based on sequence and structural 
characteristics 4-1BBL can be grouped with other TNF family members including 
GITRL, and OX40L which are characterized by divergent sequences having relatively 
low sequence homology (15-34%) with other TNF family members. Like other TNFR 
family ligands 4-1BBL forms trimeric structures, binding to three receptor molecules. 
Unlike other TNF Ligand structures which have been solved including GITRL and 
OX-40L, 4-1BBL shows a novel trimer organization, a 3-fold symmetric, three-
bladed propeller as opposed to a canonical bell shape or blooming flower-like 
structure of other TNF family members (Won et al., 2009). 
 
4-1BBL can be expressed by a number of cell types including DC, macrophage and B 
cells. In concurrence with the regulated expression of 4-1BB the expression of 4-
1BBL is also regulated. In the case of APC 4-1BBL is induced under inflammatory 
conditions in particular following TLR stimulation (Croft, 2003; Lee et al., 2003). 
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Interestingly reverse signalling by 4-1BBL can augment the expression of pro-
inflammatory cytokines including IL-6, TNF-α and IL-12 by antigen presenting cells 
(Kang et al., 2007; Lippert et al., 2008). 
1.1.2.3.4 IL-12 
IL-12 is a 70kDa heterodimer composed of the p35 light chain and the p40 heavy 
chain, which may also form a heterodimer with p19 to form IL-23. IL-12 is produced 
mainly by activated macrophages, monocytes and DC in vivo in response to TLR 
stimulation and is enhanced by cytokines such as IFNγ. This creates a positive 
feedback loop during inflammatory responses, or maturation of DC by CD40-CD40L 
interactions in which IFNγ is produced stimulating IL-12 production and vise versa.  
 
Our Ad-IL-12 vector is composed of the CMV immediate-early promoter driving p35 
and p45 expression, which are separated by an IRES (internal ribosome entry site) 
(i.e. CMV-p35-ires-p40). In concordance with what may be expected from our 
adenoviral vector the production of the p35 subunit has been shown to be in excess of 
the p40 subunit (Kang et al., 2005). The synthesis of excess p40 monomer or 
homodimer has been reported to result in either IL-12p70 antagonistic effects or 
independent agonistic stimulatory effects in in vivo murine models (Cooper and 
Khader, 2007).  
 
IL-12 was originally identified in 1989 by Kobayashi et al. from the supernatant of an 
EBV-transformed human B cell line and termed NK cell stimulatory
 
factor (NKSF), 
due to its ability to activate NK cells and increase their cytotoxicity; it was also shown 
to induce IFNγ production and T cell proliferation. 
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The receptor for IL-12 originally characterised by Presky et al. (1996) is composed of 
two chains, IL-12Rβ1 and IL-12Rβ2. Expression is primarily associated with 
activated T and NK cells, however resting NK cells have been shown to constitutively 
express the IL-12 receptor at low levels (Trinchieri, 2003). TCR ligation induces 
expression of the IL-12 receptor, which is enhanced by cytokines including IFNγ, 
TNFα and IL-12 itself, as well as by ligation of CD28. Binding of IL-12 to its 
receptor mainly signals through the activation of STAT4 (signal transducer and 
activator of transcription-4), via the JAK-STAT (Janus kinase-signal transducer and 
activator of transcription) pathway (Trinchieri, 2003; Kang et al., 2005). 
 
The IL-12Rβ1 subunit is expressed at similar levels on Th1 and Th2 cells (Szabo et 
al., 1995), commitment to the Th1 cell type is associated with expression of IL-12Rβ2 
allowing responsiveness to IL-12. The expression of the β2 chain is dependent on T 
box transcription factor (T-bet) activation through IFN-γ and Stat1 signalling (Mullen 
et al., 2001; Afkarian et al., 2002). The Th2-inducing cytokine IL-4 represses IL-12 
signalling through inhibition of β2 chain expression, antagonizing Th1 cell 
differentiation (Szabo et al., 1997). 
 
IL-12 can augment the proliferation of T cells and NK cells in response to a variety of 
stimuli including mitogenic lectins, alloantigens, CD3-specific antibodies and phorbol 
diesters, and has a direct proliferative effect on pre-activated T cells and NK cells. IL-
12 can also synergise with CD28 ligation to induce proliferation of resting T cells in 
the absence of antigen, but also facilitates proliferation and IFNγ production by 
antigen specific T cells. IL-12 can also enhance cytotoxicity by up regulation of 
perforin and granzyme and expression of adhesion molecules (Trinchieri, 2003).  
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1.1.2.4 T cell subsets 
1.1.2.4.1 T cell polarisation 
The identification of two distinct subsets of T helper cells capable of producing 
different cytokine profiles, differentially polarised from a non-polarised naïve (Th0) 
precursor cell led to the conceptualisation of Th1 and Th2 subsets. The Th1 subset is 
characterized by production of IFNγ and is involved in cellular immunity against 
intracellular pathogens (e.g. viruses) and tumours. While the Th2 subset 
predominantly produces IL-4, IL-5, and IL-13 and are required for humoral immunity. 
While the majority of interest in subsets has involved CD4
+
 T helper cells, CD8
+
 T 
cells are also polarised to form Tc1 and Tc2 subsets (Amsen et al., 2009; Zhou et al., 
2009). The polarisation of CD8
+
 T cells to Tc1/Tc2 has similar stimulating factors to 
the polarisation of CD4
+
 T cells (Croft et al., 1994). 
 
The polarisation of these subsets involves signalling via mutually exclusive cytokines 
and transcription factors. Th1 cells are polarised by IL-12 and IFNγ through induction 
of STAT4, STAT1, and T-bet. Conversely Th2 cell polarisation requires IL-4 
mediated induction of STAT6 and subsequent GATA3 expression. Under polarizing 
conditions stable cytokine production was observed only after a set number of cell 
divisions suggestive of a requirement for the generation of a stable transcriptional 
program (Bird et al., 1998; Grogan et al., 2001). Importantly once naive Th0 cells 
have been polarized into Th1 or Th2 cells, it has been generally accepted commitment 
is not reversible even under different polarizing conditions (Murphy et al., 1996). 
However the relationship, cytokine production and commitment to Th subsets may be 
more plastic than has previously recognised (O’Shea and Paul, 2010). 
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A number of other T cell subsets have been identified recently based on their cytokine 
production profiles and induction under varying cytokine milieu including the 
regulatory subsets discussed in 1.1.2.4.3 and the IL-17 producing proinflammatory 
Th17 subset. However the exact roles and plasticity of these subsets and which of 
these subsets are truly representative of differential subset commitment is currently 
debated (Locksley, 2009; O’Shea and Paul, 2010; Zhou et al., 2009). 
1.1.2.4.2 Memory T cells 
The ability of T cells to form memory is a defining feature of the adaptive immune 
response, allowing rapid response to subsequent antigen encounter. Following an 
initial clonal expansion a contraction phase occurs where ~90% of responding T cells 
undergo apoptosis, from this a small minority of cells are believed to transition to a 
memory state. As could be expected the initial size of the T cell response determines 
the size of the memory pool created. Therefore the quality of the initial stimulation (of 
which costimulation plays an important role) provided to the primary responding T 
cells has an impact on the quality of not only initial response but also the formation of 
memory (Obar and Lefraniçois, 2009; Prlic et al., 2007; Seder and Ahmed, 2003). 
The signals and mechanisms governing the formation of T cell memory are not fully 
understood. CD4
+
 and CD8
+
 T cells have been shown to develop memory as a linear 
process, i.e. naïve to effector to memory. Murine model systems, utilising Cre-
mediated recombination to irreversibly mark effector T cells with IFNγ or Granzyme 
B promoter activity, have shown these effector T cells go onto form long lived 
memory T cells (Bannard et al., 2009; Harrington et al., 2008). Additionally by 
transferring a single antigen specific T cell into mouse Stemberger et al. (2007) 
showed a single CD8
+
 T cell has the potential to form all memory and effector subsets 
observed during an immune response. These data suggest memory formation is 
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governed by signals during the immune response. Interestingly commitment to 
memory formation has been shown to occur during the initial stages of T cell division 
as shown by Chang et al., (2007). Therefore suggesting the earliest signalling events 
may dictate the final outcome of memory and effector T cell development (Obar and 
Lefraniçois, 2009). 
 
As survival of T cells is an important factor in the generation of memory, and the 
strength of initial stimulation also impacts upon memory formation costimulatory 
molecules such as OX40L and 4-1BBL have been implicated in the formation of T 
cell memory (Croft, 2009; Dawicki et al., 2004; Hendriks et al., 2005). 
 
While the development of memory may be a prerequisite for the efficacy of 
prophylactic vaccine development, a strong initial response may be as important in 
cancer immunotherapy (Rosenberg et al., 2004), which may lead to memory however 
the development of antigen loss variants may mean these do not have a role to play in 
further anti-tumour responses. 
1.1.2.4.3 Regulatory T cells 
Suppressive T cells were initially proposed in the 1960s, a seminal paper by Gershon 
and Kondo (1971) lead to the hypothesis that regulatory T cells were a specific 
lymphocyte subset. Due to inadequate techniques, lack of specific markers and 
conflicting data, for a time a consensus developed against the presence of suppressor 
T cells (Germain, 2008). Nevertheless there was growing evidence that a subset of T 
cells was able to regulate autoimmunity in murine models following neonatal 
thymectomy (Sakaguchi et al., 1985). The true renaissance of the field however was 
led by the work of Sakaguchi et al. (1995) who were able to show that a population of 
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CD4
+
CD25
+
 T cells were able to prevent autoimmune disease in a mouse model. 
Following the identification of the selective expression of FoxP3 in the CD4
+
CD25
hi
 
population in mouse a definitive phenotype and transcription factor was assigned to 
the regulatory subset (Hori et al., 2003; Fontenot et al., 2003). 
 
The presence of Tregs is vitally important for the correct function of the immune 
system. While tolerance inducing mechanism may play an important role in 
controlling pathological immune activation, in the absence of Tregs gross pathology 
will occur as shown in the scurfy mouse strain or in IPEX (immune dysregulation 
polyendocrinopathy enteropathy X-linked) syndrome in humans. Both are associated 
with mutations in the FoxP3 gene (Hori et al., 2001). Conversely in the cancer setting 
Tregs have been implicated in the suppression of anti-tumour immune responses and 
are a major target for novel therapies (Curiel, 2007; Nizar et al., 2009). Tregs are 
produced in the natural course of T cell development termed natural Tregs (nTreg), 
however there are also Treg that are induced from T cells in the periphery, so called 
induced Treg (iTreg), both share functional properties, however they have also been 
shown to have differences in responses to cytokines and costimulatory signals 
(Horwitz et al., 2008). 
 
While in mouse the CD4
+
CD25
hi
FoxP3
+
 phenotype holds true as a marker of Tregs, in 
humans the phenotype is somewhat less rigidly defined. Currently in humans, many 
groups define the classical Treg as a CD4
+
CD25
hi
CD127
lo
FoxP3
+
 T cell (Liu et al., 
2006; Seddiki et al., 2006), other markers may also be used such as LAG-3, however 
the ability of a diverse group of markers such as these to provide a pure Treg 
population is disputed (Corthay, 2009). Numerous other T cell subsets with 
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suppressive functions have also been identified, including CD8
+
 T cells; the 
phenotype and regulatory functions of these cells are varied (Shevach, 2006; Wang 
and Wang, 2007). 
 
From in vitro data Tregs have been shown to have the ability to suppress the function 
of a diverse population of cells including CD4
+
 and CD8
+ 
T cells, B cells, 
Macrophage, NKT cells and NK cells (Piccirillo et al., 2001; Ghiringhelli et al., 2005; 
Lim et al., 2005). The mechanism of suppression by Tregs and other regulatory 
subsets are as yet undefined in vivo. Many contact dependent and independent 
mechanisms have proposed including the generation of immunosuppressive 
cytokines, e.g. TGF-β and IL-10, IL-2 consumption and cytolysis, resulting in the 
induction of anergy, inhibition of proliferation, and suppression of effector functions 
(Shevach, 2009). There are therefore numerous subdivisions in the phenotypes and 
mechanisms used by regulatory T cells to suppress lymphocyte activation, involving 
various combinations of cell contact dependent and independent mechanisms.  
 
While the immune system has clearly developed mechanisms to inhibit or down 
regulate immune responses which may be harmful there are logically also 
mechanisms to allow the suppression of the suppressors or allow activation in their 
presence. Such effects can be mediated by glucocorticoid-induced tumour necrosis 
factor receptor (GITR) or OX40 mediated suppression of Tregs (Valzasina et al., 
2005). While interestingly for this project IL-12 is able to reverse Treg mediated 
suppression and allow cytokine production and proliferation by CD8
+
 T cells in the 
presence of Tregs (King and Seagal, 2005). Likewise 4-1BBL has also been shown to 
allow T cells to become resistant to Treg suppression (Choi et al., 2004), while TLR9 
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stimulation has also been shown to impair Treg conversion under Treg inducing 
conditions (Hall et al., 2008). 
 
There is substantial evidence that the polarisation of this cell type may be more plastic 
than originally thought (Zhou et al., 2009), for example nTreg and iTreg have been 
shown to be capable of being converted into IL-17 producing pro-inflammatory Th17 
cells in the presence of TGF-β and IL-6 (Xu et al., 2007; Yang et al., 2008; Zheng et 
al., 2008). However iTreg appear to be resistant to conversion under Th1 inducing 
conditions (Croxford et al., 2009).  It has also been show that Th17 cells can be 
converted into Th1 cells in the presence of IL-12 (Lee et al., 2009). Therefore in the 
presence of IL-6 produced by DC following TLR ligation (Pasare and Medzhitov, 
2003) it may be possible to repress Treg suppression by conversion to Th17 cells, 
thereby reducing the suppressive environment. Th17 cells may then be converted to 
Th1 cells. 
1.1.3 Natural Killer T cells 
Natural killer T (NKT) cells comprise a small population of peripheral blood 
lymphocytes (2.5% average). They can be described as unconventional T cells 
displaying features of both the adaptive and innate immune system, and are proposed 
to bridge between the two systems (Giroux and Denis, 2005). Classically NKT cells 
express CD3 and αβ-TCR however rearrangement is restricted producing an invariant 
TCR, in humans a Vα24-Jα18 rearranged TCR α-chain with a Vβ11-containing β-
chain. Expression of this TCR combination results in the TCR no longer recognising 
peptide bound to MHC but rather recognising glycolipids presented on the 
unconventional antigen presenting molecule CD1d. The recognition of CD1d by NKT 
 32 
cell TCR is highly conserved across species with mouse invariant NKT cell TCRs 
being able to recognise human CD1d (Godfrey et al., 2004). 
 
The invariant NKT (iNKT) cell represents the classical (type I) NKT cell however a 
second type of NKT has also been defined which does not express the Vα24-Jα18 
invariant TCR, although does retain CD1d restriction. In contrast to type I iNKT cells 
the type II NKT cells do not recognise the archetype NKT cell antigen α-GalCer (α-
galactosylceramide). Division of NKT cell subsets has additionally been proposed to 
be more reliably defined by an NKT cell’s ability to recognise this antigen. A third 
subset of NKT cells has also been suggested which rearrange TCR and are not CD1d 
restricted, however whether these cell truly represent type III NKT cells or a subset of 
T cells is debated (Godfrey et al., 2004). 
 
NKT cells also express a number of NK associated markers, most commonly CD161, 
while other markers including CD56 can also be expressed (Loza et al., 2002; Giroux 
and Denis, 2005). Like NK cells NKT cells can become activated without the need for 
additional signals, and are capable of producing large amounts of cytokine, including 
Th1 cytokines IFNγ and TNFα, and Th2 cytokines IL-4 and IL-13, rapidly upon 
activation (Loza et al., 2002), possibly allowing these cells to also coordinate the 
polarisation of adaptive immune responses. 
 
A number of potential CD1d restricted TCR ligands derived from microbial sources 
have been defined for NKT cells, the classical α-GalCer is a marine sponge derived 
glycolipid (Kawano et al., 1997). Interestingly there has been shown to be a 
differential production of cytokines dependent on the ligand used, for example 
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synthetic modification of α-GalCer can skew cytokine production towards either IFNγ 
or IL-4 (Balato et al., 2009). Additionally the cytokine milieu has also been shown to 
have effects on cytokine production by NKT cells with IL-12 able to induce high 
levels of IFNγ (Brigl et al., 2003). While NK cells are major responders to IL-12 NKT 
cells have been shown to be able to respond more strongly in response to low levels of 
IL-12, due to the higher expression of IL-12R by NKT cells (Kawamura et al., 1998). 
 
NKT cells have been implicated in a number of disease states including autoimmune 
and allergic diseases. In contrast NKT cells have also been implicated to have 
regulatory or protective roles in some autoimmune diseases, and have been shown to 
be important in anti-microbial defence. NKT cells have also been proposed to be 
important in anti-tumour responses; however the exact role of NKT cells is unclear. 
While NKT cells can express perforin and FasL, NKT cells have also been shown to 
activate NK cells and cytotoxic CD8
+
 T cells by production of IFNγ (Berzofsky and 
Terabe, 2008), therefore NKT cells may mediate direct and indirect anti-tumour 
effects. 
1.1.4 Natural Killer cells 
Human natural killer cells are defined as a population of CD3
-
CD56
+
 lymphocytes; 
NK cells are a major population of lymphocytes comprising ~10-15% of the total 
circulating lymphocytes. The initial identification of the NK cell followed the 
observation of a murine lymphoid cell which was able to kill certain target cells in 
vitro without prior activation which led to the coining of the name natural killer cells 
in 1975 (Kiessling et al., 1975; Herberman et al., 1975). However it was not until the 
subsequent proposal of the missing self hypothesis by Karre et al. (1986) that the 
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mechanisms behind the recognition of target cells by NK cells began to be 
understood. While originally regarded as a homogeneous population, the complexity 
of NK cell biology is beginning to be appreciated, with a diverse array of roles and 
the ability to recognise and respond to differing targets through the mosaic expression 
of a series of inhibitory and activatory receptors. 
1.1.4.1 Development 
As lymphocytes NK cells share a common CD34
+
 hematopoietic progenitor cell 
T and B cells as show in  
Figure 1-1. NK cells develop in the bone marrow however the complexities of NK 
cell development are currently being elucidated. Five distinct development stages 
have been proposed for human NK cells, through which NK cell markers and function 
are acquired and lineage commitment obtained. NK cell development may also occur 
in secondary lymphoid tissue, or NK cells may undergo a developmental stage within 
the secondary lymphoid tissue, however this has yet to be confirmed. Currently the γ-
chain receptor cytokine IL-15 and interactions with bone marrow stromal cells are 
considered to have importance in the differentiation of NK cells. The acquisition of 
self tolerance during developmental and the role for distinct signals between each 
stage of development have not been defined (Farag and Caligiuri, 2006; Freud et al., 
2006; Williams et al., 2006).  
1.1.4.2 Activatory and inhibitory receptors 
Unlike T cells which recognise target cells through a specific receptor and utilise 
additional (costimulatory) ligand:receptor interactions in order to become activated 
NK cells rely on the expression of a diverse array of receptors to recognise and 
become activated by target cells, and also to achieve tolerance of healthy cells. Also 
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while T cells recognise one specific peptide, NK cells rely on the balance between 
inhibitory and activating signals. Triggering of a single activating signal will in 
general (with the exception of CD16) be insufficient to allow activation (Bryceson et 
al., 2006), likewise the lack of inhibitory signals is detrimental to the ability of natural 
killer cells to become activated (Fernandez et al., 2005). 
 
NK receptors can be divided into two main categories the inhibitory and activatory 
receptors, the diversity of these receptors is shown in Figure 1-4. The inhibitory 
receptors as the name suggests hold back the activation of cytotoxicity classically 
through interactions with MHC class I molecules although other non-MHC ligands 
have also been identified, while activatory receptors are able to bind specific ligands, 
typically being associated with viral or malignant transformation. 
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Figure 1-4 Natural killer cell receptor repertoire. The diverse inhibitory (blue) and 
activating receptors (green) expressed by NK cells are shown. The receptor 2B4 is 
also shown (in grey) which can have inhibitory and activating roles. NK cells have 
variegated expression of the shown activating and inhibitory receptors allowing 
response to a diverse range of targets. Adapted from Vivier et al. (2008). 
1.1.4.2.1 Inhibitory ITIM associated receptor signalling 
There are numerous inhibitory receptors including, killer cell immunoglobulin-like 
receptors (KIRs) and leukocyte immunoglobulin-like receptors (LILRs) both of which 
are type I glycoprotein members of the immunoglobulin superfamily, whereas the 
CD94-NKG2A receptor is a type II glycoproteins with a C-type lectin-like scaffold. 
While there is a diverse set of inhibitory receptors and ligands, all share a common 
signalling motif in the cytoplasmic domain, the immunoreceptor tyrosine-based 
inhibitory motif (ITIM) which is defined by the sequence (I/L/V/S)XYXX(L/V) 
(where X represents any amino acid and forward slashes denote alternative amino 
acids which may be in that position) (Lanier, 2008).  
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Upon ligation of an inhibitory receptor the tyrosine residue is phosphorylated (by Src 
family kinases) leading to the recruitment of the phosphatases SHIP-1, SHP-1 or 
SHP-2. By recruiting these phosphatases to the immunological synapse between the 
NK cell and its prospective target these phosphatases can inhibit Ca2
+
 influx, 
degranulation, cytokine production and proliferation by dephosphorylating the 
substrates of the tyrosine kinases linked to activating NK receptors. Interestingly 
unlike the permanent tolerance or anergy instilled in T cells to avoid activation, 
inhibition of NK cell responses by ligation of inhibitory receptors is transient and 
spatially localised, resulting in an NK cell which has encountered inhibition 
subsequently being able to become activated upon encounter with a valid target 
lacking inhibitory ligands and/or expressing adequate activatory ligands (Lanier, 
2008). 
1.1.4.2.2 Activating ITAM associated receptor signalling 
All mature NK cells constitutively express FcεRIγ, CD3-δ and DAP12 signalling 
subunits as hetero and homodimers. These interact with NK cell activating receptors 
through oppositely charged amino acids in the transmembrane regions of the 
activating receptor and signalling subunits. In a similar manner to the inhibitory 
receptors FcεRIγ, CD3-δ and DAP12 are characterised by the presence of specific 
motifs in the cytoplasmic domain, the immunoreceptor tyrosine-based activation 
motif (ITAM) which is defined by the sequence (D/E)XXYXX(L/I)X6-8YXX(L/I) 
(Lanier, 2008).  
 
Similarly to the consequences of inhibitory receptor ligation, ligation of the activating 
receptor allows the ITAM tyrosine to become phosphorylated by Src family kinases, 
leading to binding of the tyrosine kinases Syk and Zap70, resulting in a signalling 
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cascade that is very similar to that of T and B cells. Interestingly there appears from 
knockout studies in murine NK cells to be a separation of cytotoxicty and cytokine 
production dependent on differential regulation of downstream signalling events 
(Huntington et al., 2005; Hesslein et al., 2006), likewise it has been suggested that 
different adaptor molecules or kinases may be utilised by different receptors although 
this has yet to be confirmed (Lanier, 2008). 
1.1.4.2.3 Non-ITIM/ITAM signalling 
While the majority of inhibitory and activatory NK receptors function through ITIM 
or ITAM motifs respectively, there have also been a number of other signalling 
systems defined. These include most importantly the activating receptor NKG2D and 
the inhibitory/activatory receptor 2B4 (CD244) (Garni-Wagner et al., 1993; Schatzle 
et al., 1999; Billadeau et al., 2003). 
 
NKG2D is a member of the C-type lectin-like receptor (CTLR) superfamily, with 
diverse expression on NK cells, γδ-T cells, activated CD8+ T cells and macrophages. 
NKG2D has been of great interest due to its role in recognition of stressed cells such 
as those undergoing viral infection or malignant transformation. In contrast to other 
activating receptors NKG2D does not associate with ITAM containing subunits but 
rather exclusively associates with a DAP10 homodimer, in humans. DAP10 contains 
the signalling motif YINM, the downstream signalling events associated with 
activation of this receptor are therefore distinct from ITAM associated receptors 
utilising PI3K and Grb2 rather than Syk family kinases (Billadeau et al., 2003). 
 
2B4 is a member of the signalling lymphocytic activation molecule (SLAM) family of 
receptors (members of the immunoglobulin superfamily), which in humans also 
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includes NK, T- and B-cell antigen (NTB-A) and CD2-like receptor-activating 
cytotoxic cells (CRACC), the expression of which is present on the majority of 
mature NK cells (Veillette, 2006). 
 
The signalling pathway of 2B4 is the most widely studied. SLAM-related receptors, 
such as 2B4, bind members of the SAP family of adapters; SAP or Ewing's sarcoma-
activated transcript-2 (EAT-2), through interactions of the SH2 domain of SAP family 
adapters and the tyrosine-based motif TIYXXV/I, an immunoreceptor tyrosine-based 
switch motif (ITSM) of 2B4. It has been suggested that the differential binding of 
either SAP or EAT-2 may control the ability of 2B4 to act as an inhibitory or 
activatory receptor, expression of which may depend on the maturational status of the 
NK cell (Lanier, 2008; Veillette, 2006).  
 
2B4 has been shown to act as an inhibitory receptor during NK development prior to 
expression of ITIM associated inhibitory receptors, possibly also explaining the 
widespread expression of the 2B4 ligand CD48 on hemopoietic cells. Alternatively 
the prior activation of NK cells by receptor ligation or cytokines may influence the 
ability of 2B4 to be activating or inhibitory (Sivori et al., 2002; Bryceson et al., 2006; 
Veillette, 2006). 
1.1.4.3 NK Education, Arming and Licensing 
While early experiments indicated NK cells recognise ‘Missing self’, a paradox exists 
in that NK cells derived from TAP-2 deficient patients are tolerant of autologous 
cells, although they lack MHC expression, likewise it has been shown that NK cells 
from healthy individuals which lack inhibitory receptors are also tolerant of self; 
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however both these groups are also hyporesponsive to missing self (Yawata et al., 
2008). This suggests that there is a complex mechanism behind the endowment of NK 
cells with the ability to kill, allowing the tuning of NK responses to the individual. 
 
The phenomenon of ‘hybrid resistance’ in mice where parental grafts are rejected by 
F1 hybrid offspring was originally observed in 1971 by Cudkowicz and Bennettin, it 
was not until much later however that the significance of these finding could be 
explained. Yawata et al. (2008) elegantly showed that there is a chimeric expression 
pattern of inhibitory receptors associated with human NK cells with every possible 
combination being present to varying degrees in every donor. As the expression of 
KIR genes is hypervariable, and not linked to HLA inheritance, individuals may also 
possess KIR for which they do not possess cognate ligands (Parham, 2005). There is 
therefore a requirement for a process of ‘education’ of NK cells during their 
development to allow self tolerance to be achieved. Hence in hybrid resistance a 
population of F1 NK cells will recognise parental cells as having ‘missing self’ as 
they do not possess the appropriate ligands for the inhibitory receptor with which 
those NK cells have been educated to achieve self tolerance. 
 
NK cells lacking inhibitory receptors are hyporesponsive, likewise NK cells which 
only possess an inhibitory receptor for which the individual does not possess a 
corresponding HLA ligand cannot experience self and are therefore also 
hyporesponsive. In order to acquire cytotoxic potential NK cells must achieve 
tolerance through the expression of at least one inhibitory receptor to become 
‘armed’; the ‘at least one’ model (Anfossi et al., 2006). While there is evidence to 
support the expression of all inhibitory receptors encoded by an individual’s genotype 
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within the human NK cell population, there is also a suggestion that the expression of 
inhibitory receptors may be influenced by the presence of appropriate ligand (Yu et 
al., 2007). Therefore NK cells express every combination of inhibitory receptor 
possible for each individual, but this expression may be skewed to allow the 
production of the biggest repertoire of functional NK cells, allowing the highest 
chance of recognition of appropriate targets. 
 
To add to the complexity of the process of NK cell education, the process appears to 
be dynamic, in contrast to T cell anergy. Using a mouse transgenic model on a H-2
d
 
background Johansson et al. (1997) created a mosaic transgenic line expressing H-2D
d
 
on 10-80% of cells. Despite the mosaic expression of ligand and inhibitory receptors, 
mice were tolerant of cells lacking trangene expression. However tolerance could be 
broken by separating the H2D
d
 negative and positive cells in vitro, suggesting NK cell 
tolerance is also regulated by interactions with surrounding cells during education. 
This is similar to the breakdown of tolerance associated with the in vitro cytokine 
stimulation of NK cells derived from TAP-deficient patients (Zimmer et al., 1998). 
Likewise NK cells lacking inhibitory receptors as previously mentioned are 
hyporesponsive, however these cells are still capable of responses to PMA and 
ionomycin, suggesting a block in activatory signalling (Anfossi et al., 2006). 
 
At present however there has not been an agreement on the model which best fits to 
the in vivo process of NK cell education, and so far the molecular mechanisms 
governing NK cell education and tolerance have not been defined (Raulet and Vance, 
2006; Colonna, 2008).  
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1.1.4.4 CD56dim and CD56bright subsets 
Human NK cells identified by their lack of CD3 and expression of CD56 can also be 
subdivided into two subsets (CD56
bright
 and CD56
dim
) on the basis of the level of 
CD56 expression. These two subsets have been shown to have different distribution 
and functional abilities as shown in Error! Reference source not found..  
Table 1-1 Differential markers and functions of the CD56
bright
 and CD56
dim
 NK 
cell subsets. 
 
CD56
dim
 CD56
bright
 
CD56 + ++ 
CD16 ++ -/+ 
CD25 - + 
CD62L -/+ ++ 
CCR7 - ++ 
CXCR3 -/+ + 
CD27 -/+ + 
KIR ++ -/+ 
CD94 -/+ ++ 
NKG2A -/+ + 
Cytokine production + ++ 
Natural cytotoxicity ++ + 
++ High level expression; + expressed; +/- variable expression, low or absent; - not 
expressed. Adapted from Cooper et al. (2001) and Vossen et al. (2008). 
 
The CD56
dim
 subset is the dominant subset in the periphery accounting for ~90% of 
the circulating NK cell population. This subset has been shown to be the more 
cytotoxic subset when resting, expressing higher levels of perforin and granzyme, 
compared with CD56
bright
 NK cells. The CD56
bright
 NK cell population in contrast to 
the CD56
dim
 population is enriched in secondary lymphoid tissues. While basal 
cytotoxicity of CD56
bright
 NK cells is lower than for CD56
dim
 cells pre-activation with 
IL-2 results in an increased cytotoxic ability (Robertson et al., 1992). While the 
CD56
bright
 NK cells may be less capable of conducting NK cell mediated cytotoxic 
functions they are however superior in the production of a plethora of 
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immunoregulatory cytokines such as IFNγ, TNFα, and GM-CSF (Cooper et al., 
2001). 
 
It has also been suggested that the CD56
bright
 subset represents an immature form of 
NK cell from which CD56
dim
 cells are derived, conversely it has been suggested that 
CD56
bright
 NK cells are an activated from of CD56
dim
 cells, whereas there is an 
argument that these two subsets are distinct being derived from a common progenitor. 
As yet it is unclear which of these models is correct or equally whether in vivo a 
combination of these models may function (Cooper et al., 2001). 
 
The general definition of the CD56
dim
 population relies on the differential expression 
CD16 (FCγRIII), expression of which defines the classical CD56dim NK cell, allowing 
the ADCC function of this cell population. The CD56
bright
 and CD56
dim
 subsets of NK 
cells also display major differences in the expression patterns of many other 
molecules, firstly associated with the homing phenotype of these cells, but also 
suggestive of the functional differences of these cell populations. The CD56
bright
 
population lacks expression of CD16, there is exclusive expression of CD25 (the IL-2 
receptor α-chain) allowing the formation of the high affinity IL-2 receptor in complex 
with CD122 (β-chain) and CD132 (γ-chain), suggestive of differential roles and 
responsiveness of these different subsets. This population is also well placed to utilise 
IL-2 produced by activated T cells in the secondary lymphoid tissues (Caligiuri et al., 
1990; Fehniger et al., 2003). The CD56
bright
 population also typically expresses higher 
levels of the inhibitory CD94-NKG2A receptors complex while expressing low levels 
of KIR in contrast to the CD56
dim
 subset (Cooper et al., 2001; Jacobs et al., 2001). 
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Given these differences the CD56
bright
 subset may be more suited to coordinate an 
immune response, which could potentially be a powerful tool for the immunotherapy 
of cancer. 
1.1.4.5 Interactions with the adaptive immune system 
As stated the CD56
bright
 NK cell subset is present in secondary lymphoid tissue. These 
cells have been shown to localise to the parafollicular T-cell region of lymph nodes, 
facilitating interactions with DCs and T cells (Fehniger et al., 2002). Besides the 
localisation of CD56
bright
 NK cells to lymph nodes both subsets of NK cells may be 
recruited to inflammatory sites following pathogen entry or tumour formation through 
expression of the chemokine receptors CXCR1 and CXC3R1 by CD56
dim
 NK cells 
and CXCR3 by CD56
bright
 NK cells (Qin et al., 1998; Lazzeri and Romagnani, 2005; 
Marcenaro et al., 2006). 
 
The interaction of CD56
bright
 and CD56
dim
 NK cells with DCs has been shown to 
promote activation of the NK cell, it is however the CD56
bright
 population which are 
subsequently able to proliferate (Vitale et al., 2004). Mature DC are able to produce a 
variety of stimulatory cytokines, including IL-12 and IL-15 which are capable of 
inducing NK activation and proliferation, however there is not a detailed 
understanding of the mechanisms responsible for the induction of NK cell 
proliferation by DCs (Trinchieri, 2003; Fehniger and Caligiuri 2001). 
 
While resting NK cells are able to recognise and kill target cells without prior or 
additional activation, NK cells are not capable of producing immunostimulatory 
cytokines (including IFNγ and TNFα) in response to target cells without additional 
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stimulus. The production of cytokines can be induced upon interaction with target 
cells by type 1 IFNs, IFNα and IFNβ, (which are produced by cells in response to 
viral infection). The production of cytokines by NK cell co-activation with type 1 IFN 
(or the pro-inflammatory cytokines IL-18 and IL-12) are a prerequisite for the NK cell 
induced enhancement of DC function and stable polarisation of the DC towards Th1 
induction (Mailliard et al., 2003; Marcenaro et al., 2005; Garcia-Sastre and Biron, 
2006). The production of IFNγ has also been shown to directly influence the Th1 
polarisation of naïve T cells (Afkarian et al., 2002; Morandi et al., 2006). The 
stimulation of TLR3 and TLR9 on NK cells in the presence of IL-12 without further 
activation also induces the production of immunostimulatory cytokines and promotes 
cytotoxicity against immature DC and also tumour cell targets (Sivori et al., 2004). 
The engagement of TLRs on DC and NK may provide the initial stimulus to drive an 
effective immune response.  
 
The process of DC editing, killing of immature DC by NK cells, may seem 
paradoxical to the ability or necessity of NK cells to drive an effective immune 
response, however immature DC are less well equipped to drive effective immune 
responses and may induce tolerance (Dhodapkar et al., 2001; Levings et al., 2005), 
particularly in the cancer setting (Ghiringhelli et al., 2005). The ability of NK cells to 
recognise immature DC has been shown to be dependent on the differential 
expression of HLA-E (the ligand for the CD94/NKG2A) by mature and immature 
DC. Interestingly it has been shown that the population of NK cells responsible for 
DC editing functions are CD94/NKG2A
+
KIR
-
, i.e. the CD56
bright
 subset, which are 
also well placed to interact with DC during an immune response (Chiesa et al., 2003). 
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The process of reciprocal activation of DC and NK cells has been shown to have both 
contact dependent and independent components. In contrast to mouse, human NK 
cells separated from DC by transwells are able to induce the maturation of immature 
DC, however the ability of NK to induce maturation of immature DC has also been 
shown in vitro to be dependent on the ratio of NK:DC where high NK ratios result in 
the inhibition of DC function (Fernandez et al., 1999; Nishioka et al., 2001; Gerosa et 
al., 2002; Piccioli et al., 2002). The NK cell mediated process of DC editing may be 
responsible for this paradoxical relationship, whereby killing of immature DC may 
allow the activation of NK cells and associated cytokine production and provision of 
additional danger signals aiding DC maturation. 
 
In a series of experiments using an in vivo murine model system, Krebs et al. (2009) 
administered OVA expressing cells with or without ‘missing self’ as an antigen 
source to mice. CD8
+
 and CD4
+
 T cell and B cell responses showed that killing of 
antigen expressing target cells by NK cells was necessary to promote the generation 
of an effective adaptive immune response. Antigen specific responses driven by NK 
cells mediated killing of target cells was also very sensitive; generating a response to 
as few as 10
4
 target cells.  
 
There is therefore a reciprocal interaction between NK, APC and T cells during the 
progression of an immune response. APC may become activated to produce 
monokines, activating NK cells. Activated NK cells produce immunostimulatory 
cytokines and provide DC editing functions, enhancing the antigen presenting 
capacity of APC and promoting the generation of Th1 T cells. NK cells could also 
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provide antigen for APC to present to T cells by killing targets. Activated T cells in 
turn produce IL-2 for the further activation of NK cells. 
1.2 Interaction of the immune system and cancer 
1.2.1 Tumour development 
The development of a malignant carcinoma is a progressive multi-step process 
analogous to Darwinian evolution, requiring the production of many mutations. On 
average 90 mutated genes are present per tumour in colorectal and breast cancer 
tumours, however only a subset of these are likely to be ‘driver’ mutations promoting 
tumorigenesis (Sjöblom et al., 2006). Insightful work performed by Shah et al. (2009) 
showed the accumulation of mutations during the progression of a primary breast 
tumour over a period of nine years with biopsies from the same patient. In the course 
of progression not only had low frequency mutations come to fixation in the tumour 
but new mutations had also occurred and become prevalent. Similarly, following on 
from earlier work by Hunter et al. (2006) showing prevalence of a mutation in a 
specific mismatch repair gene (MSH6) in glioma tumours following treatment with 
the alkylating agent temozolomide, work by Yip et al. (2009) showed the occurrence 
of this mutation during therapy due to the selective pressure exerted by 
temozolomide. The occurrence of MSH6 mutations were also shown to have a causal 
relationship with the occurrence of resistance. 
 
There are a number of distinct prerequisite properties required for the development of 
a cancer; in order for these ‘Hallmarks of cancer’ to develop there is a requirement to 
overcome multiple cellular mechanisms and checkpoints (Hanahan & Weinberg, 
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2000). The progression to malignancy bypasses such controls due to the plasticity of 
the cancer cell genome resulting from defects in nucleotide-excision repair, and 
chromosome and microsatellite instability. Work by Sjöblom et al. (2006) and also 
Wood et al. (2007) has shown the presence of mutations in an assortment of genes 
proposed to drive cancer development from different tumour samples, however there 
are a minority of mutations which are present in a high proportion of tumours, 
demonstrating that certain mutations must be selected for during tumour progression. 
Cancer cells become self sufficient in growth signals, and insensitive to growth 
inhibitory signals, whether this be through the corruption of signalling pathways, the 
autonomous production of growth factors or the coercion of accessory neighbouring 
cells to generate growth signals. Evasion of apoptosis represents an important facet of 
tumour development, allowing the continuation of growth and thus increasing the 
potential for further mutations to take place, ultimately leading to the development of 
limitless replicative potential. Tumours also spread and recruit a nutrient source 
through sustained angiogenesis, tissue invasiveness and metastasis facilitated by 
changes in the expression of adhesion molecules and extracellular proteases by the 
cancer cell or by recruited stromal cells. Ultimately the development of metastases is 
the final step in the progression of cancer as this results in the cause of 90% of deaths 
from cancer (Hanahan and Weinberg, 2000; Lengauer et al., 1998). 
 
While there is a requirement for the development of sustained growth and the 
subversion of tumour suppressor mechanisms to facilitate the growth of a tumour, 
tumour development does not occur in an unperturbed environment, there is evidence 
to suggest the immune system is also a controlling factor in this process (Zitvogel et 
al., 2006). 
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1.2.2 Recognition of tumour cells by the immune system 
There is substantial evidence to suggest a role for the immune system in the 
development of cancer. However evidence as to the effector cells which may be 
mediating this protective effect is mixed, in murine models both elements of the 
innate and adaptive immune responses have been implicated. Given the complex 
interactions of the immune system it may be likely that multiple cell types are 
involved during anti-tumour immune responses; dependent on the tumour cells origin, 
mechanism of transformation, and its ability to be recognised by the immune system 
(Dunn et al., 2004). 
1.2.2.1 T cell antigens 
Multiple methods have been utilised to identify the tumour antigens recognised by T 
cells. This includes initial autologous typing experiments using the recognition of 
tumour cells versus normal tissue by autologous cells or serum. The identification of 
specific antigens is now possible utilising cDNA libraries to express antigens in target 
cells which possess the HLA class of interest. The SEREX (serological expression) 
cloning technique is an alternative high-throughput method relying on the generation 
of humoral responses to tumour antigens with T cell help, whereby cancer patient 
serum is used to detect proteins expressed by prokaryote cDNA libraries (Rosenberg, 
2001).  
 
These techniques have allowed the identification over 1000 putative tumour antigens, 
not including antigens from contributing pathogens. These antigens can be grouped 
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into four main categories, differentiation antigens, mutated protein antigens, over-
expressed proteins, and cancer testis antigens (Dunn et al., 2004; Rosenberg, 2001). 
1.2.2.2 Innate recognition 
As NK cells were initially defined by their ability to kill target cells lacking HLA 
class I (HLA-I) molecules, the inability of NK cells to recognise tumours lacking 
HLA-I was hard to reconcile until the identification of the diversity of NK activating 
and inhibitory receptors. More recently the identification of the activating Natural 
Cytotoxicty Receptors (NCRs) NKp30, NKp44 and NKp46 and the CTLR NKG2D, 
which have been strongly implicated in the lysis of tumour cells by NK cells, has 
sparked much interest in the recognition of tumour cells by NK cells (Moretta et al., 
2000; Waldhauser and Steinle, 2008). 
 
Ligands for the NCRs NKp30, NKp44, and NKp46 have yet to be defined. However a 
number of ligands have been identified for NKG2D, of most interest are the MHC 
class I chain related proteins A and B (MICA/MICB) and the UL16-binding protein 
(ULBP). The expression of the NKG2D ligands is generally absent in healthy cells; 
however expression is induced by various forms of cellular stress such as UV 
radiation, genotoxic and oxidative stress, and has been shown to be expressed on a 
wide variety of tumour cell types (Groh et al., 1999; Waldhauer and Steinle 2008). 
Despite the expression of these activating ligands there is still a lack of tumour 
regression. There are likely to be multiple reasons for this: firstly, as subsequently 
described, many immunosuppressive mechanisms operate within the tumour, 
increased expression of inhibitory ligands, the suppression of activating receptors and 
ligands by TGF-β, and also suppression of NKp30 mediated DC editing functions by 
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TGF-β, the secretion of soluble ligands may attenuate the response of NKG2D 
expressing cells as may the presence of Tregs (Ferlazzo et al., 2002; Ghiringhelli et 
al., 2006; González et al., 2008). Furthermore NK cells derived from cancer patients 
have been shown to fail to effectively infiltrate the tumour site, and show a 
generalised dysfunction and increased susceptibility to apoptosis (Kadish et al., 1981; 
Costello et al., 2002; Bauernhofer et al., 2003). Thus again while the immune system 
is able to recognise and respond to transformed cells the response is ineffective due to 
immunosuppressory mechanisms manifested or induced by the tumour. 
1.2.3 Immunosuppression by the tumour  
The vast array of mechanisms employed by a tumour to suppress the anti-tumour 
immune response is likely to be the biggest hurdle to the success of cancer 
immunotherapy. Most simplistically the tumour may lose expression of HLA-I, such 
as is common in lung cancer. Likewise there is also often a loss of elements of the 
antigen presentation machinery, such as TAP1 or LMP2. Alternatively expression of  
specific antigens may be lost. Besides the loss of antigen presentation or antigen there 
may be active processes by which the immune system is suppressed by the tumour. 
Tumours create intricate suppressive and tolerising conditions, which range from the 
tolerising conditions of the tumour microenvironment to systemic immune 
suppression (Willimsky and Blankenstein, 2005; Zitvogel et al., 2006; Zou, 2005). 
 
TAA specific T cell priming may occur in the tumour microenvironment itself, where 
antigen may be presented ineffectively either by the tumour itself or by APCs which 
have entered or been recruited to the tumour where they may become dysfunctional or 
tolerogenic (Zou, 2005). Tumour cells are able to actively recruit many regulatory cell 
 52 
types, for example the chemokine CCL2 expressed at high levels in tumours incite the 
recruitment of myeloid suppressor cells (MSC) (Huang et al., 2007). Found in many 
tumour types (head and neck squamous-cell carcinoma, non-small cell lung 
carcinoma, metastatic adenocarcinoma of the pancreas, colon and breast), MSC are 
able to produce nitric oxide. This interferes with the IL-2 signalling pathway and 
inhibits arginase-1 (ARG1) which is essential for function and development of T cells 
and responses to IL-2. Likewise plasmacytoid DC (pDC) have been shown to be 
abundant in many tumours. Expression of CXCL12 by the tumour recruits pDC where 
they induce CD4
+
 and CD8
+
 IL-10 producing regulatory T cells. In contrast the 
presence of mature myeloid DC has been shown to be rare in tumours. Furthermore, 
many factors in the tumour microenvironment e.g. VEGF, IL-10 and TGF-β actively 
inhibit DC maturation and also promote the generation of tolerogenic DC by down 
regulating CD80 and CD86 and inducing B7-H1 and B7-H4. B7-H1 has been shown 
to further inhibit DC function through reverse signalling with Treg, and also induce 
apoptosis of effector T cells. B7-H4 also suppresses T cell function. Besides the 
induction of Tregs and suppression of effector functions the presence of TGF-β may 
also have an impact on the DC editing functions of NK cells, as TGF-β has been show 
to induce the down regulation of NKp30, which has been implicated in the 
recognition of immature DC by NK cells. B7-H1 has also been shown to be expressed 
by a number of tumour types (Ferlazzo et al., 2002; Li et al., 2006; Zou, 2005). 
 
Tryptophan is essential for T cell proliferation and differentiation. Tolerogenic DC 
and tumour cells may also produce indoleamine-2,3-dioxygenase (IDO) which 
catalyses the breakdown of tryptophan, preventing clonal expansion and encouraging 
AICD and anergy (Zou, 2005).  TGF-β and IL-10 produced by the tumour favour the 
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development of Treg (Chen et al., 2003; Levings et al., 2005), as well as tolerogenic 
APC. Cancer patients have been shown to have increased levels of Treg within the 
tumour and circulating in the periphery. The presence of increased levels of Treg 
within tumours has been associated with a decrease in patient survival (Curiel et al., 
2004; Zhou et al., 2009a; Zou, 2005). TGF-β reduces antigen presentation by DC, 
inhibits the activity of IFNγ, inhibits the proliferation of T cells and suppresses the 
activation of NK cells (Gorelik and Flavell, 2002). 
 
Although there may be a selective pressure to actively suppress the immune system, 
suppression of the immune response may also be mediated as a by product of the gain 
of the other prerequisite hallmarks of cancer. IL-10 can also act as an autocrine 
growth factor. Resistance to apoptosis is contributed to in many cancers by the over 
expression of MUC1, however MUC1 is also able to inhibit the differentiation DCs, 
and promote IL-10 producing DCs. The over expression of COX-2, and production of 
proangiogenic PGE-2 and VEGF also suppress macrophage and T cell mediated 
cytotoxicity and may also suppress the maturation of DC (Zitvogel et al., 2006). 
 
Therefore tumours exert significant immune-suppression; from an evolutionary 
standpoint the acquisition of such diverse immunosuppressive features alludes to the 
selective pressure the immune system must exert on the developing tumour, and thus 
the potential of immunotherapy. 
1.2.4 Prognostic value of tumour infiltrating lymphocytes 
The presence of tumour infiltrating lymphocytes has been shown to be a significant 
predictor of prognosis and survival in a variety of tumour types including melanoma, 
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colon and breast cancer (Naito et al., 1998; Hadden, 1999; Piras et al., 2005). 
However some of the most thorough work has been performed in ovarian cancer. 
Zhang et al. (2003) showed that the presence of tumour infiltrating T cells 
independently correlated with delayed recurrence and improved survival. The five-
year overall survival rate for patients whose tumours contained T cells was 38.0% 
while survival was 4.5% for patients whose tumours contained no infiltrating T cells. 
The prognostic significance of tumour infiltrating T cells was even more striking in a 
subset of 74 patients who had a complete clinical response after surgical debulking 
and platinum-based chemotherapy, the five-year survival rate was 73.9% compared 
with 11.9% for patients whose tumours contained no T cells. These results have been 
confirmed and furthered by Sato et al. (2005) who showed frequencies of 
intraepithelial CD8
+
 T cells to be a prognostic factor for improved survival compared 
with patients with lower frequencies, the subgroups with high versus low 
intraepithelial CD8
+
/CD4
+
 TIL ratios had median survival of 74 and 25 months 
respectively. This unfavourable effect of CD4
+
 T cells on prognosis was found to be 
due to CD25
+
 FOXP3
+
 regulatory T cells. Han et al. (2008) also reported 
heterogeneous expression of components of antigen presentation pathway components 
(TAP1, TAP2, HLA-I heavy chain and β2 microglobulin), with defects in antigen 
presentation being associated with a poorer prognosis. 
 
The activity of NK cells have also been shown to be a prognostic factor in gastric and 
hepatocellular carcinoma (Taketomi et al.,1998; Takeuchi et al., 2001) while the 
absence of NK cells within renal cell carcinoma tumours has been shown to be 
associated with poor survival (Donskov and von der Maase, 2006). Furthermore low 
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activity of NK cells towards NK cell targets in vitro has also been shown to be 
predictive of increased risk of cancer (Imai et al., 2000). 
1.2.5 Immunosurveillance and immunoediting 
It has been a century since Ehrlich initially suggested that the immune system was 
able to repress the development of cancer, which ultimately led to the formation of the 
theory of immunosurveillance in 1957 by Burnet and Thomas. Initially there was 
considerable controversy surrounding this theory. The limitations of the murine model 
systems of the 1960s and 70s disproved a role for the immune system in the 
prevention of tumourigenesis. However with the use of pfp (perforin) -/- and IFNγ 
insensitive mouse models in the 1990s and the subsequent use of RAG-2 -/- 
immunodeficient mice interest in the immune control of tumour formation was 
renewed, and confirmed to have a role in the prevention not only of carcinogen 
induced tumour formation, but also in the suppression of spontaneous tumour growth 
(Dunn et al., 2004). 
 
As this theory has been investigated and confirmed it has become clear that the 
immune system’s role in cancer development is far from the initial black and white 
concept of immunosurveillance. Not only does the immune system act in the early 
stages of tumorigenesis either protecting an individual from cancer or not, but also in 
the event that immunosurveillance may fail there is continued interaction between the 
immune system and the developing tumour, sculpting its development. 
 
There is now a vast body of literature to corroborate the role of the immune system in 
tumour development: firstly there is an increased risk of cancer seen in the 
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immunocomprimised and the immunosuppressed, secondly cancer patients have been 
shown to develop spontaneous immune responses to autologous tumours, and finally 
the presence of tumour infiltrating lymphocytes has been shown to be an independent 
predictor of prognosis and survival in multiple cancer types. The process of 
immunosurveillance/immunoediting has been suggested to be composed of three 
phases, if the tumour cell is able to avoid initial elimination by the immune system, it 
may then enter a phase of latency where it may stay indefinitely in equilibrium with 
the immune system until it escapes control by the immune system and goes on to 
cause clinical disease with limited intervention from the immune system. 
1.2.5.1 Elimination, equilibrium and escape 
The immunosuppression of transplant patients predisposes those individuals to a 
range of cancers with viral etiology including Kaposi’s sarcoma, non-Hodgkin’s 
lymphoma and cervical cancer. However, more importantly other cancers including 
colon, pancreas, lung and malignant melanoma all without viral causes have also been 
shown to be increased (Domhan et al., 2008; Dunn et al., 2004). Likewise Chediak-
Higashi syndrome a genetic disorder which causes abnormal NK cell cytotoxic 
function results in a 200 fold increased risk of developing cancer, while genetic traits 
such as differences in NKG2D haplotypes have also been shown to result in an 
increased risk of cancer (Imai et al., 2000; Hayashi et al., 2006; Nakachi et al., 2004; 
Dunn et al., 2004). These data suggest that without the presence of a fully functional 
immune system there is an increased risk of cancer development, therefore the 
immune system must be eliminating tumour cells prior to the clinical development of 
cancer. 
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The principles of the equilibrium phase may represent the most intense period of 
immunoediting by the immune system, whereby the tumour may be actively 
recognised by the immune system; although unable to eliminate the tumour the 
immune system constrains the development of the tumour. An interesting case in 
support of this was published by MacKie et al. (2003) whereby two patients receiving 
an allogenic kidney transplant from a donor who had previously been diagnosed with 
melanoma but who had been in remission for 16 years prior to death, both developed 
metastatic melanoma within two years of transplant. There are numerous other 
examples of donor derived tumours (Shiel, 2001), which may suggest that the donors 
immune system was suppressing sub-clinical metastasis, which when transplanted to 
new hosts under immunosuppressed conditions were able to escape to clinical 
significance. 
 
In keeping with Darwinian evolution in order for a tumour to escape the selective 
pressure exerted by the immune system during equilibrium a tumour cell variant must 
lose the ability to be recognised by the immune system. This may be achieved by the 
loss of a specific antigen targeted by the immune system, for example following 
clinical responses recurrence of tumours has been reported to be associated with the 
outgrowth of antigen loss variants following peptide vaccination and adoptive T cell 
therapy for advanced melanoma. Likewise the global loss of antigen presentation has 
also been reported, for example 40-90% of human tumours are seen to completely or 
selectively lose HLA-I expression, suggesting a selective pressure has been exerted 
(Boon et al., 2006; Khong et al., 2004; Yee et al., 2002) while the tumour may also 
gain the ability to suppress the immune response as discussed. These variations 
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ultimately allow the tumour to overcome the bottleneck imposed by the immune 
system. 
1.2.6 Immunotherapy 
The observation of an association of bacterial pathogen associated diseases and a 
regression of tumours was made in the 1700s. This subsequently led Coley in 1897 to 
develop Coley’s toxins (a mixture of heat killed Streptococcus and Serratia 
marcescens) for the treatment of Sarcomas. Long before the advent of conventional 
chemotherapy and radiotherapy this strategy provided clinical success (Starnes, 
1992). The mechanism of action for Coley’s toxins remains unknown however it is 
assumed to be through the systemic activation of the immune system, and as such 
represents the first immunotherapy to be developed (Davis et al., 2003). 
 
Currently there are a number of immunotherapies licensed for use in cancer, and a 
number of more conventional therapies which have been shown to depend partially on 
the actions of the immune system for their efficacy. Below are a few examples of 
immunotherapy in the clinic which have had significant effects or are showing 
promising and interesting proof of principle. 
1.2.6.1 Non-specific immune activation: Bacillus Calmette-Guerin Therapy 
Similarly to Coley’s toxins, Bacillus Calmette-Guerin (BCG) is an attenuated strain of 
Mycobacterium bovis used primarily as a vaccine for the prevention of tuberculosis, 
BCG has also gained acceptance as an effective treatment for cancer. The use of 
intravesical BCG therapy for the treatment of bladder cancer was first proposed by 
Morales et al. for the treatment of high risk Non-Muscle-Invasive bladder cancer 
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(NMIBC) in 1976, and has now become the gold standard treatment along with 
surgery for high risk NMIBC. The efficacy of BCG therapy is drastic with remission 
rates averaging 70% over 5 years (Alexandroff et al., 1999; Horvath and Mostafid, 
2008). 
 
The administration of BCG to the bladder is capable of inducing the recruitment of an 
assortment of cell types including CD4
+
 and CD8
+
 αβ-T cells, γδ-T cells, NKT cells, 
monocytes, DC, and NK cells, and induces the release of a substantial assortment of 
cytokines (Patard et al., 1998). However the specific mechanism by which BCG is 
having anti-tumour efficacy has yet to be defined.  
 
A possible mechanism may however be the activation of NK cells, it has been shown 
that BCG stimulation of PBMC results in the activation of NK cells and that these NK 
cells are able to recognise and kill autologous tumour cells following stimulation 
(Patard et al., 1998). It has also been shown by Suttmann et al. (2004) that the 
activation of NK cells was dependent on the production of IL-12 and IFNα by 
monocytes. Importantly it has also been shown that the expression of higher levels of 
activating ligands for NKp30, NKp44 and NKp46 had a significant influence on the 
disease free survival of patients treated with BCG (Yutkin et al., 2007). The role of 
NK cells in anti-tumour effects of BCG therapy were further strengthened by Brandau 
et al. (2001) who, using a murine model of bladder cancer, were able to show that the 
dominant anti-tumour effects of BCG required NK cells both in vitro and in vivo.  
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These data suggest that BCG therapy is able to significantly activate the whole 
immune response allowing anti-tumour activity which is likely to be at least partially 
mediated by NK cells. 
1.2.6.2 Cytokine therapy: IL-2 
The first clear evidence that manipulation of the immune system through the use of 
recombinant cytokines as an effective therapy for the treatment of cancer in humans 
came from the initial work of Rosenburg et al. (1985a) who administered high dose 
IL-2 to cancer patients with metastatic disease, including melanoma and renal cell, 
colon and lung cancer, who had failed standard therapy. This work followed on from 
initial animal studies showing the efficacy of IL-2 against established implanted 
tumours (Rosenburg et al., 1985b). High dose IL-2 was administered with autologous 
ex vivo IL-2 activated Lymphokine Activated Killer (LAK) cells to 25 patients. 
Objective regression of tumour (more than a 50% decrease in tumour volume) was 
observed in 11 of the 25 patients with a sustained complete response observed in one 
patient with metastatic melanoma, and partial responses in nine patients with 
pulmonary or hepatic metastases (Rosenburg et al., 1985a). However it was later 
shown that the transfer of LAKs did not enhance responses compared to IL-2 alone 
(Rosenberg et al., 1993). 
 
Subsequent studies confirmed the efficacy of IL-2 for treatment as a single agent, with 
work by Fyfe et al. (1995) showing that while an albeit modest (5%) complete 
response rate was achieved this response was durable (to the limit of the study) 
facilitating the approval of IL-2 in 1992 by the United States
 
Food and Drug 
Administration (FDA) for the treatment of renal cell
 
carcinoma. Subsequently IL-2 
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was also licensed for the treatment of metastatic melanoma in 1998, having been 
shown to have similar response rates (Atkins et al., 1999). The durability of the 
complete responses achieved by renal cell and metastatic melanoma patients was later 
confirmed by Rosenburg et al. (1998) with a median follow-up time of 7.1 years, 82% 
of the complete response patients remained in complete remission from three to over 
12 years, with no patient seen to relapse after sustaining a response for three years. 
 
Due to the pleiotropic effects of IL-2 on the immune system the mode of action of IL-
2 therapy has not been elucidated. However evidence for both T cell and NK cell 
mediated effects have been produced (Parton et al., 2006). It is most probable that 
therapy with IL-2 is having effects on many cell types to mediate clinical efficacy. 
1.2.6.3 Adoptive transfer: Autologous Natural Killer cells 
Following on from the success of systemic administration of IL-2 there has been 
much interest in the expansion and activation of autologous NK cells ex vivo for 
adoptive transfer back to the patient. The majority of trials in humans have been 
conducted using IL-2 based expansion and activation protocols, with mixed success. 
Escudier et al. (1994) for example expanded autologous CD3 depleted non-adherent 
PBMC from 10 RCC patients who had achieved a partial response with initial 
systemic IL-2 therapy. Cells were expanded with 200U/ml IL-2 for 13-21 days, 
achieving a median 55 fold expansion of NK cells. These activated cells were then 
infused back into patients along with high dose IL-2. Out of the 10 patients four 
patients showed a complete response following infusion, and a further two patients 
achieved a complete response following surgery. Ishikawa et al. (2004) also activated 
and expanded NK cells from 9 glioma patients with 200U/ml IL-2. Following 6-7 
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days ex vivo culture cells were re-infused along with IFNβ, resulting in a modest 
response rate. 
 
While these studies are encouraging a number of other studies have failed to show 
efficacy associated with the expansion and activation of autologous NK cells. For 
example Burns et al. (2003) combined prolonged systemic IL-2 therapy with the 
periodic transfer of autologous NK cells which had been activated overnight with 
200U/ml IL-2 ex vivo in 37 patients (19 patients with lymphoma, 18 with breast 
cancer), however despite an increase in cytotoxicity and cytokine production in vitro, 
no clinical efficacy could be shown compared with matched controls. Likewise Lister 
et al. (1995) activated NK cells ex vivo from 12 patients (11 lymphoma, 1 breast 
cancer) for 14-18 days with 6000U/ml IL-2, however again despite in vitro activity 
clinical efficacy was not shown. 
1.2.6.4 Adoptive transfer: Allogeneic Natural Killer cells 
Barnes and Loutit (1956) first noted an association between a Graft versus Leukaemia 
(GvL) effect at the time mice were experiencing Graft versus Host Disease (GvHD) in 
a murine Leukaemia model following allogenic bone marrow transplant. 
Subsequently Weiden et al. (1979) were able to show an association between GvHD 
and a decreased risk of relapse in human leukaemia patients, this was attributed to a 
GvL affect. 
 
Following on from these data and the demonstration of successful engraftment of 
fully mismatched T cell depleted stem cell transplants in terminal leukaemia patients 
by Aversa et al. (1994), Ruggeri et al. (1999) went onto examine the potential of 
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mismatched NK cells to provide a GvL effect in 20 leukaemia patients. Following 
transplant no GvHD was observed, however at 6 months no AML or CML patient had 
relapsed, while 5/7 ALL patients
 
relapsed. Despite the lack of GvHD there was shown 
to be an initial graft versus host effect, which could not be detected following the four 
months post-transplant. Likewise allo-reactive NK cells were shown to recognise all 
host myeloid leukaemia targets. In contrast leukaemias of lymphoid origin were less 
susceptible to killing by NK cells, mirroring the clinical effects of this study. 
 
Subsequent analysis of further haploidentical transplants showed that the presence or 
absence of a KIR mismatch in the direction GvH was the only independent predictor 
of survival or poor outcome respectively in AML but not in ALL. The requirement for 
NK cell KIR mismatch was then confirmed in a murine model using transfer of 
human leukaemia cells. While KIR matched NK cells resulted in no survival 
advantage over untreated controls, transfer of KIR mismatched NK cells resulted in 
survival of all mice (Ruggeri et al., 2002). 
 
These data show that NK cell KIR mismatches have the ability to exert a powerful 
clinical effect in certain haematological malignancies. Further trials involving solid 
tumours or AML have also provided some evidence of efficacy, for example Miller et 
al. (2005) tested the use of ex vivo activated, CD3 depleted haploidentical 
haematopoietic cell transplants in which NK cells were enriched (~40%) and 
activated with 1000U/ml IL-2 overnight prior to transfer. 43 patients in total were 
treated, 5/19 poor prognosis AML patients achieved complete remission using this 
regime, while 4/10 metastatic melanoma patients and 2/13 RCC patients showed 
stabilisation of disease (although the melanoma patients subsequently progressed 5-10 
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months after initial treatment). The disparity in the efficacy of this treatment may not 
come solely from the different disease types (i.e. solid tumour vs. haematological) as 
AML patients received a high intensity conditioning regime prior to infusion while 
other patients received low intensity conditioning. It was shown that only the patients 
undergoing prior high intensity conditioning had a significant in vivo expansion of 
NK cells. KIR mismatched NK cells have been shown to have significant cytotoxicty 
against RCC and melanoma cell lines in vitro, but not against KIR matched targets 
(Igarashi et al., 2004). Earlier work by Childs et al. (2000) also suggests that allogenic 
stem cell transplants in RCC can provide an anti-tumour response, with 3/19 patients 
achieving a complete response and 7/19 achieving a partial response. While this study 
used high intensity conditioning, grafts were not T cell depleted; therefore GvHD was 
seen in many patients, but was associated with response. Unfortunately NK cells were 
not monitored in this study. So while clinical efficacy was shown the mechanism by 
which this was achieved was not defined. 
1.2.6.5 Therapeutic antibodies: ADCC 
Since the mid-1990s the field of therapeutic antibodies has increased drastically with 
more than 20 antibody therapies now approved for use in a number of disease settings 
including autoimmune disease and cancer. Predominantly these antibodies have been 
humanised, the constant and Fc regions replaced with human domains. In the cancer 
setting there has been suggestion that a number of antibodies are partially achieving 
efficacy through eliciting the ADCC function of NK cells. This has been shown in in 
vitro models and in mouse xenograph models (Kubota et al., 2009). Importantly there 
is an association with CD16 polymorphisms associated with the improved ability of 
CD16 to bind Fc domains and responses to Rituximab and Trastuzumab (Herceptin) 
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(Treon et al., 2005; Varchetta et al., 2007). Also the response of breast cancer patients 
to Trastuzumab has been shown to correlate with ADCC and NK cytotoxicity in short 
term responses, while longer term progression-free survival correlates with sustained 
NK cells activity (Beano et al., 2008). 
1.2.6.6 Tumour antigen and Dendritic cell vaccines 
The use of prophylactic vaccination for the prevention of infectious diseases has been 
very effective in a number of cases (Banchereau et al., 2009), and has including the 
development of the human papilloma virus (HPV) vaccine for the prevention of 
cervical cancer (Kahn, 2009). The experience gained from prophylactic vaccinations 
and the identification of TAA has encouraged the development of vaccines for use in 
the treatment of various cancers, most notably melanoma. Strategies have included 
the use of TAA peptides, DNA or viral delivered TAA and ex vivo modified tumour 
cells, mixed with various adjuvants or cytokines including incomplete Freund’s 
adjuvant or IL-12 (Sun et al., 1998; Lee et al., 2001; Marshall et al., 2005; Hamid et 
al., 2007). While there has been a great deal of success in the prevention of infectious 
disease there has been relatively little success in the treatment of cancer. A number of 
clinical trials have shown evidence of immune responses to the vaccine in terms of 
sensitive ELISPOT or tetramer assays, or systemic immune responses in delayed 
hyper-sensitivity tests, however in general there are poor objective clinical response 
rates (2.6%) (Rosenburg et al., 2004). This could be for a number of reasons including 
the general immune suppression of cancer patients, and presumable previous 
encounter and tolerisation to antigens derived from the tumour. 
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This has led to the development of DC vaccines; DC matured ex vivo and returned to 
the patient to prime tumour antigen responses. Again a number of strategies have been 
used to provide antigen for DC, including the use of peptides, recombinant proteins, 
autologous and allogenic tumour cells, and DNA or RNA encoding tumour antigens. 
Likewise a number of strategies have been used to produce DCs for transfer, 
including generation from CD34
+
 progenitor cells and maturation from monocytes, 
leading to heterogenatity in the DCs used in trial. It has been shown however after 
proof of principle experiments in healthy donors and patients that in order to generate 
an effective immune response there is a requirement for generation of mature DCs. 
The use of DC vaccines in a number of trials has resulted in an overall response rate 
of 9.6%, which is higher than other vaccination strategies including viral vectors 
(1.9%) and tumour cells (4.6%). The ability to generate immune responses in vivo has 
also been associated with improved survival (Davis et al., 2003; Banchereau and 
Palucka, 2005; Paluka et al., 2007).  
 
Ultimately the use of vaccine strategies must overcome prior encounter of the antigen 
by the immune system and must also overcome immune suppression orchestrated by 
the tumour to be effective, many new strategies are under investigation to achieve 
these aims (Paluka et al., 2009). 
1.2.6.7 Adoptive transfer: T cells  
In order to circumvent the problems associated with previous encounter and 
tolerisation to TAA and the necessity to provide sufficient effective in vivo priming a 
number of strategies have been used to generate tumour specific T cells for adoptive 
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transfer to allow the generation of high numbers of functional tumour specific T cells 
(Offringa, 2009; Rosenberg and Dudley, 2009). 
 
The first evidence that the in vitro manipulation and generation of tumour specific T 
cells was possible came from Muul et al. (1987), who were able to expand tumour 
specific T cells from the autologous TIL of melanoma patients. Following on from 
these studies Rosenberg et al. ex vivo expanded TIL with 6000U/ml IL-2 from 
melanoma patients and returned un-selected cultures to patients. Despite no selection 
taking place objective clinical response rates were achieved in approximately a third 
of patients (Rosenberg and Dudley, 2009). Later protocols have utilised selection of 
cells based on the in vitro antitumour reactivity (Dudley et al., 2003). Initial studies, 
while encouraging, provided only short term responses and short term persistence of 
transferred T cells in vivo (Rosenberg et al., 1990). Subsequent studies corroborate the 
observation that the persistence of transferred T cells in vivo may be a limiting factor 
in the ability to sustain long term clinical response (Robbins et al., 2004). 
 
Other methods for the expansion of tumour specific T cells such as the use of 
alternative cytokines and DCs pulsed with tumour antigen are being investigated 
(Dudley and Rosenburg, 2003; Gattinoni et al., 2006). However the most significant 
response rates have been seen with the use of non-myeloablative conditioning prior to 
transfer. In murine models a requirement for lymphodepletion had been identified 
(North, 1982; Rosenburg et al., 1986) which led Dudley et al. (2002) to test the use of 
high intensity conditioning prior to adoptive T cell transfer to 13 melanoma patients 
with tumours refractory to standard therapies, including high dose IL-2. Patients were 
treated with cyclophosphamide and fludarabine prior to adoptive transfer. Six of 13 
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patients achieved objective clinical response, four of which were sustained. This trial 
was subsequently extended to treat 35 patients, 51% of whom achieved an objective 
clinical response. Furthermore these studies provided evidence showing the long term 
persistence of transferred cells was obtained in four of five patients, who could be 
tested (Dudley et al., 2005). Adoptive transfer following lymphodepletion now 
represents the most effective treatment for late stage melanoma patients (Rosenberg 
and Dudley, 2009). 
 
The mechanisms behind the ability of lymphodepletion to improve responses 
following adoptive transfer of T cells are still being elucidated, however a number of 
non-mutually exclusive mechanisms have been proposed. Conditioning may remove 
immune suppression allowing greater T cell expansion and expression of effector 
functions, likewise depletion could remove the ‘cytokine sink’ present in non-
depleted patients allowing homeostatic expansion (Gattinoni et al., 2006).  
 
While adoptive transfer has been successful tumour specific T cells are in general a 
rare population and require extensive manipulation ex vivo to provide sufficient 
numbers for adoptive transfer. There has therefore been a growing interest in 
transgenic TCR (tTCR) technology. This involves the in vitro identification of TCRs 
capable of recognising specific TAA epitopes. The identified TCR can then be cloned 
into retroviral vectors and used to transduce non-specific PBMC populations, 
resulting in the ability to produce a large population of TAA specific T cells (Morgan 
et al., 2006; Geiger et al., 2009). The use of tTCRs also allows greater control to 
produce T cells with high avidity for TAAs, which has been shown to be important 
for in vitro and in vivo activity (Zeh et al., 1999).  
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1.2.6.8 Subverting suppression 
Cyclophosphamide which was used in the conditioning of adoptive transfer patients 
(section 1.2.6.7) has long been used in the clinic as an anti-angiogenic chemotherapy 
(Kerbel and Kamen, 2004). However cyclophosphamide is also capable of reducing 
immune suppression. In the 1980s the use of cyclophosphamide was revealed to 
specifically inhibit an unidentified regulatory cell population in both murine cancer 
models and cancer patients (Berd and Mastrangelo, 1987; Awwad and North, 1989). 
Following these initial reports and with increased knowledge of immunosuppressive 
mechanisms, Ghiringhelli et al. (2006) were able to show cyclophosphamide 
selectively depletes putative Treg in late stage cancer patients. These data corroborate 
the earlier studies of Berd and Mastrangelo, (1987) who were able to show a specific 
effect on a suppressive cell population. Cyclophosphamide has also been tested in 
combination with other therapies and has been shown to enhance the immune 
response in melanoma patients, as shown by increased DTH reaction, and increase 
survival in breast cancer patients when combined with tumour vaccination, compared 
to vaccine alone (Berd et al., 1986; MacLean et al., 1996). 
 
The ability of standard treatments to provide a specific inhibition of regulatory cells is 
important. At the same time a number of targeted therapies have also been developed 
including the IL-2-diphtheria toxin fusion protein denileukin diftitox (ONTAK). 
ONTAK was originally developed to target haematological malignancies expressing 
CD25, but is also capable of depleting Tregs due to the constitutive high level of 
expression of CD25 by this population (LeMaistre et al., 1992; Mahnke et al., 2007). 
ONTAK has been tested in a number of clinical trials and has been shown to reduce 
circulating Treg levels in cancer patients. The administration of ONTAK prior to 
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vaccination with peptide or DC based vaccines has also been show to allow the 
induction of vaccine specific responses and increase the response compared with 
vaccine alone. While ONTAK can enhance vaccine responses, convincing clinical 
responses have not yet been achieved (Mahnke et al., 2007; Morse et al., 2008). 
 
Arguably the most exciting of the immune modulators are the CTLA-4 antagonistic 
antibodies Ipilimumab and Tremelimumab, which may inhibit Treg function or allow 
an enhancement of T cell activation (Fong and Small, 2008). Building on pre-clinical 
murine models showing the ability of CTLA-4 blockade to allow the rejection of 
poorly-immunogenic tumours following vaccination (van Elsas et al., 1999) Hodi et 
al. (2003) administered Ipilimumab to seven melanoma and two ovarian cancer 
patients who had previously been vaccinated with either TAA peptides, TAA 
expressing DC or autologous tumour cells modified to express GM-CSF. Extensive 
tumour necrosis was seen in three melanoma patients, while the two ovarian cancer 
patients showed reduced or stabilised serum CA-125 levels. Further phase I trials with 
Tremelimumab predominantly for the treatment of melanoma have also been 
conducted and showed clinical responses (Ribas et al., 2005; Reuben et al., 2006). 
Interestingly successful treatment has been associated with the manifestation of 
autoimmune reactions, suggesting CTLA-4 blockade is able break tolerance (Reuben 
et al., 2006; Weber et al., 2009; Hodi et al., 2010; Wolchok et al., 2010). Subsequent 
phase II trials have confirmed these early results showing durable objective responses 
in response to CTLA-4 blockade alone or in combination with dacarbazine or peptide 
vaccine (Phan et al., 2003; Fischkoff et al., 2005). Recently phase II (Wolchok et al., 
2010) and phase III (Hodi et al., 2010) studies have been completed, with 217 and 676 
(pre-treated) advanced melanoma patients respectively. In a dose-ranging study 
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Wolchok et al. (2010) showed a response rate of 4.6% with 3mg/kg Ipilimumab every 
three weeks for four cycles (72 patients total) rising to 11.1% at a dose of 10mg/kg 
(72 patients). This is similar to the response rate of 10.9% following 3mg/kg 
Ipilimumab every three weeks for four cycles (137 patients) which is oddly 
significantly higher than the 5.7% response rate reported with Ipilimumab plus a 
gp100 peptide vaccine (403 patients) reported by Hodi et al. (2010). Interestingly, a 
number of trials have shown a delay in the initiation of response, while perhaps more 
surprisingly the initial objective response is not a prerequisite for the achievement of 
increased survival. These studies suggest that transient CTLA-4 blockade is able to 
have long lasting effects on the immune system (Hodi et al., 2003; Bulanhagui et al., 
2006). 
1.2.6.9 CD80 and IL-12 clinical trials 
There is a vast body of evidence from animal models and in vitro data for the use of 
many costimulatory molecules and cytokines, alone and in various combinations for 
the treatment of cancer. There have been many clinical trials using various approaches 
to utilise costimulation including the use of recombinant cytokines for cancer therapy. 
Some of the most utilised molecules include CD80 and IL-12. As show in Table 1-2, 
there have been a number of good clinical responses to therapy with CD80 and IL-12; 
however these responses are relatively rare. Interpretation of these data is also 
hampered by the relatively small size of these trials, with assessment of safety and 
maximum tolerated dose (MTD) being the primary aim of many studies. Equally the 
use of highly sensitive techniques such as ELISPOT may be able to identify responses 
in peripheral blood however these may not provide a representative indication of 
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immune effects within the tumour (Bamias et al., 2007), nor correlate with actual 
clinical responses (Rosenburg et al., 2004). 
 
The systemic delivery of recombinant IL-12 results in significant toxicity, likewise 
with IL-2 (Siegel and Puri, 1991; Atkins et al., 1997). Intratumoural delivery of IL-12 
DNA or expression vectors offer significant advantages over systemic cytokine 
delivery as this does not increase circulating levels of cytokine significantly, and good 
responses are seen with very limited toxicity (Rakhmilevich et al., 1999). 
 
In general these therapies have been applied as a monotherapy to patients with 
significant tumour burden. While there have been many animal models demonstrating 
the efficacy of monotherapy, later models using less immunogenic tumours or more 
representative tumour burdens have shown a requirement for combinations of 
costimulatory molecules. Studies such as those undertaken by Xu et al. (2004) in a 
murine melanoma model using intratumoural IL-12 gene transfer and systemic 
activating anti-4-1BB antibody, may suggest that a combined approach utilising 
multiple treatment options or a combination of costimulations may be required for 
efficacy in vivo. 
 
It may also be important to choose the correct costimulatory molecules. CD80/CD86 
have been show to activate and enhance Tregs (Lohr et al., 2004; Zhou et al., 2009), 
perhaps explaining relatively transient responses to CD80 therapies. Likewise 
different costimulatory molecules may be better suited for differing roles in the 
immune response such as enabling long term expansion and survival or following 
chronic antigen exposure (Bansal-Pakala et al., 2001; Lathrop et al., 2004; Melero et 
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al., 2007). Therefore with identification of novel costimulatory molecules and a better 
understanding of the interactions of various costimulatory molecules response rates 
and clinical outcomes may improve.  
Table 1-2 Examples of previous clinical trials of CD80 or IL-12 
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1.2.6.10 Trial of agonist CD137 antibodies 
As mentioned in sections 1.2.6.5 and 1.2.6.8 there has been marked success using 
recombinant antibodies as novel cancer therapies. Alongside the use of recombinant 
cytokines and gene transfer techniques there are a number of costimulatory agonistic 
antibodies in early stage clinical development. Including the exciting development of 
BMS-663513 an agonist CD137 antibody developed by Bristol-Myers Squibb, which 
has been reported to show initial promising results in the early stages of phase I trial 
(Sznol et al., 2008). The initial results from the BMS-663513 trial are in stark contrast 
to those shown from the initial testing of TGN1412, a CD28 super-agonist, in humans 
resulting in all six test subject being hospitalised with four developing severe multi-
organ failure (Melero et al., 2007). 
1.3 Gene therapy 
Since the first in man gene therapy trial for the treatment of adenosine deaminase 
(ADA) deficient severe combined immunodefiency (SCID) began on 14
th
 September 
1990 (Culver et al., 1991) there have been a further 1536 gene therapy trials, utilising 
a variety of approaches for the treatment of a variety of diseases 
(www.wiley.co.uk/genmed/clinical).  
 
The targeted indication for the vast majority (64.6%) of the gene therapy trials 
has been the treatment of cancer, with the delivery of antigenic, cytokine or 
genes being among the most prevalent approaches of the many trialled ( 
Figure 1-5A). As  
Figure 1-5B shows the choice of vector is also varied, with viral vectors 
predominating over other delivery methods, and adenoviral vectors being the most 
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commonly utilized. The use of adenoviral vectors in man for gene therapy also 
includes the first commercial gene therapy, licensed for the treatment of head and 
neck squamous cell carcinoma in china in 2003 (Pearson et al., 2004). 
 
 
Figure 1-5  Gene and Vector types used in gene therapy trials. 
Taken from www.wiley.co.uk/genmed/clinical. 
1.3.1 Adenovirus 
Adenovirus is a linear, non-enveloped double stranded DNA virus that was first 
isolated and cultured by Rowe et al, in 1953 from tonsils and adenoid tissue. There 
have now been 51 adenoviral serotypes identified. Wild type adenoviral infection is 
generally mild. Associating symptoms are mainly of the upper respiratory and 
gastrointestinal tracts and the eye, dependent on virus serotype (Horwitz, 2001). 
1.3.1.1 Replication defective adenoviral vectors 
There is a packaging limit of ~2kb to the size of transgene insert that can be 
accommodated by addition to the adenovirus genome, therefore in order to allow 
larger transgene inserts portions of the adenoviral genome have been removed. 
Primarily the E1 region has been deleted in the majority of vectors used in clinical 
trial, with the additional removal of the E3 region (which is not required for 
replication) allowing the insertion of a ~7.5kb fragment to the adenoviral genome. 
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The deletion of the E1 region of adenovirus also has the advantage of rendering the 
virus replication defective, necessitating the use of helper cell lines stably expressing 
complimentary fragments of the adenoviral genome to allow propagation of the virus 
in vitro. 
 
A major attraction for the use of adenoviral vectors is its ability to transduce a wide 
variety of dividing and non-dividing cell types in vivo. Allowing with the use of an 
appropriate promoter/enhancer sequence very high levels of transgene expression, 
however in comparison to other viral vectors e.g. retrovirus, expression of the 
transgene is relatively short lived (5-10 days), making adenoviral vectors a suitable 
choice for treatments which require only short lived, but high level expression of the 
transgene, e.g. suicide gene therapy. 
1.3.1.2 Immunity to adenovirus 
As would be expected for all viruses adenovirus and adenoviral vectors are able to 
have a profound stimulatory effect on the immune system following infection or 
administration. There have been a number of HLA class I and class II T cell epitopes 
identified, predominantly from capsid proteins, and neutralizing antibodies 
predominantly against hexon have also been defined. Seroprevalence of adenovirus is 
high (Cheng et al., 2010; Onion et al., 2007).  
 
Following administration of adenoviral vectors for VDEPT (virus directed enzyme 
prodrug therapy) of prostate cancer it has been shown previously that there is a 
dramatic increase in adenoviral specific responses, both humoral and cellular. 
However, no correlation was seen between pre-treatment anti-adenovirus responses 
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and patient outcome (Onion et al., 2009), suggesting while there is a existing immune 
response to adenovirus this does not impact significantly on the efficacy of gene 
delivery, possibly due to the extremely high titre of virus administered. 
 
The administration of virus is likely to cause a number of immune responses to be 
triggered by both immune and non immune cells. Infection of epithelial and 
endothelial cells or cancer cell lines with Ad has been shown in vitro to induce the 
production of a number of important chemokines, including IP-10, RANTES, and 
MIP-2 and may also induce the expression of type I IFN. Likewise triggering of Toll 
like receptors by Ad has been show to promote DC activation and maturation 
(Hartman et al., 2008; Sakurai et al., 2008). It could also be expected that adenovirus 
would activate NK cells via Toll like receptors or other pattern recognition receptors, 
resulting in production of proinflammatory cytokines. Likewise NK cells may 
recognise Ad infected cells (Tomasec et al., 2007). T cells are also likely to be able to 
recognise Ad infected cells, which may be contributed to by the ‘leaky’ expression of 
viral proteins by the vector (Christ et al., 1997; Sakurai et al., 2008). 
 
Therefore while individuals may have preformed immune response against 
adenovirus this need not impact on the efficacy of gene delivery, while activation of 
innate immune responses may assist as an adjuvant for the activation of anti-tumour 
immune response. 
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1.4 Aims of this project 
Costimulation may hold significant potential for cancer immunotherapy, the 
intratumoural delivery of costimulatory molecules for the activation or generation of 
anti-tumour immune response is a potentially important strategy. It was therefore the 
aim of this thesis to investigate the effects of the expression of CD80, 4-1BBL and IL-
12 for the activation of an anti-tumour immune response. 
 
The initial aim was to revalidate the superiority of the combination of CD80+4-1BBL 
compared to each costimulatory molecule alone and investigate the effects of the 
addition of IL-12 to the combination in a model system utilising antigen mimetic 
OKT-3 stimulation. 
 
It was then aimed to move onto assess the effects of these costimulatory molecules 
alone and in combination to stimulate viral antigen specific T cell responses from 
healthy lab donors as a prelude to assessing the response of T cells from ovarian 
cancer patients to viral antigens, and ultimately to TAAs. 
 
During the course of this project the presentation of 4-1BBL and IL-12 was found to 
stimulate significant proliferation of an NK cells. As these data were novel and 
potentially important to cancer immunotherapy it was also decided to further 
investigate and characterise the response of NK cells to 4-1BBL and IL-12. 
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2 Materials and Methods 
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2.1 Suppliers of Materials 
Unless otherwise stated all materials were purchased from Sigma-Aldrich (Poole, 
UK). De-ionised water was obtained from a Maxima Ultrapure Water (ELGA, High 
Wycombe, UK). 
2.2 Molecular biology 
2.2.1 DNA restriction digestion 
Restriction endonuclease enzymes were supplied by Boehringer Mannheim or New 
England Biolabs. These enzymes were used in accordance with the reaction 
conditions described in the manufacturers instructions using the appropriate enzyme 
buffers. 
 
Typically for diagnostic DNA digestions, 0.5 μg of DNA was cut in a total volume of 
20 μl, with 2 μl of appropriate 10x enzyme buffer and 1 U of restriction endonuclease. 
This was incubated at the optimum temperature for a minimum of two hour unless 
otherwise instructed. In situations where the use of multiple enzymes was required, an 
appropriate buffer was selected in accordance with the manufacturer advice which 
allowed activity for all enzymes being used. Digestion of larger quantities of DNA, up 
to 20 μg (e.g. for fragment purification) was carried out in a similar way except for 
the use of 1.5 U of enzyme per μg DNA in a total reaction volume of 100-200 μl. 
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2.2.2 DNA extraction using phenol and chloroform 
Phenol and chloroform were routinely used to remove contaminating proteins from 
DNA preparations. The DNA solution to be purified was made up to a volume of at 
least 500l with 10mM Tris 1 mM EDTA (T10E1) buffer and an equal volume of 
aqueous phenol was added. The tube was vortexed for 15 seconds to mix, the phases 
were then separated again by centrifugation in a microfuge for one minute at 13,000 
rpm. The lower organic phase was removed into a designated waste container and an 
equal volume of a 1:1 mixture of phenol and chloroform was added to the remaining 
supernatant. Vortexing, centrifugation and organic phase removal were repeated and 
then chloroform alone was added to the aqueous phase. The processing was repeated a 
third time but on this occasion, the aqueous phase was removed to a fresh tube, 
ensuring no transfer of organic solvent. In order to allow the DNA to be used in 
downstream applications, or if the DNA needed to be concentrated, ethanol 
precipitation was subsequently carried out. 
2.2.3 DNA precipitation using ethanol or isopropanol 
DNA precipitation in the presence of salt and alcohol was carried out by the addition 
of either 0.1 volumes of 3 M sodium acetate, or 1/50 volume of 5 M NaCl followed 
by the addition of 2 volumes of absolute ethanol or 1 volume of propan-2-ol. If small 
mounts of DNA were to be precipitated linear polyacrylamide (LPA) was also added 
as a carrier. The solution was then mixed and incubated at -20C for 20-30 minutes. 
The DNA was recovered by centrifugation in a microfuge at 16000g for 15 minutes. 
The supernatant was discarded and the pellet was then air dried before re-suspension 
in an appropriate volume of T10E1 buffer. 
 84 
2.2.4 Agarose gel electrophoresis 
DNA fragments of between 0.1 kb and 20 kb were separated and visualised by use of 
submerged horizontal gel electrophoresis. DNA size markers (1kb ladder) were 
supplied by Invitrogen. Agarose (Invitrogen) was dissolved by heating in a 
microwave oven, having been prepared in 1 x TAE running buffer (0.04 M Tris 
acetate, 0.001 M EDTA pH8), at 0.7% - 1.0% for most applications. DNA samples (5-
20μl) were made up in 1:6 volume of 6 x Ficoll loading buffer (0.25% bromophenol 
blue, 0.25% xylene cyanol FF, 15% Ficoll Type 400; Pharmacia) before loading onto 
the submerged gel. The DNA electrophoresis was then performed by application of 
100 volts for 1-3 hours. The gel was then stained for approximately 10 minutes in 
ethidium bromide diluted to 1 g/ml in water or 1 x TAE. The DNA was then 
visualised by use of a Spectroline TVC-312A variable intensity UV transilluminator. 
Photographs of gels were taken using a Kodak EDAS290 digital camera. 
2.2.5 DNA fragment purification   
DNA (20-40g) was endonuclease restriction digested and run on a Seakem agarose 
gel following the addition of 6x Ficoll loading buffer (1:6 v/v) and 1/10,000 dilution 
of stock SYBR® Gold nucleic acid gel stain (Molecular Probes, Eugene, Oregon 
USA). Visualisation of DNA bands was carried out under blue light (in order to avoid 
UV damage to the DNA that would occur with EtBr visualisation) with a Dark 
Reader™ (Clare Chemical Research), and the required band was excised with a fresh 
scalpel blade. The DNA was subsequently recovered from the gel slice using a 
QIAquick Gel Extraction kit (Qiagen) following the manufacturers protocol. 
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2.2.6 Measurment of DNA concentration: Picogreen assay 
DNA standards were made in duplicate from serial two fold dilutions of a standard 
DNA stock solution (New England Biolabs) in a 96-well Falcon Microtest assay 
plate. Concentrations ranged from 0-200 ng per well in a final volume of 100 μl per 
well. Subsequently, 100 μl of 1/200 diluted Picogreen (Invitrogen) solution was added 
to each well. Fluorescence was determined using an absorption wavelength of 485 nm 
and emission wavelength of 595nm (fluorescein settings) on a Wallac Victor2 1420 
Multilabel Counter and the DNA concentration calculated from a standard graph. 
2.2.7 Ligation of DNA 
Fragments of DNA were joined using T4 DNA ligase (Roche Diagnostics) in order to 
construct recombinant DNA plasmids and viral vectors. In some cases the 5' ends of 
the linear DNA fragments were dephosphorylated using calf intestinal alkaline 
phosphatase (CIAP) (New England Biolabs), dephosphorylation prevented re-
circularisation of plasmid vectors without insert, thereby increasing the chance of 
obtaining the desired product. Dephosphorylation was achieved prior to ligation by 
incubation with CIAP at 37C for one hour with 1 x concentration of supplied buffer. 
The enzyme was then heat inactivated at 75 C for 10 minutes and the DNA 
recovered by phenol/chloroform extraction and ethanol precipitation.  
 
In general, 3:1 molar excess of insert to vector was used in sticky end ligations and a 
10:1 excess for blunt ended ligations. Reactions were incubated overnight at 14 C. 
Following overnight incubation, the DNA was cleaned up by phenol/chloroform 
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extraction and ethanol precipitation. The pellet was then resuspended in 10l T10E1 
and a small volume was checked on an agarose gel. 
2.2.8 Preperation of competent cells 
Transformation competent E. coli cells were prepared using the calcium chloride 
method. 1ml of overnight culture was used to inoculate 100ml of LB medium and 
incubated at 37
o
C until the O.D.600 was 0.45-0.55 but for no longer than 4 hours. The 
culture was equally divided into two 50ml tubes and cooled on ice for 15 to 20 
minutes. Cells were pelleted by centrifugation at 4
o
C (500g for 10 minutes in a 
Beckman GS-6R benchtop centrifuge), pellets resuspended in 10ml of ice-cold 0.1M 
calcium chloride and incubated on ice for 30 minutes. Cells were repelleted, 
resuspended in 2ml of ice-cold 0.1M calcium chloride, incubated on ice for 2-3 hours, 
repelleted and finally resuspended in 2ml of 0.1M calcium chloride / 15% glycerol. 
200µl aliquots were transferred into 1.5ml microcentrifuge tubes, frozen in liquid 
nitrogen and stored at -80
o
C until required.  
2.2.9 Bacterial growth media 
Media for bacterial cultures was prepared as detailed in Table 2-1, prior to 
autoclaving.  
 87 
 
Table 2-1 Bacterial growth media 
Culture Medium Ingredients 
LB medium 
6g LB broth base (Invitrogen) in 300ml 
ddH20 
SOB medium 8.4g SOB mixture (Difco) in 300ml ddH2O 
LB agar 
6g LB broth base (Invitrogen), 4.5g 
Bactoagar (Difco) in 300ml ddH20 
SOC medium 
SOB medium supplemented with 20mM 
filter sterilised glucose 
2.2.10 Transformation of competent cells with plasmid 
Frozen competent bacteria were thawed and kept on ice for 10 min. Approximately 
1ng of the control plasmid or the product of a ligation reaction containing ~ 100 – 
300ng DNA was added to 100µl of XL-10 competent cells, mixed, and kept on ice for 
45 minutes. The cells were subject to a 90-120 second heat shock in 42 °C water bath 
and then transferred to 900μl of room temperature SOC media. Bacterial mixture was 
incubated at 37C for one hour. Bacteria were then plated on SOB agar contained 
100μg/ml ampicillin to select transformed cells. 
2.2.11 Small scale preparation of plasmid DNA: mini-prep 
For small scale preparation of plasmid DNA a single bacterial colony was picked with 
a sterile loop and used to inoculate 20ml of LB medium containing 100μg/ml of 
ampicillin. Cells were cultured at 37
o
C overnight in a shaking incubator. The next day 
10ml of the culture was centrifuged for 5 minutes at 5000 rpm in a Sorvall GSA rotor. 
The resultant cell pellet was kept on ice and DNA extracted using a QIAprep spin 
miniprep kit (Qiagen). If restriction digests confirmed the desired clone large scale 
production of the plasmid DNA could be carried out. 
 88 
2.2.12 Large scale preparation of plasmid DNA: bulk-prep 
For bulk preparation of plasmid DNA bacteria (containing the desired plasmid) in the 
exponential growth phase were inoculated into 200ml of LB medium containing 
100μg/ml of ampicillin. Cells were cultured at 37oC overnight in a shaking incubator. 
The next day cells were pelleted in a centrifuge pot by centrifugation for 5 minutes at 
5000 rpm in  Sorvall SM24 rotor. The resultant cell pellet was kept on ice throughout 
the procedure. First the pellet was resuspended in 4ml of ice cold solution 1 (50 mM 
glucose, 10 mM EDTA pH 7.5, 25 mM Tris. Cl pH 8.0), followed by the addition of 
1ml of lysozyme (10 mg/ml in solution 1) the solution was left on ice for 10 minutes. 
10ml of solution 2 (0.2 M NaOH, 1% w / v SDS) was then added and the tube 
inverted five times and left for 5 minutes on ice. Following this 7.5ml of solution 3 (5 
M acetate and 3 M potassium, pH 4.8-5.0) was added and vortexed followed by 
incubation on ice for 10 minutes. Cellular debris was pelleted by centrifugation for 15 
minutes at 8000 rpm at 4
o
C in GSA rotor and the supernatant was transferred to a new 
centrifuge pot. The DNA was precipitated with 22.5ml of isopropanol for 30 minutes 
at -20
o
C and pelleted by centrifugation at 8000 rpm in GSA rotor. The supernatant 
was discarded and the crude plasmid DNA pellet was resuspended, usually overnight, 
in 2.5ml of T50E10. The resultant solution was ready for purification by caesium 
chloride density gradient centrifugation. 
2.2.13 Purification of plasmid DNA by caesium chloride density 
gradient centrifugation 
Crude plasmid DNA from bulk prep was purified by caesium chloride (CsCl) density 
gradient centrifugation. In a 15-ml tube, 3.03 g of Ultrapure caesium chloride 
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(CsCl) (Invitrogen) and 275l of EtBr solution (10mg/ml) were then added to the 
plasmid solution. The liquid weight of the plasmid solution was made upto 3.025 g by 
the addition of T50E10. The solution was stored on ice for 10 minutes before 
centrifugation at 10000 rpm for 10 minutes in a Sorvall SM24 rotor to precipitate 
contaminating RNA. Cleared plasmid preparation was transferred into 3.9ml 
Beckman Quick-Seal™ centrifuge tubes, with any gap between the liquid and neck of 
tube filled with isopycnic CsCl solution (1 g CsCl:1ml T50E10). The tube was then 
spun overnight in a Beckman Optima TLX bench top ultracentrifuge TLN 100 rotor 
for 4 hours at 100000 rpm followed by 4 hours at 95000 rpm and one hour at 55000 
rpm. 
 
After centrifugation the DNA band was harvested by piercing the side of the tube with 
a 21-gauge needle and 2-ml syringe. The recovered solution was diluted with three 
volumes of T10E1N100 solution in a 15-ml tube. The DNA was extracted with 
phenol/chloroform to remove the ethidium bromide, precipitated with two volumes of 
ethanol, and pelleted by centrifugation. The DNA pellet was resuspended in 500μl of 
T10E1N100, transferred to an Eppendorf tube and precipitated again with 1ml of 
ethanol. Finally the DNA pellet was resuspended in 0.2 to 1ml of T10E1 solution, 
ready for further experiments. 
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2.3 Virus production 
2.3.1 Replication defective Adenoviral vectors 
Seed stocks of the replication defective adenovirus vectors expressing CD80, 4-1BBL 
and GFP which had previously been produced by the Gene Therapy group (Institute 
for Cancer Studies, University of Birmingham) (Habib-Agahi et al., 2007), were 
obtained from Dr. P.Searle (Institute for Cancer Studies, University of Birmingham). 
2.3.2 IL-12 adenoviral vector resurrection 
2.3.2.1 Virus production 
Previously a plasmid containing the p35 and p40 subunits of IL-12 driven from the 
CMV promoter and inserted into the left end of an E1 deleted adenovirus genome had 
been created within the Gene Therapy group (Institute for Cancer Studies, University 
of Birmingham). In order to generate a functional Ad-IL-12 vector the following steps 
were performed. Following verification of the plasmid by restriction digest the 
plasmid containing the Ad-IL-12 left end was linearised by restriction digest with 
SwaI and phenol-chloroform extraction and ethanol precipitation performed. A 
second plasmid containing an overlapping right end of adenovirus was linearised with 
ClaI and purified as for the left end Ad-IL-12 plasmid (as shown in Figure 2-1). The 
concentration of the linearised DNA was determined and the two plasmids mixed at a 
2.7:1 ratio to give equal molar amounts of each plasmid. This mixture was transfected 
into 293 cells in a 25cm
3
 flask using Fugene 6 (Roche) following the manufacturers 
instructions, to allow homologous recombination, (culture of 293 and 911 cells is 
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described in chapter 2.4). Cells were harvested, and pelleted by centrifugation when 
cytopathic effect was observed and resuspended in 500μl of infection media and 
stored at -80
o
C.  
 
Figure 2-1 SwaI linearised Ad-IL-12 left end plasmid. Shown is a schematic of the 
Ad-IL-12 left end plasmid linearised following restriction digest with SwaI. Inserted 
regions and the overlapping region of the Ad right end ClaI linearised plasmid are 
highlighted.  
2.3.2.2 Plaque Purification 
In order to obtain a homogeneous stock of virus plaque purification was performed. 
1x10
6
 911 cells were seeded onto 60mm diameter plates (Nunc), 24 h prior to 
infection. The virus stock was serially diluted 10-fold in infection media 
(DMEM+2%FCS, see section 2.4.2). Medium was removed from the plates and 500µl 
of the virus dilution (10
-1
-10
-8
) was added to each plate in triplicate. Plates were 
returned to the incubator and virus allowed to infect for 90 min, with frequent rocking 
of the plates. Infection media was then removed and 4mls agar-medium overlay (1:1 
mixture of 1.4% noble agar, and 2 x DME medium (supplemented with 4% FCS, 
2mM glutamine, 5mM NaHCO3, 10mM MgCl2 and 100iu/ml Penicillin and 100mg/ml 
Streptomycin) was applied to each plate. Once solidified, plates were returned to the 
incubator. At 4, 7 and 10 days post-infection, cells were re-fed by the addition of 2ml 
agar-medium overlay. Once plaques were well developed, well isolated plaques were 
picked using the tip of a transfer pipette into infection media, this was then freeze 
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thawed three times and used to infect 25cm
3
 flasks of 911. When cytopathic effect 
was evident cells were harvested and plaque purification repeated and used again to 
infect 911 cells. The harvested virus at the end of this process was used as a seed 
stock for large scale virus production. The presence of the IL-12 transgene 
downstream of the CMV promoter was confirmed by PCR using primers specific for 
regions of the CMV promoter and IL-12 p40 subunit. 
2.3.3 Large scale virus production 
Large scale crude virus production from stocks of virus were prepared by inoculating 
sub-confluent monolayers of 293 or 911 cells in 10-20 175cm
2
 culture flasks (Nunc) 
for each virus at a multiplicity of infection (moi) of 10 in 5 ml infection media. Cells 
were incubated at 37C for 90 min to allow virus adsorption. A further 20 ml of media 
was added. Incubation was continued at 37C until an extensive viral cytopathic effect 
was observed (bunch of grape like appearance), usually between 4-5 days post 
infection.  
 
The cell suspension of infected cells were harvested into 50 ml tubes (Falcon) and 
centrifuged at 840g for 10 min in a refrigerated centrifuge. The supernatant was 
discarded and the cell pellet re-suspended in 0.5 ml medium per original flask. Cells 
were subject to three freeze and thaw cycles in liquid nitrogen and 37C water bath. 
This crude extract was stored at -80C prior to purification. 
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2.3.4 Density gradient virus preparation 
Following three freeze thaw cycles n-butanol was added to a final concentration of 
1% (V/V), mixed, and incubated on ice for 1 hr. The lysate was then centrifuged at 
840g, 10min at 4
o
C, and the supernatant loaded onto a preformed glycerol/caesium 
chloride gradient. The gradient consisted of 2ml caesium chloride density ρ=1.45g/ml 
t the bottom, followed by 3 ml caesium chloride density  
ρ=1.32g/ml 9 on 
top. Viral supernatant was layered on top of the glycerol, and the tubes centrifuged at 
25000 rpm, overnight at 4°C, in a Beckman SW40Ti rotor. Purified virus was visible 
as an opalescent band at ρ=1.345. The purified virus was collected by puncturing the 
tube with a 21 gauge needle with 5 ml syringe attached. The collected virus was 
dialysed to remove contaminating CsCl by inserting the collected virus solution into a 
5ml Slidealyser dialysis cassettes (Pierce) and dialyzed against PBS/10% glycerol 
overnight at 4
o
C, changing the PBS/glycerol three times. Virus was finally removed 
from the cassette and aliquoted into Sarstedt O ring sealed 1 ml tubes and stored at -
80°C. 
2.3.5 Determination of virus particle number by Picogreen assay 
0.1% (W/V) SDS solution was mixed in a 1:1 ratio with a sample of virus and heated 
at 56C for 30 min to inactivate the virus and release the viral DNA. The titre of viral 
particles was determined based on DNA concentration using Picogreen reagent 
(Molecular Probes) as above.  
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Adenoviruses have one double stranded DNA chromosome therefore every single 
DNA molecule represent one virus particle. Virus particle number was determined 
based on the calculated DNA concentration, number of bases in viral DNA, and the 
average weight of bases by using the following formula: 
 
2.3.6 Determination of viral titre by plaque assay 
Plaque assay were used to determine the titre of infectious particles. 1x10
6
 911 or 293 
cells were seeded per 60mm diameter plate (Nunc), 24 h prior to infection. Viruses 
were serially diluted 10-fold in media. Medium was removed from the plates and 
500µl of the virus dilution (10
-6
-10
-10
) was added to each plate in triplicate. Plates 
were returned to the incubator and virus allowed to infect for 90 min, with frequent 
rocking of the plates. Subsequently 4mls agar-medium overlay was applied to each 
plate, once solidified plates were returned to the incubator. At 4, 7 and 10 days post-
infection cells were re-fed by the addition of 2ml agar-medium overlay. Plaques were 
counted as they appeared up until 14 days post infection. The virus titre in plaque 
forming units (pfu)/ml was then calculated. 
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2.4 Tissue culture 
2.4.1 Maintenance of primary human fibroblasts 
Previously primary human fibroblasts had been established from skin punch biopsies 
from donors in the Institute of Cancer Studies. Cells were fed by half medium change 
until cells were nearly confluent; each well was then trypsinised and seeded 1:3 in 
wells of a 6 well plate. 
2.4.2 Culture Media 
Dulbecco’s modified Eagle’s medium with HEPES (DMEM-HEPES, Sigma) 
supplemented with 10% foetal calf serum (FCS), 2mM L-glutamine and 100iu/ml 
Penicillin and 100μg/ml Streptomycin was used to grow A549, HEK-293 and 911 cell 
lines (see Table 2-2). Complete Roswel Park Memorial Institute medium with L-
glutamine (RPMI, Sigma), supplemented with 10% FCS in addition to antibiotics at 
the above concentrations was used to culture PBMCs (as detailed in section 2.4.7) and 
for the culture of OVCAR-3 (see Table 2-2). RPMI supplemented with 8% human 
(h)-AB serum (HD supplies) in addition to antibiotics at the above concentrations was 
used to culture PBMCs for autologous culture models. Media supplemented as above 
will be referred to as complete media. 
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2.4.3 Maintenance and passage of mammalian cell lines in culture 
 Table 2-2 shows cell lines used in this study. All cell lines were obtained from 
colleagues (as indicated) in the CRUK Institute for Cancer Studies, University of 
Birmingham. 
 Table 2-2 Cell lines. 
Cell line Cell type Source ATCC No. 
HEK293 Primary human embryonic kidney 
transformed by sheared human 
Ad5 
Dr. V. 
Mautner 
CRL-1573 
911 Human embryonic retinoblasts 
(HER) transformed by a plasmid 
containing base pairs 79-5789 of 
Ad5 
Dr. V. 
Mautner 
n/a 
OVCAR-3 Human ovarian adenocarcinoma  Dr. P.Searle HTB-161 
A549 Human lung carcinoma Dr. P.Searle CCL-185 
K562 Human chronic mylogenous 
leukaemia 
Dr. O. 
Goodyear 
CCL-243 
 
Cultures were kept at 37C in humidified incubator with 5% CO2. At approximately 
80% confluence cultured cells were passaged by removing the media, washing with 
Phosphate Buffered Saline (PBS) and incubating in trypsin (0.05%) until cells were 
detached. Trypsin was inactivated by the addition of complete culture media. 
Harvested cells were either grown in cell culture flasks typically at a 1:5 or 1:10 
dilution or were collected by centrifugation at 680g for five min. and diluted to a 
known concentration for use in experiments.  
2.4.4 Cryopreservation/Recovery 
Cell lines were kept as frozen stocks in liquid nitrogen.  To prepare cells for cryo-
storage, trypsinised cells were centrifuged as before at 4
o
C and re-suspended in a 
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appropriate volume of freezing media (10% DMSO in FCS) 1ml aliquots in Cryo-
tubes (NUNC) were placed into a NALGENE Mr Frosty pre-cooled to 4
o
C and 
transferred immediately to a -80C freezer overnight. Cells were transferred to vapour 
phase of liquid nitrogen storage tanks for long term storage.  To revive frozen stocks, 
cells were warmed to 37C rapidly and washed in 10mls of appropriate pre-warmed 
complete media by centrifugation at 300g for 10 min. before transfer to flasks in the 
appropriate medium for growth. 
2.4.5 Microscopy 
A Zeiss Axiovert 25 inverted microscope was used for all phase-contrast and 
fluorescence microscopy using 5, 10, 20 and 40x objectives. 
2.4.6 Subjects and ethics 
Local ethical approval (LREC) was obtained; Healthy volunteers 06/Q2604/156, 
Ovarian cancer patients 04/Q2707/190, Renal cell carcinoma patients 06/Q2706/82. 
 
Blood and tissue samples were obtained following an informed written consent from 
healthy consenting members of the Institute for Cancer Studies, Birmingham or renal 
cell carcinoma patients undergoing partial or complete nephrectomy at Queen 
Elizabeth Hospital, Birmingham. Ascitic fluid was obtained from ovarian cancer 
patients undergoing paracentesis at the Cancer Centre, Queen Elizabeth Hospital. The 
HLA types of donors used for HLA restricted peptide specific responses had 
previously been determined within the Institute for Cancer Studies, Birmingham by 
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molecular tissue typing of the HLA class I locus, carried out by the Blood Transfusion 
Service (BTS). 
2.4.7 Isolation of peripheral blood mononuclear cells, PBMCs and 
depletion of plastic adherent cells 
Peripheral blood mononuclear cells (PBMC) were isolated from heparinised 
peripheral blood samples by Ficoll density-gradient centrifugation. Whole blood was 
diluted 1:1 with Complete RPMI, 30mls was then layered over 15mls Ficoll  
(Lymphoprep, Norway) and centrifuged for 30 min at 680g at 20
o
C with the brake off. 
The layer of PBMC was transferred with a transfer pipette to a fresh sterile tube and 
re-suspended in complete RPMI. Following two washes by re-suspension in RPMI 
and centrifugation at 540g for 10min the cell pellet re-suspended in complete RPMI. 
The lymphocyte yield was determined by haemocytometer (ISL) count.  
 
The isolated PBMCs (5x10
6
 cells/ml) were incubated in tissue culture flasks in 
complete RPMI at 37°C for a further 2 hr. The non-adherent cells were washed off 
with pre-warmed media and transferred to a fresh container. Isolated cells were used 
immediately or cryo-preserved in freezing media in liquid nitrogen. 
2.4.8 Isolation of tumor infiltrating lymphocytes from ascitic fluid 
Ascitic fluid was transferred to 250ml centrifuge tubes (BD Falcon) and spun at 840g 
for 15 min, the pellet was then resuspended (volume dependent on pellet size and 
volume of initial ascitic fluid sample) with complete RPMI and passed through a 
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100μm cell strainer (BD Falcon). The sample could then be treated as for PBMC 
isolation (2.4.7). 
2.4.9 Isolation of ‘normal’ and tumour cells from RCC patient 
tissue 
Samples of tumour tissue or normal margin were collected. Tissue was finely minced 
with sterile scalpel blades in a 60cm tissue culture dish (Nunc). The tissue was then 
either centrifuged (680g, 10 min) and cryopreserved or immediately processed for 
culture. 
 
Minced tissue to be used to culture primary cell lines was suspended in complete 
RPMI and passed through a 100 μm cell strainer (BD Falcon); further tissue 
dissociation was carried out using a cell scraper to break tissue apart through the cell 
strainer. Cells were then centrifuged (680g, 10 min), re-suspended in complete RPMI 
and transferred to a 75cm
2
 tissue culture flask. Following overnight culture at 37
o
C 
non adherent cells were removed. Adherent cells were then cultured in complete 
RPMI and passaged as required. 
2.4.10 Infection with recombinant adenovirus 
Adenoviral vectors were used at the following MOI unless otherwise stated; Ad-
CD80 was used at 300 virus particles/cell, Ad-4-1BBL and Ad-GFP were used at 
3000 virus particles/cell and Ad-IL-12 was used at 600 virus particles per cell, (For 
clarity standard infections will use the following notation; Costimulatory 
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combinationCell type i.e. A549 infected with 300 particles/cell Ad-CD80 and 3000 
particles/cell of Ad-4-1BBL will be defined as CD80+4-1BBLA549).   
 
These doses of Ad-CD80 and Ad4-1BBl were initially determined by flow cytometric 
analysis of expression by A549 cells 48hrs post infection, Ad-GFP was used in a dose 
equivalent to Ad-4-1BBL, i.e. the highest level of single virus used. 
 
A549, OVCAR-3, cultured fibroblast and adherent PBMC (monocytes) were used to 
express CD80, 4-1BBL, IL-12 or GFP after infection with the corresponding 
adenoviral vectors. 24 or 48 hours in advance, cells were harvested from tissue culture 
flasks or purified from peripheral blood. The cells were re-suspended in DMEM 
supplemented with 2% FCS in addition to antibiotics for infection of cell lines or 
complete RPMI media for primary cell infection at 1x10
6
 cell/ml. The required 
number of virus particles for each infection were calculated and added to the cell 
suspensions. The virus-cell mixture was incubated at 37C for 90 min. with frequent 
rocking to allow virus adsorption. Cells were then distributed to appropriate wells of 
tissue culture plates and additional media added to form a uniform monolayer growth. 
 
Expression of the transgenes was examined by flow cytometry using specific 
monoclonal antibodies or fluorescence in the case of GFP expression. 
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2.5  T cell and Natural Killer cell assays 
2.5.1 Anti-CD3 T cell activation 
A schematic of the OKT-3 response model system is shown in Figure 2-2. A549 cells 
were infected with the appropriate adenovirus vectors as described in section 2.4.10 
and cultured at 1x10
5
 cells/well of a 24 well plate 48 hrs in advance. Infection media 
was removed and 1x10
6 
PBMCs then added to each well in a total volume of 2 mls of 
complete RPMI supplemented with 100ng/ml OKT-3 (Orthoclone, Janssen-Cilag). 
Lymphocyte proliferation was studied by cell counting (in the presence of trypan blue 
to exclude dead cells), cell surface marker staining and flow cytometry or CFSE 
dilution at appropriate time points. 
 
Figure 2-2 OKT-3 response model system. A549 were infected with adenoviral 
vectors for 90min in suspension at 1x10
6
 cells/ml prior to plating into wells of a 24 
well plate. 48hrs after infection media was removed and 1x10
6
 non adherent PBMC 
added. PBMC responses were assessed by differing methods after 5 or 7 days. 
2.5.2 Allogenic stimulation of Natural Killer cells 
A schematic of the NK cell response model system is shown in Figure 2-3. OVCAR-3 
cells were infected with the appropriate adenovirus vector as described in section 
2.4.10 and cultured at 1x10
5
 cells/well of a 48 well plate 48 hrs in advance. Infection 
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media was removed and 0.5x10
6 
PBMCs then added to each well in a total volume of 
1 ml of complete RPMI. Lymphocyte proliferation was studied by cell counting, cell 
surface marker staining and flow cytometry or CFSE dilution at appropriate time 
points. 
 
Figure 2-3 Allogeneic NK cell culture model. OVCAR-3 cells were infected with 
adenoviral vectors for 90min in suspension at 1x10
6
/ml then plated at 1x10
5
 cells/well 
of a 48 well plate. 48hrs after infection media was removed and a non adherent 
PBMC population or an isolated NK cell population added. Responses of the PBMC 
or NK cell population was assessed between 24hrs to 7 day of culture, dependent on 
experiment. Long term stimulations were also performed by the addition of 20U/ml 
IL-2 at day 7 and re-stimulation with OVCAR-3 pre-infected as for day 0 at day 14. 
2.5.3 Autologous viral peptide stimulation of T cells 
A schematic of the OKT-3 response model system is shown in Figure 2-4. 24 hrs prior 
to the addition of non-adherent PBMC or purified T cells autologous adherent PBMC 
were allowed to adhere in 75cm
2
 tissue culture flasks for two hours, non adherent 
PBMC were removed by washing with media. Adherent cells were removed by 
scraping and re-suspended at 1x10
6
 cells/ml for infection. Cells were distributed and 
infected with the appropriate adenovirus vectors at 2x10
5
 cells/well of a 48 well plate 
and the volume adjusted to 0.5mls with complete RPMI after a 90min infection. Four 
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hours before the addition of non-adherent PBMC or purified T cells, the stimulating 
cells were peptide-pulsed by the addition of 5μg/well of peptide (Table 2-3); unbound 
peptide was removed after four hours by three washes by the gentle addition and 
removal of media. 0.5x10
6
 non-adherent PBMC or purified T cells were then added 
and cultured for 7 days.  
 
48 hours prior to the addition non-adherent PBMC or purified T cells  fibroblasts were 
trypsinised and re-suspended at 1x10
6
 for infection with the appropriate adenovirus 
vectors cells, then plated out in 48 well plates at 1x10
5
 cells/well and the volume 
adjusted to 0.5mls with complete RPMI after a 90min infection. Fibroblasts were 
peptide pulsed in the same manner as for adherent cells. 
Table 2-3 Virus specific peptide epitopes. 
Peptide 
Sequence 
Origin HLA 
Restriction 
Manufacturer 
CLGGLLTMV LMP-2 (EBV) HLA-A2 Mimotopes 
LTDLGQNLLY Hexon 
(Adenovirus) 
HLA-A1 JPT Peptide 
Technologies 
NLVPMVATV pp65 (CMV) HLA-A2 JPT Peptide 
Technologies 
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Figure 2-4 Viral peptide specific response model. Adherent PBMC or autologous 
fibroblasts were infected with adenoviral vectors for 90min in suspension at 1x10
6
 
cells/ml in wells of a 48 well plate (2.5x10
5
 cells/well). 24-48hrs after infection cells 
were peptide pulsed with 5μg of peptide for 4hrs. Media was then removed and 
unbound peptide removed by gentle washing with media. 0.5x10
6
 isolated T cells 
were then added. T cell responses were assessed after 7 days of culture. 
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2.5.4 Isolation of lymphocyte subsets 
2.5.4.1 Negative isolation of T cells 
A population of untouched T cells was obtained using the Miltenyi Biotec Pan T Cell 
Isolation Kit II following the manufactures protocol. Non-T cells were removed by a 
two step process. Firstly a cocktail of biotin-conjugated antibodies against CD14, 
CD16, CD19, CD36, CD56, CD123, and Glycophorin A was added to bind Non-T 
cells followed by the addition of anti-biotin microbeads to allow the capture and 
magnetic removal of these cells.  
2.5.4.2 Isolation of Natural Killer cells 
A population of purified NK cells was obtained using the Miltenyi Biotec 
CD56
+
CD16
+ 
NK Cell Isolation Kit. This kit firstly allowed the purification of an 
untouched pan NK cell population by negative isolation. As with the negative 
isolation of T cells, Non-NK cells were removed by two steps, involving first binding 
with a cocktail of biotin-conjugated antibodies against lineage specific antigens 
followed by the addition of anti-biotin microbeads to allow the capture and magnetic 
removal of these cells. This kit also allowed the subsequent separation of CD16
+/-
 
cells, by the positive selection of CD16
+
 cell by anti-CD16 microbeads. Following the 
initial negative isolation NK cells, this allowed the isolation of a highly purified 
population of NK cells of the CD56
dim
 subset. These procedures were carried out 
following the manufacturers’ protocol.  
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2.5.5 Cell staining for flow cytometry analysis 
Cultured or fresh PBMC or cell lines were washed with PBS/FCS (2%) and incubated 
with appropriate fluorochrome-conjugated antibodies at 4
o
C in the dark for 30 min. 
Cells were washed with PBS/FCS (2%) and cells were re-suspended in 500l buffer 
for flow cytometry or fixed with 2% paraformaldehyde for later analysis. Cells were 
analysed using a four-colour Beckman Coulter XL flow cytometer using Coulter 
System II software for data acquisition or a 16 colour Beckman Coulter LSR II. Data 
was analysed using FlowJo or WinMDI software.  
 
Unstained or isotype control stained samples were used first to set forward scatter and 
side scatter properties. Voltages were set so the peak fluorescence generated from the 
negative control in each channel was between 10 and 1. If multicolour staining was 
being used then appropriate colour controls were analysed and compensation 
performed with reference to every other colour being analysed. Once this was 
completed voltages, gates and compensation were kept constant for all cells analysed. 
Table 2-4 lists the anti-human monoclonal antibodies and the flurochrome labels used 
in the course of this project. 
 
Data was analysed using two parameters: percentage positive and mean fluorescent 
intensity (MFI). Percentage positive refers to the percentage of gated cells fluorescing 
above the level of the negative control (isotype control) (Serotec or Beckman 
Dickinson) this was measured using a marker set to include less than 1% of the 
negative control cells. Mean fluorescence was taken as the arithmetic mean 
fluorescence in each channel for all the cells gated. 
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Table 2-4 Main antibodies used in this project. 
 Antibody Label Supplier 
Anti-CD3 FITC/Pacific Blue BD Pharmingen 
Anti-CD4 FITC DAKO 
Anti-CD4 PE Beckman Coulter 
Anti-CD8 FITC/PE-Cy5 Beckman Coulter 
Anti-CD16 FITC BD Pharmingen 
Anti-CD25 PE Serotec 
Anti-CD56 APC/PE Becton Dickinson 
Anti-CD62L APC BD Pharmingen 
Anti-CD80 FITC BD Pharmingen 
Anti-CD137 PE BD Pharmingen 
Anti-CD137L PE BD Pharmingen 
CCR5 PE-Cy7 BD Pharmingen 
CCR7 PE-Cy7 Beckman Dickinson 
CXCR3 Unconjugated Beckman Dickinson 
IFNγ PE BD Pharmingen 
FoxP3 (PCH101) PE eBioscience 
2.5.6 Measurement of lymphocyte division using CFSE (Carboxy 
Fluorescein diacetate, Succinimidyl Ester) dilution 
2.5.6.1 CFSE labelling of lymphocytes 
PBMCs were washed three times with PBS, centrifuged at 540g, 10 min and re-
suspended at 2×10
7
cells/ml in PBS. 10 mM stock CFSE (Molecular Probes) in DMSO 
was diluted in PBS to achieve a 5 µM stock. Diluted CFSE was added to the cells at a 
ratio of 1:1 (vol:vol) and vortexed gently. The cell suspension was then incubated for 
15 minutes at 37C agitating periodically. An equal volume of complete RPMI culture 
medium was added to the cells and left for one minute at room temperature to stop the 
labelling process. The cells were washed 3 times with media and re-suspended in 
culture media. 
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2.5.6.2 Analysis of cell proliferation by CFSE dilution 
CFSE is a fluorescein related dye consisting of a fluorescent molecule containing a 
succinimydyl ester functional group and two acetate moieties. CFSE diffuses freely 
into cells where intracellular esterases cleave the acetate groups converting it to a 
fluorescent, membrane impermeable dye which binds to intracellular proteins. As 
cells divide the dye is partitioned equally between mother and daughter cells, the 
number of cell divisions can therefore be determined according to the number of 
equally spaced peaks of CFSE fluorescence, typically up to six divisions can be 
discerned from CFSE dilution. The area under each peak was determined to calculate 
the percentages of dividing lymphocytes in each round of cell division or simply as a 
measure of dividing and undivided populations. 
2.5.7 Production of CLG Tetramer 
2.5.7.1 Induction of protein expression 
Glycerol stocks of E.coli transformed with expression plasmids for HLA-A2 or β2M 
were a kind gift from Geothy Chakupurakal, (Institute for Cancer Studies, 
Birmingham). All bacterial culture media were supplemented with 100μg/ml 
ampacillin. Bacteria were streaked out onto LB Agar plates, and cultured overnight at 
37
o
C. Plates were removed from the incubator and stored at 4
o
C, colonies were picked 
using a sterile loop into 10mls LB medium which was cultured overnight at 37
o
C. The 
following day 4L of low salt LB medium and 2L of LB were prepared for HLA-A2 
and β2M growth respectively, 10mls of the overnight culture was added per litre of 
media and cultured at 37
o
C. The OD600 was measured using a spectrophotometer 
periodically until OD600 reached between 0.3-0.4 at which point protein expression 
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was induced by the addition of Isopropyl-β-D-1-thiogalactopyranoside (IPTG) at a 
final concentration of 0.5mM for 4 hours, cultures were then stored at 4
o
C overnight. 
Cultures were centrifuged at 4000 rpm in a Sorvall GSA rotor at 4
o
C for 20 mins. The 
pellet was then resuspended in ice cold PBS ice cold and transferred to a 50ml tube, 
and made up to 25ml and stored at -80˚C. 
2.5.7.2 Purification of protein 
In order to release the inclusion bodies containing the recombinant HLA-A2 and β2M 
molecules it was necessary to sonicate the bacterial cells. Bacteria were thawed at 
room temperature and subsequently kept on ice. A flat horn was used in bursts of 45 
secs, followed by 1 minute between bursts on ice to allow the sample to cool. In total 
this was repeated eight times until the sample was completely lysed. The sample was 
then stored on ice for about 30 mins.  
 
The sonicated sample was spun at 4
o
C at 15000 rpm in a Sorvall SS-34 rotor for 10 
mins, the supernatant was discarded, and the pellet was resuspended in 4ml/l of Triton 
Wash (0.5% Triton X-100, 50mM Tris pH 8.0, 100mM NaCl, 0.1% Sodium Azide, 
1mM EDTA, 1mM DTT) and transferred into a glass homogeniser using a transfer 
pipette and homogenised until completely re-suspended. Following homogenisation 
the solution was once again spun, this procedure was repeated twice. After the final 
wash the supernatant was discarded and 2ml per litre of re-suspension buffer (50mM 
Tris pH 8.0 100mM NaCl, 1mM EDTA, 1mM DTT) was added, the solution was 
again transferred into a clean glass homogeniser and completely re-suspended. The 
sample was then spun at 15000 rpm in a Sorvall SS-34 rotor for 10 mins at 4
o
C. 15mls 
of freshly prepared Urea solubilisation solution (8M Urea, 50mM Mes pH 6.5, 0.1mM 
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EDTA, 0.1mM DTT) was then added to the pellet, which was and re-suspended by 
vortexing then incubated rotating overnight at 4
o
C. The solubilised sample was 
transferred to clean centrifuge pots and centrifuged at 15000 rpm in a Sorvall SS-34 
rotor for 20 min in a precooled centrifuge, the supernatant was aliqoted and stored at -
80
o
C. The purity and concentration of the isolated protein was determined by SDS-
PAGE and Bradford assay. 
2.5.7.3 Refolding Class I complexes 
The HLA-A2 and β2M was now ready to be refolded with the CLG peptide to form 
HLA monomers. The refolding buffer was made, firstly 400ml of initial buffer 
(125mM Tris pH 8, 0.4M L-Arginine HCL 2.5mM EDTA) was made and left 
overnight stirring at 4
o
C. Continuing to stir at 4
o
C the solution was then made up to 
contain 0.6μM Reduced Glutathione, 0.06μM Oxidised Glutathione, and 0.25mM 
PMSF and 5mg of CLG peptide. A 12.5mg aliquot of β2M was then thawed and 
diluted to a concentration of 1mg/ml by drop wise addition of the refold buffer 
(containing peptide), this mixture was then added back drop wise to the bulk refold 
buffer, this mixture was left stirring at 4
o
C for 1 hr. A total of 33.68mg of HLA-A2 
was then required to form tetramer monomer. This was added as above in eight 
separate stages over a 48hr period. The HLA-A2 was thawed and the required amount 
diluted to 1mg/ml in refold buffer (containing peptide and β2M) as for β2M and 
transferred back to the main refold. Following the final addition of HLA-A2 the refold 
was left stirring for a further 2 days. 
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2.5.7.4 Purification and biotinylation of refolded CLG monomer 
The refolded complex was then concentrated to allow purification using a Millipore 
Pellicon XL (10,000 MW) plate to approximately 7 ml. In order to allow biotinylation 
of the monomer buffer exchange was performed using a PD10 column (Pierce). The 
column was washed three times with Bir A reaction buffer (100mM Tris pH 8, 20mM 
NaCl, 5mM MgCl, 0.1mM PMSF), the sample was then run onto the column and then 
eluted using Bir A reaction buffer. The monomer was then biotinylated overnight at 
room temperature by the addition of a final concentration of 1.5nM Biotin, 15mM 
ATP, Protease inhibitor cocktail and Bir A enzyme (Roche). The biotinylated CLG 
monomer was then purified on a G75 Superdex column (GE healthcare) and 
concentrated using a Millipore Centricon filter spun at 840g at 4
o
C. The concentration 
of the monomer was determined by spectrophotometry and diluted to 1mg/ml using 
FPLC buffer (20mM Tris pH8.0, 50mM NaCl) and stored as 100μg aliquots at -80oC. 
 
Successful biotinylation of the monomer was subsequently confirmed by ELISA, 
briefly monomer was bound to a well of a maxisorp plate (Nunc) at room temperature 
for 2hr, washed three times with PBS+0.1% Tween 20, and Extravidin-peroxidase 
added for 30min, washed five times and 100μl tetramethylbenzidine (TMB) substrate 
(Pierce) added, colour generation indicated successful biotinylation.  
2.5.8 Tetramer staining 
2.5.8.1 Tetramerisation with streptavidin-PE 
Tetramers were stored as frozen monomers, in order to produce tetramers the 
monomer was mixed at a ratio of 0.312mg streptavidin-PE:1mg of monomer. A 
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aliquot of frozen monomer was thawed and the required volume of streptavidin-PE 
(Invitrogen) added in 10 aliquots over a 48hr period at 4
o
C. Tetramer was generally 
considered to be stable at 4
o
C for upto four weeks. 
2.5.8.2 Cell staining with tetramers and antibodies 
0.5-1×10
6
 cultured or fresh PBMCs were incubated with appropriate PE-labelled 
MHC tetramer reagent at 37C for 15 min. After washing with cold PBS/FCS (2%) 
buffer, cells were re-suspended and incubated with the appropriate fluorescently 
labelled antibodies for 20 min at 4C. The stained cells were washed with cold 
PBS/FCS (2%) buffer and re-suspended in 300-500μl of buffer for analysis by flow 
cytometry.  
2.5.9 Quantitative enzyme linked immunosorbent assay (Elisa) 
Media was collected at appropriate time points from stimulated cultures and stored at 
-20
o
C until required. 
2.5.9.1 Interferon gamma ELISA 
Maxisorp 96-well plates (Nunc) were coated with 50μl/well of anti-human-IFNγ 
antibody (0.75μg/ml) (clone B133.5, Thermo scientific) in coating buffer (0.1M 
Na2HPO4, pH9) by overnight incubation at 4C. The unbound antibody was washed 
off by three washes with PBS+0.1% Tween 20, the plate was then blocked with 
200μl/well 1% BSA, PBS+0.1% Tween 20 for1 h incubation at RT. The plate was 
washed 5 times and 50μl sample added to each well in triplicate. Culture supernatants 
were serially diluted 1:10 to 1:1000 and IFNγ standard solutions were serially diluted 
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1:2 (range 2000-31.5pg/ml). Plates were incubated at RT for 3hrs and subsequently 
washed with PBS+0.1% Tween 20 five times. Biotinylated anti-IFNγ (clone B133.5, 
Thermo scientific) was diluted in the blocking buffer at 1/300 and 50μl added to each 
well. Plates were incubated at RT for 1 h and again washed five times. Extravidin-
peroxidase was diluted in blocking buffer (1:1000) and 50μl added to each well. After 
a 30 min incubation at RT and nine final washes, 100μl TMB chromogen (Pierce) was 
added to each well. The reaction was stopped with 100μl of 1M hydrochloric acid and 
the absorbance was measured at 450nm by a Wallac Victor2 1420 Multilabel Counter 
(Perkin Elmer, Monza, Italy (Formally Wallac)). 
2.5.9.2 IL-10 ELISA 
IL-10 concentrations were determined using a matched antibody set and recombinant 
IL-10 standard purchased from ebioscience following the manufactures guidelines. 
Briefly a Maxisorp 96 well plate (Nunc) was coated with anti-IL-10 (clone JES3-9D7) 
diluted in supplied coating buffer, overnight at 4
o
C. Following blocking with 1%BSA 
in 0.1%PBS-Tween samples were incubated at room temperature for 5hr, washed 
with 0.1%PBS-Tween and anti-IL-10-biotin (clone JES3-12G8) added in blocking 
buffer for a further 1hr. Detection was then achieved following washing by addition 
50μl/well of Extravidin-peroxidase diluted in blocking buffer (1:1000). After a 30 min 
incubation at RT and nine final washes, 100μl TMB chromogen was added to each 
well. The reaction was stopped with 100μl of 1M hydrochloric acid and the 
absorbance was measured at 450nm by a Wallac Victor2 1420 Multilabel Counter 
(PerkinElmer, Monza, Italy (Formally Wallac)) 
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2.5.9.3 Granulocyte-macrophage colony-stimulating factor ELISA 
GM-CSF concentrations were determined using a GM-CSF Elisa Max kit (Bioledged, 
Cambridge Bioscience) following the manufacturers guidelines. Briefly anti-GM-CSF 
antibody was coated onto Maxisorp plates overnight at 4
o
C, followed by blocking, 
incubation with sample and labelling with detection antibody and Steptavidin-HRP. 
Analysis was performed as for detection of IFNγ ELISA; timings followed the 
manufacturers’ instructions. 
2.5.10 Interferon gamma capture 
To allow the detection of specific populations of cells producing IFNγ within a 
cultured population a Miltenyi Biotec IFNγ Secretion Assay - Cell Enrichment and 
Detection Kit was used following the manufacturers protocol. Cells were initially 
labelled with a bi-specific antibody (anti-lymphocyte/anti-IFNγ) following a period of 
culture with constant rotation (45min at 37
o
C) to allow secretion and capture of IFNγ. 
IFNγ production was detected by the addition of an anti IFNγ PE conjugated 
antibody. Additional phenotype markers were also stained at this point by addition of 
the appropriate fluorescently labelled antibodies for 20 min at 4C. The stained cells 
were washed with cold MACS buffer and re-suspended in 300-500μl of buffer for 
analysis by flow cytometry. 
2.5.11 Intracellular interferon gamma staining 
Intracellular staining was performed using ADG (Caltag) Fix & Perm reagents 
following the manufacturers’ instructions. Briefly cells were cultured in the presence 
of 10μg/ml brefeldin A for 4hr. Cells were then washed with cold PBS+2%FCS and 
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stained with surface antibodies as described in 2.5.5. Following washing cells were 
fixed with Reagent A (formaldehyde). Following fixing, cells were washed and 
permeabilised with Reagent B (Saponin/Formaldehyde), to which 20μl anti-IFNγ-PE 
antibody was added or the appropriate isotype control. Following 30 min incubation 
at 4
o
C, cells were washed and analysed by flow cytometry. 
2.5.12 Intracellular FoxP3 staining 
Intracellular staining was performed using a FoxP3 staining buffer set (eBioscience) 
following the manufacturers’ instructions. Briefly cells were stained with surface 
antibodies as described in 2.5.5, following washing cells were fixed and 
permeabilised (Saponin/Formaldehyde). Following blocking with 2% rat serum for 15 
min at 4
o
C 20μl anti-FoxP3-PE antibody was added or an appropriate isotype control. 
Following 30 min incubation at 4
o
C cells were washed and analysed by flow 
cytometry. 
2.5.13 Chromium release cytotoxicity assay 
2.5.13.1 K562 cells as targets 
Typically K562 cells were counted and 1x10
6
 were spun down, 540g 10min. The 
media was removed with a transfer pipette, taking care to ensure all media was 
removed, the cells were then resuspended in 0.25 mCi 
51
Cr (Sodium Chromate) 
(Amersham) and incubated at 37
o
C for 90 min. 
 
Cells were washed twice with 8 ml of complete RPMI, target cells were then 
resuspended at 5x10
4
/ml in complete RPMI. 100μl of the target cell suspension was 
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added to appropriate wells of a 96 well V bottom plate (Nunc). Effector cells were 
also counted and resuspened and added to targets to give Effector:Target ratios of 
33:1, 10:1, 3:1 and 1:1 or 0.3:1. Targets were also plated out with the addition of 
media only (to determine spontaneous release) and with RPMI+0.1% SDS (to give 
maximal release). Controls were typically plated out in four separate triplicate sets. 
The plates were the centrifuged at 355g for 3min then incubated at 37
o
C for 5hrs. 
 
100μl of the supernatant was then removed from each well and placed into individual 
LP2 tubes. These were then loaded on a Packard Cobra II D5010 Ten Detector 
Scintillation Gamma Counter. Results are expressed as percentage specific lysis 
which was calculated using the following formula; 
 
2.5.13.2 Autologous tumour and ‘normal’ cells as targets 
In the case of frozen tissue, tissue was defrosted as 2.4.3. Dissociated tissue was 
resuspended and cells isolated as for fresh tissue (2.4.9). In the case of cultured cell 
lines, cells were trypsinised (2.4.2). 
 
Target cells from tissue isolated by either method were now treated identically. Cells 
were counted by hemocytometer and typically 1-5x10
5
 cells spun down (540g 10 min) 
and media removed with a transfer pipette. 
51
Cr labelling was as for K562 cells 
(2.5.13.1). 
 
% Specific Lysis = 
 
Exp. Release – Spontaneous 
Release 
 
Max. Release – Spontaneous 
Release 
 
 
x100 
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Target cells were mixed with effector cells at appropriate ratios or plated as minimal 
and maximal lysis controls. Following 5 hour incubation 100 μl supernatant was 
removed from each well and specific lysis determined as above. 
2.5.14 Syto 16 cell death assay 
SYTO dyes are cell permeable dyes that are non-fluorescent in aqueous medium but 
become highly fluorescent when bound to nucleic acids. Previously SYTO dyes have 
been used to distinguish live, apoptotic and necrotic cells. The green fluorescent 
SYTO 16 especially has been used to detect early apoptotic changes in lymphocytes. 
As SYTO 16 fluoresces when bound to nucleic acids live cells fluoresce brightly, 
while apoptosis can be discerned by a reduction in florescence (Sparrow and Tippett, 
2005). With the addition of propidium iodide (P.I.) late stage apoptotic/necrotic cells 
could be discerned as P.I.
+
 having lost membrane integrity while early apoptotic cells 
appeared P.I.
-
 retaining membrane integrity. 
 
Cells were removed from culture and washed with cold saline 540g 10 min at 4
o
C. 
The cell pellet was then resuspended in 500μl Saline+10nM Syto 16 (Invitrogen) 
supplemented with 0.5%BSA+ 30 μM verapamil (a gift from Yi-Jun Qi, Institute for 
Cancer Studies, Birmingham) and incubated at 37
o
C for 45min. Cells were then 
washed in MACS buffer (PBS(pH7.2)+0.5%BSA+2mM EDTA), subsequently 
antibody staining was performed with the required antibodies, and cells were then 
analysed by flow cytometery on a BD LSR II. 
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2.6 Graph plotting and statistical analysis 
All graphs were plotted and statistical analysis performed using Graphpad Prism 
version 4 software (Graphpad software Inc., La Jolla, CA, USA).  
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3 Results: T cell Stimulation 
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3.1 Costimulation of T cell Response to OKT-3 
3.1.1 Introduction 
Costimulation is a prerequisite for the generation of an adequate T cell response. In 
order to study the ability of costimulation delivered by adenoviral vectors to provide 
costimulation for the activation and expansion of a T cell response a model system 
was used. A549 cells where used to express costimulatory molecules of interest, while 
the anti-CD3 antibody OKT-3 was used to provide a generic antigenic stimulation to 
the T cell population. While this system is highly artificial it allows a large scale 
response to be easily monitored without the added complexities of small peptide 
specific responses. 
 
Previously within this laboratory the cDNA sequence for human CD80 and 4-1BBL 
or green fluorescent protein (GFP) have been isolated and inserted into replication 
defective adenoviral vectors, where the E1 region was replaced with one of the 
aforementioned genes, under the control of the CMV immediate–early promoter, to 
drive high level expression. The sequence for the p35 and p40 subunits of IL-12 had 
also been isolated and linked with an IRES, expression was also driven by the CMV 
immediate–early promoter, this was used to create a replication defective adenovirus 
vector to express IL-12 within the course of this project. 
3.1.2 Expression of CD80 and 4-1BBL by adenoviral vector 
 In order to validate the ability of these vectors to express the required costimulatory 
molecules a range of virus particles per cell were used to infect the cell line A549. 48 
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hours following infection expression of the relevant molecules were assayed by flow 
cytometry. It was determined that a virus particle/cell ratio of 300 was required for 
Ad-CD80 to provide good infection and expression, while Ad-4-1BBL required a ten 
fold higher level of virus. This level of virus was shown to also be consistently 
effective for OVCAR-3, adherent PBMC and fibroblasts (Figure 3-1). 
 
Figure 3-1 Expression of CD80 and 4-1BBL following infection with Ad-CD80 
and Ad-4-1BBL. The cell types shown were infected in suspension with 300vp/cell 
and 3000vp/cell of Ad-CD80 and Ad-4-1BBL respectively. Following culture for 
48hrs expression of CD80 and 4-1BBL were assessed by flow cytometry. Shaded 
histogram show mock infected cells stained with antibody. Results shown are typical 
of at least three A549 and OVCAR-3 experiments, four donor adherent PBMC 
samples, and results from fibroblasts of one donor used for long term stimulation. 
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3.1.3 Costimulation of short term OKT-3 stimulated T cells 
Using a similar model system Habib-Agahi et al. (2007) previously showed that a 
combination of CD80/CD86+4-1BBL was superior to either costimulatory molecule 
alone in the ability to promote the expansion of T cells during short term (7 day) 
culture. In order to revalidate the ability of CD80+4-1BBL to allow the expansion of 
T cells, and also to investigate the effect of the addition of IL-12 to the combination; 
experiments were set up using A549 infected to express our chosen combinations of 
costimulation. 
 
Assessing the total number of PBMC  (rather than actual expansion of the T cell 
population) we were able to show that after short term culture within our system there 
is little expansion in CD80 stimulated cultures (1.3 fold), while 4-1BBL alone is able 
to stimulate a modest increase in cell number (2.3 fold). As expected the combination 
of CD80+4-1BBL is superior (3 fold) to either single costimulation. Interestingly the 
addition of IL-12 to the combination further enhances the proliferation of these 
cultures (3.9 fold), while IL-12 alone has no effect, likewise there is no expansion in 
GFP controls (Figure 3-2A). 
 
Having reconfirmed the superiority of the dual combination of CD80+4-1BBL 
costimulation to costimulation with either ligand individually, we wished to further 
assess the ability of the addition of IL-12 to the dual combination to allow enhanced 
proliferation of cultures. As shown in Figure 3-2B, the triple combination of CD80+4-
1BBL+IL-12 is able to significantly enhance the proliferation of cultures in response 
to OKT-3 compared to the dual stimulation. 
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Figure 3-2 Expansion of whole PBMC populations in response to OKT-3 and 
adenoviral vector directed costimulation. 1x10
6
 adherent cell depleted PBMC were 
cultured in wells of a 48 well plate with 1x10
5
 pre-infected A549 cells/well 
(expressing costimulation as detailed in the figure) for 7 days in the presence of 
100ng/ml OKT-3. A. shows fold increase of the total PBMC number  from four 
healthy lab donors (N=4) compared to day 0 cell numbers, determined by 
haemocytometer count. Standard deviation (SD) and mean are shown, paired t-test. B. 
Shows fold increase in total PBMC number for six healthy lab donors following 
culture for 7 days with A549 expressing the combination of CD80+4-1BBL±IL-12, 
paired t-test. 
3.1.4 Inclusion of IL-12 increases CD8 T cell expansion 
In order to validate the expansion of a T cell population using our combinations of 
costimulation I examined the expansion of CD4
+
 and CD8
+
 T cells in culture. The 
populations following 7 day culture were predominantly T cells (Figure 3-3A), 
looking at the type of cell which were expanding we found that the CD4
+
 T cell 
population was exhibiting minimal proliferation in response to either the dual or triple 
costimulation combinations. The majority of the expansion in response to CD80+4-
1BBL appeared to be coming from the CD8
+
 T cell population, the addition of IL-12 
further enhanced proliferation of the CD8
+
 T cell subset (see Figure 3-3). 
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Figure 3-3 Expansion of CD8
+
 and CD4
+
 T cells. 1x10
6
 adherent cell depleted 
PBMC were cultured in wells of a 48 well plate with 1x10
5
 pre-infected A549 
cells/well, (expressing costimulation as detailed in the figure following infection with 
adenoviral vectors) and 100ng/ml OKT-3 for 7 days. CD3
+
CD4
+
 and CD3
+
CD8
+
 
populations were then determined by flow cytometry (A). Total PBMC number was 
also assessed by haemocytometer and total CD4 and CD8 T cell numbers obtained, 
the expansion of these cells was then determined as fold change in comparison to the 
number present at day 0. B. shows expansion of CD8
+
 T cells, C. shows expansion of 
CD4
+
 T cells. Paired t-test. 
 
These data therefore reconfirm the superior ability of CD80+4-1BBL compared to 
either alone to enhance the expansion of a PBMC population in response to OKT-3 
stimulation. Interestingly the addition of IL-12 to the combination further enhances 
expansion, although IL-12 alone was unable to induce expansion of the PBMC 
population. This suggests additional stimulation is able to enhance expansion further. 
The CD8 T cell population was shown to be the main subset proliferating in this 
model system which was enhanced by the addition of IL-12 which is in contrast to 
previous data using this model system. 
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3.1.5 Cytokine production following costimulation 
Having shown the ability of our system to promote the expansion of T cells in 
response to antigen-mimetic OKT-3 stimulation we were also keen to infer 
functionality of these cells. In order to do this we measured production of the 
cytokines IFNγ and IL-10 by the various cultures. As shown in Figure 3-4, cultures 
stimulated with CD80+4-1BBL+IL-12 show a higher level of IFNγ compared to other 
cultures, however cultures stimulated with CD80+4-1BBL also show good levels of 
IFNγ albeit dwarfed by the effects of addition of IL-12 to the combination. IL-12 
alone induced a slightly higher levels of IFNγ production compared to CD80+4-
1BBL, mean 499.8ng compared to 254.7ng respectively, but was significantly lower 
than the combination of CD80+4-1BBL+IL-12 (mean 2115ng) (data not shown). In 
order to ensure that we were promoting a Th1 type response and to rule out the 
production of regulatory CD8
+
 T cells we also assessed the production of IL-10 
within the cultures. In comparison to IFNγ production there is very little IL-10 
produced (Figure 3-4), suggesting that these cultures contained cells predominantly of 
the Th1 subset. 
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Figure 3-4 Cytokine production by cultured PBMC. 1x10
6
 adherent cell depleted 
PBMC were cultured in wells of a 48 well plate with 1x10
5
 pre-infected A549 
cells/well (expressing costimulation as detailed in the figure following infection with 
adenoviral vectors) and 100ng/ml OKT-3 for 5 days. Supernatant was collected and 
concentrations of IFNγ and IL-10 determined by ELISA. N=3 SD. 
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3.1.6 TGF-β reduces IFNγ production but not proliferation 
As discussed in section 1.2.3 tumours and associated regulatory T cells are capable of 
producing TGF-β, which is a major immunosuppressive cytokine. To test the effect 
TGF-β may have on IFNγ production and proliferation of PBMC in response to 
costimulation, PBMC were cultured on adenovirus infected A549 with OKT-3 as 
previously described with or without the addition of 2ng/ml recombinant human TGF-
β, which had previously been shown to induce Treg (Chen et al., 2003; Zheng et al., 
2007). TGF-β has also previously been reported to inhibit cytokine production 
(Schröder et al., 2003). The effect of TGF-β on the production of IFNγ by cultured 
cells was determined by ELISA, as shown in Figure 3-5A TGF-β was able to reduce 
the production of IFNγ in response to OKT-3 and CD80+4-1BBL or CD80+4-
1BBL+IL-12 costimulation, therefore showing this concentration of TGF-β is 
sufficient to suppress function in this model system. However, as Figure 3-5B shows 
the addition of TGF-β did not inhibit expansion of the PBMC population. This 
suggests in a tumour micro environment the ability of the combination of CD80+4-
1BBL+IL-12 to stimulate cytokine production may be impaired by the presence of 
TGF-β, however overall expansion may be unaffected. Further studies would be 
required to determine further functional consequences of TGF-β or other inhibitory 
factors during T cell stimulation in the presence the active costimulatory 
combinations. As this is a highly artificial model further studies were intended to be 
carried out during assessment of viral antigen specific responses in section 3.3. 
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Figure 3-5 Effects of TGF-β on proliferation and IFNγ production by cultured 
PBMC. 1x10
6
 adherent cell depleted PBMC were cultured in wells of a 48 well plate 
with 1x10
5
 pre-infected A549 cells/well (expressing costimulation as detailed in the 
figure following infection with adenoviral vectors) and 100ng/ml OKT-3, in the 
presence or absence of 2ng/ml TGF-β. A. At 5 days of culture supernatant was 
collected and concentrations of IFNγ determined by ELISA. N=4, SD, paired t-test. B. 
Shows fold expansion of the total PBMC number following 7 days of culture from 
three healthy lab donors relative to total starting PBMC number, determined by 
haemocytometer count. 
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3.1.7 FoxP3 expression by expanded T cells 
As there have been reports of costimulatory molecules’ promoting the proliferation of 
Tregs under appropriate conditions it was of interest to determine if there was an 
effect on the Treg population. Figure 3-6A shows an example of FoxP3 staining from 
one donor and Figure 3-6B shows four out of five donors with no difference in the 
overall proportion of CD4
+
FoxP3
+
 T cells following costimulation with CD80+4-
1BBL+IL-12 or CD80+4-1BBL. 
 
As discussed, tumours tend to develop many immunosuppressive mechanisms in 
order to evade the immune system. This includes the production of TGF-β, which has 
been show to attenuate IFNγ production in our culture system. In order to further test 
the effect the costimulatory combinations of CD80+4-1BBL with or without IL-12 
may be having on a Treg population, cultures were supplemented with 2ng/ml TGF-β; 
conditions know to promote Treg generation. Following 7 day culture under these 
conditions there is a significant increase (p=0.0308) in the proportion of CD4
+
FoxP3
+
 
T cells following culture with CD80+4-1BBLA549 supplemented with TGF-β 
compared with culture without TGF-β. The addition of IL-12 to the combination 
partially ablates the TGF-β induced increase in CD4+FoxP3+ T cells. However there is 
not a statistically significant difference between the CD4
+
FoxP3
+
 population 
following culture in the presence or absence of IL-12 in cultures supplemented with 
TGF-β (Figure 3-6A and Figure 3-6C).  
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Figure 3-6 Foxp3 expression by CD4
+
 T cells in response to TGF-β. 1x106 
adherent cell depleted PBMC were cultured in wells of a 48 well plate with 1x10
5
 pre-
infected A549 cells/well (expressing costimulation as detailed in the figure following 
infection with adenoviral vectors) and 100ng/ml OKT-3 for 7 days in the presence or 
absence of 2ng/ml TGF-β. FoxP3+ expression and associated markers were then 
determined by flow cytometry as shown for one donor in A. Percentage of the total 
CD4
+
 population which are FoxP3
+
 are shown in A (bold numbers) and B. Percentage 
of total CD4
+
 population which are FoxP3
+
 in the presence or absence of 2ng/ml 
TGF-β are shown in A and C. N=5, paired t-test. 
 
The population of CD4
+
 T cells is typically reduced in cultures with CD80+4-
1BBL+IL-12A549 compared with CD80+4-1BBLA549 (p=0.0186) most likely due to 
increased proliferation of CD8
+
 T cells (3.1.4). Interestingly, in the presence of 
there is a marked increase in the proportion of CD4
+
 T cells present in cultures 
(p=>0.0001) abolishing the dominance of CD8
+
 T cells induced by the addition of 
12 (Figure 3-6A and  
Figure 3-7). 
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Figure 3-7 CD4
+
 population is increased by the addition of TGF-β. 1x106 adherent 
cell depleted PBMC were cultured in wells of a 48 well plate with 1x10
5
 pre-infected 
A549 cells/well (expressing costimulation as detailed in the figure following infection 
with adenoviral vectors) and 100ng/ml OKT-3 for 7 days in the presence or absence 
of 2ng/ml TGF-β. The percentage of CD4+ cells was determined by flow cytometry. 
N=5, SD, Paired t-test. 
 
These data suggest that the combination of CD80+4-1BBL±IL-12 does not induce or 
expand a significant CD4
+
FoxP3
+
 population in this model system. However in the 
presence of the Treg inducing cytokine TGF-β, the addition of IL-12 to the 
combination reduces the proportion of FoxP3
+
 CD4
+
 cells, suggesting the addition of 
IL-12 to a costimulatory combination maybe be important if used as an 
immunotherapy, and therefore warrants further investigation. Interestingly the 
addition of TGF-β increased the proportion of CD4+ cells in cultures stimulated with 
CD80+4-1BBL+IL-12 to levels similar to CD80+4-1BBL stimulated cultures, without 
an associated decrease in expansion of these cultures (Figure 3-5), this would suggest 
that there is a positive effect on the expansion or survival of CD4
+
 T cells. As IFNγ 
production is reduced in these cultures (as shown in Figure 3-5) to levels similar to 
CD80+4-1BBL stimulated cultures, this may suggest that the production of high 
levels of IFNγ is suppressing or having a negative effect on the CD4+ T cell 
population, contributing to the predominant expansion of CD8
+
 T cells. 
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3.2 Ovarian cancer patient responses to OKT-3 with co-
stimulation 
3.2.1 Introduction 
Ovarian cancer is highly prevalent with a lifetime incidence of 1/50 in the UK and is 
the leading cause of death from gynaecological cancers. Patient five year survival is 
low and recurrence is common. However the infiltration of lymphocytes to tumour 
has been shown to correlate with better prognosis and survival. There is therefore a 
requirement for new and novel treatment for ovarian cancer and a rational for the 
investigation of immunotherapy strategies. 
 
I was therefore keen to investigate the ability of our system to allow the expansion of 
T cells from ovarian cancer patients. Tumour associated lymphocytes were isolated 
from a sample of ascitic fluid and stimulated using our model system. Unfortunately 
these data are preliminary only, due to a lack of further samples. 
3.2.2 PBMC expansion 
Figure 3-8A shows the expansion of a total TAL population from one ovarian cancer 
patient in two independent experiments performed in duplicate. As can be seen 
CD80+4-1BBLA549 is able to allow the expansion of TAL in response to OKT-3 
stimulation, albeit at a lower level than was generally seen in healthy donors, while 
the addition of IL-12 to the combination seems to have little impact on expansion. 
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3.2.3 Cytokine production 
The general immunosuppression associated with ovarian cancer, the 
immunosuppressive environment which may exist within the tumour, and the active 
recruitment of regulatory T cells to the tumour environment could potentially lead to a 
lack of effector function, also as the cells isolated from ascetic fluid could be 
regulatory it was important to ensure that the cells which were being expanded were 
functional. Again we assayed the production of IFNγ and IL-10. As shown in Figure 
3-8B the dual costimulation produced a notable level of IFNγ whereas IL-10 remains 
virtually undetectable. The addition of IL-12 to the combination enhanced the 
production of IFNγ as was previously seen, and the levels of IL-10 remain low. 
 
Therefore we can conclude that the combination of CD80+4-1BBL is also capable of 
expanding a TAL population. As could be expected there seems to be a reduction in 
the level of expansion of TAL in response to OKT-3 compared with PBMC from 
healthy donors. This could be for a number of reasons including the age of the donor 
(57 years old), the general immunosuppression of ovarian cancer patients, or the 
health of lymphocytes isolated from ascitic fluid, or this may be due to donor 
variation. Likewise the lack of increase in expansion associated with the addition of 
IL-12 was reproducible for this donor however it is impossible to draw general 
conclusions from these data without investigation of TAL from further ovarian cancer 
patient. 
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Figure 3-8 Expansion and cytokine production of TAL isolated from an ovarian 
cancer patient. TAL were isolated from the ascitic fluid of an ovarian cancer patient 
1x10
6
 TAL were cultured in wells of a 48 well plate with 1x10
5
 pre-infected A549 
cells/well (expressing costimulation as detailed in the figure following infection with 
adenoviral vectors) and 100ng/ml OKT-3. A. Total TAL number was determined by 
haemocytometer cell count and fold change compared to the starting population 
determined, from two independent experiments in duplicate. B. IFNγ and IL-10 
concentrations in supernatant of cultures after 5 days of culture were determined by 
ELISA. 
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3.3 Costimulation of T cell Response to Viral Peptide 
3.3.1 Introduction 
Having reconfirmed the superiority of combination of CD80+4-1BBL over individual 
stimulations to allow the expansion of T cells in response to OKT-3 and shown that 
the addition of IL-12 to the combination could further enhance the proliferation of T 
cells and more specifically enhance the proliferation of CD8
+
 T cells we were keen to 
move away from the strong generic antigenic stimulus of OKT-3 to a more 
physiologically relevant antigenic response, with the ultimate goal of assessing TAA 
specific responses.  In order to assess the ability of our chosen costimulatory 
molecules to induce antigen specific responses we chose to begin by examining viral 
peptide specific responses. Primarily by using autologous adherent cells which were 
infected with combinations of adenoviral vectors 24 hours prior to loading with 
peptide and establishment of co-culture with PBMC for 7 days. Expansion of peptide 
specific T cells was tracked with tetramer. Primary human fibroblasts were also used 
in some experiments in order to allow the repeated stimulation of T cells. Fibroblasts 
were infected with combinations of adenoviral vectors 48 hours prior to loading with 
the appropriate peptide and use for stimulation of T cells. 
3.3.2 Stimulation with viral peptides results in expansion of non-T 
cells 
Initial experiments using adenoviral vector infected, peptide pulsed autologous 
adherent PBMC to stimulate a mixed population of non adherent PBMC showed that 
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in cultures stimulated with either 4-1BBL or IL-12, or to a greater degree those 
cultures combining 4-1BBL+IL-12 showed a large population and presumable 
expansion of a non-T cell (CD3
-
) population, which will be discussed in the next 
chapter. In order to remove any effect the stimulation or proliferation of a non-T cell 
population may be having on the response of peptide specific T cells, it was decided 
that a pure T cell population would be used. An untouched T cell population (above 
95% T cells) was isolated using a Miltenyi Pan T Cell Isolation Kit II; these data are 
based on a purified T cell population. As shown in Figure 2-4 adherent PBMC or 
autologous fibroblasts were infected with adenoviral vectors for 90min in suspension 
at 1x10
6
 cells/ml in wells of a 48 well plate (2.5x10
5
 cells/well). 24-48hrs after 
infection cells were peptide pulsed with 5μg of peptide for 4hrs. Media was then 
removed and unbound peptide removed by gentle washing with media. 0.5x10
6
 
isolated T cells were then added. T cell responses were assessed after 7 days of 
culture. 
3.3.3 Costimulation of adenoviral TDL peptide specific T cells 
Initial experiments began by examining the effect of adenovirus delivered 
costimulation on the proliferation of specific T cells in response to the adenovirus 
hexon derived TDL peptide. 
 
Autologous adherent cells infected with combinations of adenoviral vectors were 
peptide pulsed and used to stimulate isolated autologous T cells in a 7 day culture 
without the use of exogenous cytokines. The results for one donor are shown in 
Figure 3-9. It can be seen in the case of TDL specific CD8
+
 T cells that the 
combination of CD80+4-1BBLMono with or without IL-12 is able to induce a 
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significant population of TDL specific T cells compared with mock cultures. 
Surprisingly stimulation with 4-1BBLMono alone or in combination with IL-12 is able 
to produce similar levels of tetramer specific T cells as the combinations with the 
addition of CD80. In contrast the combination of CD80+IL-12Mono appears to produce 
the greatest population of TDL specific CD8
+
 T cells. Whereas the population in the 
Mockmono (peptide pulsed monocytes) stimulated culture had a negligible tetramer 
specific T cells population. Puzzlingly however the GFPMono control cultures show a 
marked population of TDL specific CD8
+
 T cells, only surpassed by the combination 
of CD80+IL-12Mono. The dominance of CD80+IL-12Mono and the significant 
population of tetramer specific T cells in response to GFPMono culture were seen in 
two donors in independent experiments. 
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Figure 3-9 Expansion of TDL specific T cells in response to peptide stimulation. 
0.5x10
6
 isolated T cells were cultured for 7 days with 2x10
5
 autologous adherent cells 
which had been pre-infected with appropriate adenoviral vectors 24hrs earlier and 
pulsed with TDL peptide for 4hrs prior to addition of T cells. Tetramer staining was 
then performed following 7 days of culture and analysed by flow cytometry, data 
shown are gated on the T cell lymphocyte population (CD3
+
). Bold numbers indicate 
the percentage of CD8
+
 T cells which are tetramer
+
. 
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3.3.4 Costimulation of CMV NLV peptide specific T cells 
The presence of a seemingly stimulatory effect of the GFP control virus was startling 
and inexplicable. In order to examine whether this was possibly due to the adenovirus 
vector somehow stimulating a better TDL specific recall response than stimulation 
with combinations of costimulatory molecules I chose to examine an unrelated 
peptide response. 
 
The chosen epitope was the CMV pp65 derived NLV peptide. As for the TDL 
stimulated cultures isolated T cells were stimulated with adenovirus vector infected 
autologous adherent cells for 7 days. In a different pattern to that that seen for TDL 
specific responses and in contrast to the results of stimulation with OKT-3 it can be 
seen in Figure 3-10 that stimulation with combinations of costimulatory molecules 
appear to be resulting in a smaller portion of the population being specific for 
tetramer. Stimulation with IL-12Mono or CD80Mono however results in a significant 
population of tetramer specific CD8
+
 T cells. As with the results of TDL stimulation a 
significant population of tetramer specific CD8
+
 T cells is also present in GFPMono 
cultures; in this donors case higher than any of the active costimulatory cultures. A 
similar pattern of tetramer specific CD8
+
 T cells was again seen in three donors in 
independent experiments. 
 
 
 140 
 
Figure 3-10 Expansion of NLV specific T cells in response to peptide stimulation. 
0.5x10
6 
isolated T cells were cultured for 7 days with 2x10
5
 autologous adherent cells 
which had been pre-infected with appropriate adenoviral vectors 24hrs earlier and 
pulsed with NLV peptide for 4hrs prior to addition of T cells. Tetramer staining was 
then performed following 7 days of culture and analysed by flow cytometry, data 
shown are gated on the T cell lymphocyte population (CD3
+
). Bold numbers indicate 
the percentage of CD8
+
 T cells which are tetramer
+
. 
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3.3.5 Costimulation of EBV CLG peptide specific T cells 
A third viral response was examined using the EBV LMP2 derived CLG epitope. This 
was also hoped to provide a starting point for the investigation of the effects of 
adenovirus directed costimulation on the proliferation of T cells specific for TAA, as 
EBV is associated with a number of malignancies including Burkitt's lymphoma, 
other non-Hodgkin's lymphomas, Hodgkin's disease, nasopharyngeal carcinoma and 
gastric cancer (Hsu and Glaser, 2000). 
3.3.5.1 Short term culture 
Again isolated T cells were cultured with autologous adherent PBMC infected with 
combinations of adenoviral vector for 7 days. As is shown in Figure 3-11 stimulation 
with IL-12Mono resulted in the greatest expansion of tetramer specific CD8
+
 T cells, 
while the addition of CD80 does not seem to affect proliferation in response to IL-12 
other combinations of costimulatory molecules show reduced levels of tetramer 
specific CD8
+
 T cells compared with IL-12Mono or CD80+IL-12Mono stimulation. 
Again however there is a significant tetramer positive population in GFPMono 
stimulated cultures. 
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Figure 3-11 Expansion of CLG specific T cells in response to peptide stimulation. 
0.5x10
6
 isolated T cells were cultured for 7 days with 2x10
5
 autologous adherent cells 
which had been pre-infected with appropriate adenoviral vectors 24hrs earlier and 
pulsed with CLG peptide for 4hrs prior to addition of T cells. Tetramer staining was 
then performed following 7 days of culture and analysed by flow cytometry, data 
shown are gated on the T cell lymphocyte population (CD3
+
). Bold numbers indicate 
the percentage of CD8
+
 T cells which are tetramer
+
. 
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3.3.5.2 Long term expansion 
In order to test whether the benefit of stimulation with IL-12 alone was transient, only 
allowing short term proliferation, while a combination of costimulatory molecules 
may become more important in longer term cultures, cultures were set up using 
autologous fibroblasts in place of adherent PBMC. The use of fibroblasts allowed 
repeated restimulation. Isolated T cells were stimulated with virus infected peptide 
pulsed fibroblasts on day 0 and day 14 of culture with 20U/ml of IL-2 added to 
cultures after 7 days. This method of stimulation was in accordance with the method 
used for long term culture of NK cells in section 4.2. The actual number of tetramer 
specific T cells rather than the proportion of the population which was tetramer 
specific was determined in these experiments, to allow for any changes in the non-
tetramer specific population. 
 
As can be seen in Figure 3-12 there is a benefit of 4-1BBLFibro culture between day 7 
and 14 of stimulation, with the addition of CD80 to 4-1BBL reducing the increase in 
CLG specific CD8
+
 T cells, with 4-1BBLFibro alone or in combination with IL-12 
allowing the greatest expansion. Following re-stimulation at day 14 however a 
significant decrease in the population of 4-1BBL+IL-12 Fibro or 4-1BBL Fibro stimulated 
T cells can be seen with the exclusion of CD80+4-1BBL Fibro stimulation which shows 
a marginal increase in the tetramer specific population. However again even in long 
term culture there is a baffling increase in tetramer specific T cells in the GFPFibro 
stimulated cultures which continues until day 21. 
 
Alongside the perplexing increase in tetramer specific T cells in response to FibroGFP 
stimulation it was also noted that despite initial isolation of T cells prior to culture 
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there was a significant population of non T cells becoming apparent in longer term 
proliferation (Figure 3-13). 
 
Figure 3-12 Long term expansion of CLG specific T cells. 0.5x10
6
 isolated T cells 
were stimulated with 2x10
5
 autologous fibroblasts which had been infected with 
appropriate adenoviral vectors 48hrs earlier and pulsed with CLG peptide for 4hrs 
prior to stimulation of T cells at days 0 and day 14. Cultures were supplemented with 
20U/ml IL-2 from day 7. Tetramer staining and haemocytometer counts were 
performed at days 0, 7, 14 and 21 and the total CLG tetramer specific CD8
+
 T cell 
population calculated, and expansion determined relative to the starting population. 
 
Figure 3-13 Non T cell population in long term peptide cultures. 0.5x10
6
 isolated 
T cells were stimulated with 2x10
5
 autologous fibroblasts which had been pre-
infected with appropriate adenoviral vectors 48hrs earlier and pulsed with CLG 
peptide for 4hrs prior to stimulation of T cells at days 0 and day 14. Cultures were 
supplemented with 20U/ml IL-2 from day 7. The percentages of cells staining CD3
-
 in 
cultures was determined by flow cytometry at days 0, 7, 14 and 21 of culture. 
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These results show that in contrast to initial results using OKT-3 the stimulation of 
peptide specific responses requires differing costimulatory requirements and may vary 
on the peptide antigen which is used. There is however a stimulatory effect seen in 
response to Ad-GFP suggesting adenovirus is able to stimulate T cell expansion. 
Additionally the presences of small numbers of non T cells in cultures and their 
expansion during long term culture makes interpretation of long term T cell cultures 
problematic. 
3.3.6 Ad-GFP background 
To determine whether the expansion of peptide specific T cells in response to Ad-
GFP infected cells was due directly to an effect Ad-GFP was having on the T cells or 
whether there was a possibility of Ad-GFP having an effect to stimulate the antigen 
presenting functions of the infected adherent cells, we tested the HLA-A2 restricted 
peptide NLV response comparing autologous adherent PBMC and OVCAR-3 (which 
are HLA-A2
+
) for peptide presentation. As can be seen in Figure 3-14 there is 
expansion in the NLV specific population in both cultures, thus suggesting Ad-GFP is 
having an effect on the T cell population.  
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Figure 3-14 Ad-GFP stimulate antigen specific T cells directly. 1x10
5
 OVCAR-3 
or 2x10
5
 autologous adherent cells infected with Ad-GFP 48hrs or 24hrs prior to T 
cell stimulation respectively and pulsed with NLV peptide for 4hrs were used to 
stimulate 0.5x10
6
 isolated T cells in wells of a 48 well plate. Following culture for 7 
days cells were tetramer stained and analysed by flow cytometry. Shown plots are 
gated on CD3
+
 lymphocytes. 
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I also chose to test whether the use of Ad-GFP was causing a non-specific binding of 
tetramer, to do this I cultured cells with or without peptide. As can be seen in Figure 
3-15 there is an increase in the tetramer positive population only in cultures which 
have received peptide, confirming that this is a true peptide specific response.  
 
Alternative stocks of Ad-GFP and the E1-deleted adenovirus dl312 (lacking 
exogenous transgene) were tested to rule out any contamination of the Ad-GFP stock 
with a stimulatory adenoviral vector (Figure 3-15), however all stocks tested resulted 
in an expansion of tetramer positive cells. 
 
Figure 3-15 Adenoviral vector mediated expansion of T cells is peptide specific. 
0.5x10
6
 Isolated T cells were stimulated with 2x10
5
 autologous fibroblasts pre-
infected with appropriate adenoviral vectors as detailed in the figure 48hrs prior to 
stimulation; fibroblasts were pulsed with CLG peptide or vehicle for 4hrs prior to 
stimulation. Following 7 days of culture the populations of tetramer specific T cells 
was determined by flow cytometry, shown plots are gated on CD3
+
 cells. 
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These data show that the background stimulation of antigen specific T cells is not due 
to an effect of Ad infection of monocytes stimulating APC maturation, as would also 
be suggested by fibroblast results in the preceding section. These affects are shown to 
be peptide specific, ruling out non-specific tetramer binding or effects of GFP. 
Additionally the effect of control adenoviral vector is not confined to Ad-GFP 
suggesting this is a general property of Ad infection. The use of dl312 which is 
effectively E1A
 
deleted (like all Ad vectors used), also provides evidence that this 
effect is not due to the deletion of E3 in Ad-GFP (and other vectors) as dl312 retains 
E3 (Jones & Shenk, 1979; Deryckere & Burgert, 1996). Further experiments would be 
required to determine the mechanisms responsible for the stimulatory effects of 
adenoviral infection of presenting cells; these may include the use of transwells to 
determine if this is due to cytokine production by infected cells. These data also 
suggested if future investigation of T cell stimulation is carried out other vectors such 
as lentiviral vectors may be required to provide a cleaner model system.  
3.3.7 Discussion 
I have utilised model systems initially to examine the effects of CD80 and 4-1BBL 
alone or in combination which was previously shown to be superior to either 
stimulation alone (Habib-Agahi et al., 2007). I have also added IL-12 to the 
combination in order to determine whether IL-12 would facilitate an enhancement of 
effector function. These initial experiments were conducted using OKT-3.  
 
The combination of CD80+4-1BBL was reconfirmed to enhance the proliferation of T 
cells in short term culture. The addition of IL-12 to the combination further enhanced 
proliferation of the PBMC population; I have shown that the predominant expansion 
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occurred in the CD8
+
 T cell population in response to costimulation with CD80+4-
1BBL which is enhanced by the addition of IL-12. Previous data by Habib-Agahi et 
al. (2007) showed the expansion of CD4
+
 and CD8
+
 T cells to be comparable in 
response to OKT-3; these data are therefore in contrast to the results obtained here. 
Conversely the data presented here are in accordance with numerous other reports in 
the literature showing a preference for CD8
+
 T cell expansion following 4-1BBL 
stimulation (Dawicki et al., 2004; Shuford et al., 1997). 
 
I have shown substantial IFNγ production in response to CD80+4-1BBL stimulation, 
which is increased drastically by the addition of IL-12. In a model system also 
utilising adenoviral vectors to express CD80 and 4-1BBL on autologous cells, 
Bukczynski et al. (2005) examined HIV peptide responses in uninfected healthy 
donors and early and late stage HIV infected donors. In this model system IFNγ 
produced in culture was shown to be inhibitory to the expansion of T cells from 
healthy donors; the addition of anti-IFNγ in particular augmented expansion of Flu 
peptide specific CD8
+
 T cells. Likewise perforin or IFNγ knockout mice have been 
shown to have increased CD8
+
 T cell numbers in the contraction phase of the immune 
response (Badovinac et al., 2000), while there is an increase of 30-40% in the CD4
+
 T 
cell population in IFNγ-deficient mice during a model of mycobacterial infection 
(Dalton et al., 2000). The production of IFNγ by cultured cells therefore could be 
exerting a negative effect on the proliferation of T cells in this in vitro culture system; 
As I have shown TGF-β reduces the production of IFNγ in response to costimulation, 
if IFNγ was having a negative effect on the CD4+ T cell population the increased 
population of CD4
+
 T cells may be attributed to this. However as overall expansion is 
not affected an associated negative effect would need to be exerted on the CD8
+
 T cell 
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population in this case either by TGF-β directly or through competition with the 
increased CD4 T cell population. Also as 4-1BBL has been suggested to favour the 
survival of CD8
+
 T cells it could be suggested that the predominant expansion of 
CD8
+
 T cells is due to stimulation with 4-1BBL overcoming the negative effects 
exerted by high concentrations of IFNγ in these cultures. 
 
The ability of 4-1BBL to promote the long term proliferation of T cells was 
documented previously by Habib-Agahi et al. (2007), in a comparable model system 
utilising OKT-3 or viral peptides (EBV derived RAK, CMV derived ELK and 
influenza ELR epitopes), however I was unable to show long term expansion of T 
cells. The inability to expand T cells long term was unfortunate, a number of 
possibilities have been considered; firstly the presence of replication competent virus 
within the culture has been suggested, however as I have later shown the long term 
expansion of NK cells this seems unlikely. Secondly the batch and origin of OKT-3 
will have varied, however this is impossible to test. It has been demonstrated that 
while the initial stimulation of T cells requires to be prolonged to induce activation, a 
prolonged stimulation of effector T cells results in the induction of apoptosis (Iezzi et 
al., 1998). Iezzi et al. (1998) also showed costimulation to extend the survival of T 
cells in response to extended antigenic stimulation. However in these cultures it is 
likely that costimulation will not be presented at all times due to death of presenting 
cells, in contrast OKT-3 will continue to be present. Therefore if the OKT-3 I used 
induced stronger TCR signals possibly this may have a negative effect on the long 
term expansion and survival of T cells. 
 
 151 
In the literature there are also a number of paradoxical or dichotomous results 
associated with 4-1BBL stimulation of T cells. While 4-1BBL has been documented 
to enhance T cell proliferation and survival, T cells have also been shown to be hyper-
responsive from 4-1BB deficient mouse models in response to protein and peptide 
antigen stimulation in vivo (Lee et al., 2005; Lee et al., 2006; Kwon et al., 2002). 
There have also been reports in the literature of negative effects of strong or continued 
4-1BB stimulation of T cells. Kim et al. (2005) showed in a murine model of GVHD 
that delivery of agonistic anti-4-1BB antibody reduced T cell numbers with a 
particularly strong effect on CD4
+
 T cells through the induction of AICD; Sun et al. 
(2002) also showed a similar effect in an experimental autoimmune encephalomyelitis 
model. Interestingly Sun et al. (2002) also showed that the administration of anti-4-
1BB did not significantly reduce initial expansion of CD4
+
 T cells, on the contrary 
expansion appears to be enhanced. Rather, anti-4-1BB induced AICD of these T cells 
at later time points. 
 
This raises the question whether 4-1BBL stimulation is having a negative effect on 
CD4
+
 T cell expansion or the expansion of peptide specific responses due to the high 
level ectopic expression provided by adenoviral vectors. Another difference between 
the model system used by Habib-Agahi et al. (2007) and that used within this thesis is 
the level of Ad-4-1BBL being higher here. As a higher amount of virus was used this 
may have an impact on levels of expression which may therefore impact on the 
outcome of stimulation. 
 
Therefore, while these data conflict in part with previous data by Habib-Agahi et al. 
(2007), and data in the literature, these data also fit with other data in the literature 
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which has been published regarding the preferential expansion of CD8
+
 T cells. In this 
manner these data and those in the literature show the effects of costimulation to be 
dynamic and highly complex. 
 
There are numerous reports of the expansion of Tregs in response to costimulation 
and their generation in response to TGF-β (Chen et al., 2003; Golovina et al., 2008; 
Perez et al., 2008). It was also therefore of interest to monitor the effect costimulation 
was having on a putative Treg population. Initial experiments showed very little 
difference between levels of CD4
+
FoxP3
+
 T cells in the tested culture conditions, the 
proportion of the FoxP3
+
 CD4
+ 
T cells observed was also in line with the size of the 
CD4
+
FoxP3
+
 T cell population expected in the peripheral blood of healthy donors 
(Liu et al., 2006); therefore further experiments were not carried out. The expression 
of FoxP3 as a marker of Tregs in the murine system is reliable, however it has 
become increasingly apparent that the expression of FoxP3 by human T cells is less 
dependable as a marker of Treg function as activated T cells transiently induce 
expression of FoxP3 (Allan et al., 2007; Tran et al., 2007) Therefore if further 
experiment were to be carried out more rigorous Treg phenotyping would need to be 
employed. 
 
Ultimately it was desired to characterise the response of T cells from ovarian cancer 
patients toward viral and ideally tumour associated antigens. Initial experiments 
examined the effect of costimulation on the proliferation of adenovirus TDL specific 
T cells; these data showed a superior expansion of TDL specific T cells in response to 
CD80+IL-12 costimulation compared to any other combination. This combination 
was not tested in initial OKT-3 stimulation experiments, as these initial experiments 
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were intended to assess the function of IL-12 when added to the combination of 
CD80+4-1BBL, therefore direct comparisons cannot be draw between these data. The 
presence of 4-1BBL in the combination of CD80+4-1BBL+IL-12 reduced the TDL 
specific population. This may be due to an effect on a non-specific population of T 
cells, or may be directly attributed to a negative effect of strong 4-1BBL stimulation 
as discussed. More perplexingly there was a significant population of TDL specific T 
cells seen to arise in the GFP adenovirus control cultures. Given these results it was 
important to examine the effects of costimulation on further peptide responses. These 
experiments showed the CMV and EBV derived NLV and CLG epitopes expanded to 
the greatest extent through costimulation with IL-12 alone, in contrast to TDL specific 
T cell results. Again cultures stimulated with the control Ad-GFP in place of viruses 
expressing costimulatory ligands were shown to result in a significant population of 
peptide specific T cells. Interestingly in the case of NLV the addition of IL-12 to 4-
1BBL reduce expansion compared to IL-12 alone. Likewise the addition of either IL-
12 or 4-1BBL to CD80 stimulation resulted in a drastically reduced peptide specific T 
cell population in comparison to CD80 costimulation alone, or other stimulations 
including Mock cultures. These data are intriguing, and interestingly bear some 
resemblance to data from Habib-Agahi (unpublished data); RAK and ELK specific T 
cell responses were shown to be greatest in response to CD80, combining CD80 and 
4-1BBL resulted in no advantage or a reduction in specific T cells respectively. While 
in contrast 4-1BBL alone was able to drive an ELR specific T cell response, while 
other costimulations were ineffective. Furthermore an effect of stimulation with the 
Ad-GFP control virus was also shown by Habib-Agahi (unpublished data).  
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The proliferation of antigen-specific T cell in response to control adenoviral vector 
infected cultures and differences seen in responses to combination of adenoviral 
vectors expressed costimulation is puzzling. There is no clear explanation for these 
effects; however a number of possible effects could be suggested to be mediating in 
part these results. A non-specific response to viral infection such as the production of 
type I IFN by the adenoviral infected cells may contribute to the stimulatory effects of 
Ad-GFP. Type-I interferon have been implicated in the activation, expansion and 
survival of antigen specific T cells in response to viral infection (Brinkmann et al. 
1993; Kolumam et al., 2005; Sikora et al., 2009). In contrast however type-I 
interferon’s have also in some studies been implicated in the suppression of T cell 
responses, which may be dependent on the activation state of the T cell at the time of 
IFN stimulation; antigen activated T cells may respond positively to IFN stimulation 
(Dondi et al., 2003; Gallagher et al., 2009). If T cells were responding to the viral 
infection of presenting cells this effect should in theory enhance proliferation of all 
cultures; therefore this alone cannot explain the expansion of antigen specific T cells 
in response to Ad-GFP. Alongside the stimulatory effects of costimulation negative 
effects have also been suggested. Besides the negative interaction with CTLA-4, 
(section 1.1.2.3.2.2) CD80 has been associated with the activation and expansion of 
regulatory cells (Golovina et al., 2008), which in the case of the NLV response may 
explain the negative effects of CD80; however this does not explain why these effects 
are only seen clearly in NLV responses. Zhu et al. (2007) have shown a role for 4-
1BBL in the antigen independent homeostatic expansion of T cells. The expansion of 
T cells in response to 4-1BBL in the absence of antigen may seem counter intuitive 
given the antigen induced expression of 4-1BB, however Pulle et al. (2006) showed 
the expression of 4-1BB could be induced by stimulation of memory T cells with IL-
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15. Exerting a non-specific activating stimulus driving expansion of a non-specific T 
cell population would increase competition within the cultures, possibly inhibiting 
antigen-specific T cell expansion. This is in contrast to type I interferon which would 
only expand cells stimulated with antigen. IL-12 on the other hand has also been show 
to act as a growth factor for the proliferation and homeostatic expansion of memory T 
cells (Kieper et al., 2001). A model of a potential mechanism by which Ad-GFP 
shows significant T cell stimulatory capacity is shown in Figure 3-16. A definitive 
explanation of these effects however is not possible. 
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Figure 3-16 Potential mechanisms of the superior Ad-GFP driven expansion of 
tetramer specific T cells.  
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Due to the inexplicable but reproducible effects of the GFP control virus, and the 
presence of a large population of contaminating non-T cells in longer term cultures, 
interpretation and validity of these experiments was questionable. These uncertainties 
would also hamper interpretation of further data as such further work would be 
required to explain these effects. Therefore it was decided that further attempts would 
not be made with antigen specific T cell culture allowing focus to be moved to the 
more novel aspect of stimulation of NK cell proliferation.  
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4 Results: Natural Killer Cell Stimulation 
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4.1  Short term Natural Killer cell responses to 4-1BBL and 
IL-12 
4.1.1 Introduction 
Natural killer cells are a powerful element of the immune response. As effectors, NK 
cells are known to recognise and kill tumour cells, while they have also been shown to 
coordinate immune responses. As discussed in chapter 1.2 and below, NK cells have 
been implicated in the efficacy of numerous in vivo animal immunotherapy models 
and human therapies, therefore understanding the potential effects adenoviral vector 
delivery of costimulatory molecules may have on the NK cell population is important.  
 
Expression of 4-1BB (CD137) was first documented in murine NK cells by Melero et 
al. (1998) who went on to show a requirement for NK cells for the anti-tumour 
efficacy of anti-4-1BB antibody in an in vivo murine tumour model. However, while 
NK cells were required they were not sufficient alone for efficacy. Therefore while 4-
1BB is able to induce anti-tumour responses in an NK cell-dependent manner, there 
was no direct effect on the cytolytic function of stimulated NK cell. 
 
Subsequent experiments combining 4-1BB stimulation with IL-12 stimulation through 
intratumoural adenoviral delivery, (Martinet et al., 2000) or intratumoural delivery of 
IL-12 DNA and systemic application of anti-4-1BB (Chen et al., 2000) have shown a 
synergistic effect for the combination in a colon cancer metastasis model. Through 
depletion experiments it has been shown that NK cells are also required for the 
efficacy of this combination in these model systems. These models have also 
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identified the ability of this combination, not only to allow long term survival of the 
mice, but also allow the development of an anti-tumour T cell mediated immune 
response to parental tumour through re-challenge experiments which has a 
requirement for NK cells. Importantly the combination of intratumoural gene delivery 
of IL-12 and systemic application of anti-4-1BB has also been shown to be 
efficacious in poorly immunogenic primary and metastatic melanoma models in 
which monotherapy was ineffective or showed only marginal therapeutic efficacy (Xu 
et al., 2004). 
 
In contrast to murine NK cells, little work has focussed on the role of 4-1BBL, or the 
ability of 4-1BBL to stimulate, human NK cells. Unlike murine NK cells, human NK 
cells do not express 4-1BB in response to IL-2 stimulation without further activation 
(e.g. PHA) (Imai et al., 2005; Lin et al., 2008). K562 cells which alone are able to 
activate NK cells were genetically modified by Imai et al. (2005) to express 4-1BBL 
and an IL-15R-CD8α (transmembrane domain of CD8) construct. NK cells were 
cultured in media containing low dose IL-2 (10U/ml) for 7 days. Unmodified K562 
were shown to induce a 2.5 fold expansion, while K562 modified to express 4-1BBL 
or IL-15 resulted in greater expansion of NK cells from some but not all donors. The 
combination of both resulted in consistently improved expansion, with a median 
expansion of 1089-fold following 3 weeks of culture. Cultured NK cells were shown 
to express higher levels of CD56 but similar levels of CD16, KIR and inhibitory 
receptors compared to the starting population, suggesting that all subsets had 
expanded, retaining the immunophenotypic diversity of the NK cell pool rather than 
targeting specific subsets. Lin et al. (2008) were able to show the induction of 4-1BB 
expression in response to the ligation of CD16 by immobilised Fc fragments (but not 
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by non-immobilised antibody), expression was transient becoming undetectable after 
72hrs. Interestingly expression of 4-1BB was shown to be inversely correlated with 
CD16 expression. 
 
Despite the knowledge that 4-1BB is expressed by human NK cells in response to 
activation there is very little work focusing on the role of 4-1BBL or its potential 
application for the expansion or activation of NK cells for immunotherapy. The work 
by Imai et al. (2005) and the subsequent work by the same group (Fujisaki et al., 
2009b) is the only relevant work which has been performed to investigate the 
potential of 4-1BBL as a NK cell-directed therapeutic. However, their system is 
directed toward the ex vivo expansion of NK cells. We were therefore keen to 
investigate the ability of adenovirus delivered 4-1BBL and IL-12 to expand human 
NK cell, with its potential to allow intratumoural delivery and activation of NK cells. 
4.1.2 Natural Killer cells proliferate in response to 4-1BBL and IL-
12 in autologous cultures 
As reported in the previous chapter (3.3.2) I initially observed an increase in the non-
T cell population in culture when using autologous monocytes to deliver 4-1BBL or 
IL-12 to PBMC. As NK cells are known to express 4-1BB and previous data from 
mouse and human studies suggested that NK cells are able to proliferate in response 
to 4-1BBL stimulation, and IL-12 is known to induce proliferation of NK cells 
(Kobayashi et al., 1989), I examined the presence of NK cells in cultures following 7 
day stimulation with autologous monocytes infected with adenovirus vectors. 
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As can be seen in Figure 4-1 there is a significant population of NK cells (CD3
-
CD56
+
) in cultures stimulated with CD80+4-1BBL+IL-12Mono, or CD80+4-1BBL 
Mono, or 4-1BBL Mono alone. In contrast, stimulation with CD80 Mono alone or GFP Mono 
results in a very small population of NK cells in these cultures. This pattern is 
consistent with the pattern of non-T cells seen in culture (data not shown). Note these 
results are from preliminary experiments following on from the OKT-3 response 
model, prior to use of an isolated T cell population. Thus only a limited range of 
costimulatory molecule combinations were used, however these data show that a large 
population of NK cells were produced in response to some combinations of 
costimulation which promoted further study.  
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Figure 4-1 NK cell population following culture on autologous adenoviral vector 
infected adherent PBMC. 2.5x10
5
 adherent PBMC were pre-infected with 
adenoviral vectors as detailed in the figure 24hrs prior to addition of 0.5x10
6
 
autologous adherent cell depleted PBMC. Following culture for 7 days cultures were 
stained to determine CD3 and CD56 populations and analysed by flow cytometry. 
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4.1.3 Natural Killer cell proliferation is masked in the presence of 
OKT-3 
Previously we observed the dominance of T cells within cultures stimulated with 
OKT-3; however in the absence of OKT-3 (i.e. when using peptides) there appeared 
to be a sizable proliferation of the NK cell population. To assess whether the strong 
antigenic stimulation of the whole T cell population by the use of OKT-3 was 
masking the effect of costimulation on the NK cell population, cultures were tested in 
parallel in the presence or absence of 100ng/ml OKT-3. A549 cells were infected with 
adenovirus vectors to express CD80+4-1BBL with or without IL-12 and GFP as a 
negative control, this combination was chosen as NK cells had been shown to 
proliferate in response to this combination of costimulation while these combinations 
had also been shown to allow the highest level of T cells proliferation.  
 
As can be seen in Figure 4-2 stimulation with OKT-3 and cells expressing CD80+4-
1BBL+IL-12A549 and CD80+4-1BBLA549 results in T cells dominating the culture as 
was previously observed. Whereas in the absence of OKT-3 CD80+4-1BBLA549 
stimulated cultures can be seen to have a sizable non-T cell population, while the 
addition of IL-12 to the combination markedly skews the proportions of the 
population towards non-T cells dominating the culture. These cells were also shown 
to be CD56
+
 (data not shown) and therefore were NK cells. These data show that the 
presence of OKT-3 in earlier experiments masked or suppressed the proliferation of a 
non-T cell population, which are NK cells. 
 
 165 
 
Figure 4-2 NK cell proliferation in the presence and absence of OKT-3. 0.5x10
6
 
adherent cell depleted PBMC were stimulated with 1x10
5
 pre-infected A549 (with the 
appropriate adenoviral vectors) in the presence (clear) or absence (red) of 100ng/ml 
OKT-3. Following 7 day culture CD3 cell populations were analysed by flow 
cytometry. 
 
 166 
4.1.4 Short term proliferation of Natural Killer cells 
It now appeared that the proliferation of Natural Killer cells in response to stimulation 
through Adenoviral vector delivery of 4-1BBL and/or IL-12 was the predominant 
effect in the absence of the strong antigenic stimulus of OKT-3. In order to further test 
the ability of our chosen costimulatory molecules to ‘costimulate’ the proliferation of 
NK cells, OVCAR-3 were infected, singly or with combinations of Ad-CD80, Ad-4-
1BBL and Ad-IL-12, or Ad-GFP (as a control for adenovirus), or OVCAR-3 alone 
(Mock). After 48h, adherent cell-depleted PBMC were added at a final concentration 
of 0.5x10
6
/ml, and cultures were assayed after a further seven days. 
 
As shown in Figure 4-3A, following stimulation of adherent cell-depleted PBMC 
there was little to no proliferation of T cells (CD3
+
CD56
-
) in response to any 
stimulation. There was however a small increase in the number of cells resembling 
NKT cells (CD3
+
CD56
+
) in response to costimulatory combinations containing either 
4-1BBL or IL-12. The combination of 4-1BBL+IL-12 further enhanced the 
proliferation of NKT-like cells. Although it can not be ruled out that these cells may 
be activated T cell, as CD56 may be expressed on T cells when activated (Kelly-
Rogers et al., 2006). 
 
While there is a notable proliferation of NKT-like cells in response to co-stimulation 
with 4-1BBL or IL-12 the predominating effect appears to be the proliferation of 
Natural Killer cells (CD3
-
CD56
+
), which again is enhanced by the combination of 
both costimulatory molecules. As there was little stimulation of proliferation of 
Natural Killer or NKT cells by Ad-CD80 above background subsequent experiments 
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used only Ad-4-1BBL and Ad-IL-12 alone or in combination, with Ad-GFP (as 
control for adenovirus), or OVCAR-3 alone (Mock). Following further experiments 
with further healthy donors, Figure 4-3B shows that the mean expansion of NK cells 
in response to 4-1BBL+IL-12OVCAR was 27 fold while stimulation with 4-1BBLOVCAR 
or IL-12OVCAR alone induced a 10 fold and 12 fold expansion respectively. While 
there is apparent variation between donors in terms of fold change the pattern for all 
donors tested held true with the proliferation of NK cells in response to the 
combination of 4-1BBL+IL-12 far exceeding the proliferation of NK cells in response 
to either alone. 
 
Therefore the stimulation of a PBMC population in the absence of the strong TCR 
stimuli of OKT-3 results in a significant expansion of NK cells in response to 4-1BBL 
and/or IL-12.  As this combination has shown promise in murine tumour 
immunotherapy models, in a NK cell dependent manner (Chen et al., 2000; Martinet 
et al., 2000; Xu et al., 2004), but remains novel for the stimulation of human NK cell 
responses, and as very little was know about the role or effects of 4-1BBL stimulation 
of NK cells we were keen to investigate the effects of this combination further. 
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Figure 4-3 Quantification of expansion of T, NKT and NK cells in short term 
culture with costimulation. 0.5x10
6
 Adherent cell depleted PBMC were stimulated 
with 1x10
5
 pre-infected OVCAR-3 for 7 days. Cultures were counted by 
haemocytometer and populations determined by flow cytometry. Lymphocyte 
populations were defined as T cells CD3
+
CD56
-
, NKT cells CD3
+
CD56
+
 and NK 
cells CD3
-
CD56
+
. A. Expansion of T, NKT and NK cells from 5 healthy lab donors, 
expressed as fold change compared to the starting population at day 0. B. Expansion 
of NK cells expressed as fold change compared to the starting population at day from 
14 healthy lab donors. SD, paired t-test. 
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4.1.5 Functionality of Short term Cultures 
While stimulation of NK cells was able to induce their proliferation it was also 
important to evaluate the functionality of these cells. The two major roles for Natural 
Killer cells in an immune response centre on their ability to produce cytokines and 
show cytotoxicity toward sensitive targets. IFNγ is a major cytokine in the host 
immune response, and is involved in Th-1 polarisation as well as having anti-tumour 
effects (Bird et al., 1998; Grogan et al., 2001). GM-CSF has a role in the generation 
of DCs, and is required for the NK cell induced maturation of DCs (Zhang et al., 
2007). Both of these cytokines may be produced by NK cells and are of direct 
functional relevance.  
4.1.5.1 Cytokine Production 
The ability of the cultures to produce IFNγ and GM-CSF was tested by ELISA; 
following 7 days of culture, cells were counted and re-suspend at 0.5x10
6
cells/ml in 
fresh medium. After overnight culture, the medium was tested for the presence of 
IFNγ and GM-CSF. Figure 4-4A shows that cultures stimulated with either 4-
1BBLOVCAR and/or IL-12OVCAR alone produce far higher levels of IFNγ than the 
GFPOVCAR or MockOVCAR control, however 4-1BBLOVCAR stimulated cultures produce 
far lower amounts of IFNγ than those stimulated with IL-12OVCAR alone or in 
combination with 4-1BBL. Figure 4-4B shows that cultures stimulated with either 4-
1BBLOVCAR and/or IL-12OVCAR are superior in their production of GM-CSF, 
compared to controls. However in contrast to IFNγ production, cultures stimulated 
with 4-1BBLOVCAR alone or in combination with IL-12 produce higher levels of GM-
CSF than IL-12OVCAR stimulated cultures. Therefore while stimulation with either 4-
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1BBL or IL-12 alone promotes differential cytokine production by cultures, 4-
1BBL+IL-12 in combination is able to promote the most robust overall production of 
these important cytokines. 
 
Figure 4-4 Production of IFNγ and GM-CSF by short term cultured cells. 
0.5x10
6
 Adherent cell depleted PBMC were stimulated with 1x10
5
 pre-infected 
OVCAR-3 cells for 7 days. Cultured cells were then re-suspended at 0.5x10
6
 cells/ml 
in fresh media and cultured overnight. Concentrations of IFNγ (A) and GMCSF (B) in 
overnight culture supernatants was then analysed by ELISA. N=6 and N=5 
respectively. 
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While these experiments demonstrate the ability of stimulated cultures as a whole to 
produce cytokine we could not be certain of the origin of the cytokines produced, 
therefore in order to assess the producers of IFNγ in culture, intracellular staining was 
performed. As can be seen in Figure 4-5, IFNγ production is not limited to a single 
cell type but is induced in the majority of NK cells, NKT-like cells and a subset of T 
cells following stimulation with either 4-1BBL or IL-12 alone or in combination. 
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Figure 4-5 Analysis of IFNγ producing populations by intracellular staining. 
0.5x10
6
 Adherent cell depleted PBMC were stimulated with 1x10
5
 OVCAR-3 cells 
(pre-infected with adenoviral vectors as detailed in right hand legend), for 7 days. 
Cultured cells were then incubated for 4hr in the presence of 10μg/ml brefeldin A and 
then assessed by intracellular staining for the production of IFNγ. Left hand panels are 
gated on CD3
+
 cells, right hand panel gated on CD3
-
 cells, staining for CD56 
expression defines T cells (CD3
+
CD56
-
), NKT cells (CD3
+
CD56
+
)  and NK cells 
(CD3
-
CD56
+
) as detailed in the lower two panels. 
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4.1.5.2 Cytotoxicity 
Cytotoxicity was tested using the NK sensitive cell line K562 in a standard 5 hour 
chromium release assay. As shown in Figure 4-6 mock stimulated cultures showed 
virtually no cytotoxicity at any effector:target ratios tested. Interestingly, the 
GFPOVCAR stimulated cultures showed higher levels of cytotoxicity compared to mock 
cultures. 4-1BBL stimulated cells however showed clearly increased cytotoxicity at 
all ratios, in excess of 60% specific lysis at an effector:target ratio of 33:1. 
 
While 4-1BBL+IL-12OVCAR stimulated cultures show the highest level of cytotoxicity 
towards K562, IL-12 stimulated cells have a similar level of cytotoxicity to the dual 
stimulated cultures at the highest ratio tested, however at lower ratios cytotoxicity was 
slightly reduced.  
 
The testing of NK cell function was of importance to indicate potential efficacy of this 
combination for tumour immunotherapy. This has become particularly pertinent 
following the reports of Baessler et al. (2010) of a negative effect of 4-1BBL 
stimulation of NK cells. Within this model system NK cells are cytotoxic and capable 
of producing IFNγ. 
 
 174 
 
Figure 4-6 Cytotoxicity following short term culture. 0.5x10
6
 Adherent cell 
depleted PBMC were stimulated with 1x10
5
 pre-infected OVCAR-3 cells for 7 days. 
Cultured cells were then assessed for cytotoxicity against K562 targets in a standard 
5hr chromium release assay (SD). Data shown are representative of four healthy 
donors. 
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4.1.6 Phenotype of Natural Killer cells following short term culture 
Previously it had been shown that the expansion of NK cells through the K562-4-
1BBL-IL15 expansion system resulted in an expansion of the whole population 
without a skewing effect in terms of subsets or receptor expression (Imai et al., 2005). 
Given the functional differences in the subsets of NK cells we wished to elucidate the 
effect of stimulation with our costimulatory molecules delivered by adenovirus on the 
subsets of NK cells. 
 
Through staining of CD56 during our initial studies of NK cell proliferation I noted 
that the majority of the NK population were CD56
bright
 by the seventh day of culture 
as shown in Figure 4-7A and Figure 4-7C, which is in contrast to proportion of these 
cells at Day 0. I therefore wished to determine if these cells displayed further 
phenotypic markers consistent with the CD56
bright
 subset. One of the major hallmarks 
dividing the CD56
dim
 and CD56
bright
 subsets is high level expression or absence of 
CD16 respectively. As can be seen in Figure 4-7B and Figure 4-7C the NK cells 
which have been stimulated with 4-1BBL+IL-12OVCAR are predominantly CD16
-
, 
which is also the case for cultures stimulated with either 4-1BBL or IL-12 alone, 
while cells in the control cultures predominantly retain expression of CD16. 
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Figure 4-7 Expression of CD56 and CD16 following short term culture. 0.5x10
6
 
adherent cell depleted PBMC were stimulated with 1x10
5
 pre-infected OVCAR-3 
cells (infected with adenoviral vectors expressing costimulation as indicated) for 7 
days. Following 7 day culture the population of NK cells (CD3
-
CD56
+
) obtaining a 
CD56
bright
 (A) or CD16 negative (B) phenotype was assessed by flow cytometry. SD 
and mean are shown. C. shows representative plots of CD56
bright
CD16
-
 NK cell 
populations following culture (gated on NK cells (CD3
-
CD56
+
). 
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I also assessed the expression of other CD56
bright
 subset markers. As shown in Figure 
4-8 there is also a clear acquisition of CD25 expression by stimulated cells consistent 
with the CD56
bright
 subset, however the majority of NK cells lack the expression of 
CD27. 
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Figure 4-8 Expression of CD25 and CD27 following short term culture. 0.5x10
6
 
Adherent cell depleted PBMC were stimulated with 1x10
5
 pre-infected OVCAR-3 
cells (infected with adenoviral vectors expressing costimulation as indicated) for 7 
days. Following culture, expression of CD25 by the CD56
+
 cell population was 
determined (A); or expression of CD27 analysed on CD56
bright
 lymphocytes (B) by 
flow cytometry. SD and mean are shown. An example of CD25 (C) and CD27 (D) 
staining of CD56
+
 and CD56
bright
 cells respectively are shown. E shows CD27 staining 
of CD56
-
 cells. Stained cells are shown shaded red, black fill indicates isotype control 
staining. 
 
 179 
CD56
bright
 and CD56
dim
 NK cells are also reported to have a differential expression of 
homing markers. I therefore examined the expression of secondary lymphoid homing 
markers CCR7 and CD62L as shown in Figure 4-9. Although all three of the active 
stimulatory conditions induced similar percentages of CCR7
+
 and CD62L
+
 cells, 
marked differences were apparent in the levels of CD62L induced, with the MFI of 
NK cells stimulated with 4-1BBLOVCAR being substantially lower than induced by IL-
12OVCAR alone or in combination with 4-1BBL. 
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Figure 4-9 Expression of CCR7 and CD62L by short term cultured NK cells. 
0.5x10
6
 Adherent cell depleted PBMC were stimulated with 1x10
5
 pre-infected 
OVCAR-3 cells (infected with adenoviral vectors expressing costimulation as 
indicated) for 7 days. Expression of CCR7 (A) and CD62L (B) was determined as a 
percentage of the NK population (CD3
-
CD56
+
) or MFI of CD62L staining (C). SD 
and mean are shown. D. shows plots of CCR7 and CD62L staining. Gated on the NK 
cell population (CD3
-
CD56
+
). 
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I also stained for the expression of inflammatory site homing markers CCR5 and 
CXCR3 (Figure 4-10). Again there appears to be a disparity in expression of these 
molecules between the stimulations. IL-12OVCAR stimulation results in a greater 
proportion of cells expressing CCR5 than in all other stimulations, while 4-
1BBLOVCAR results in no difference compared with controls. Interestingly in 4-
1BBL+IL-12OVCAR stimulated cultures 4-1BBL results in an attenuation of the 
expression of CCR5 induced by IL-12 alone resulting in a significantly lower 
population of CCR5 expressing cells. The opposite appears to be true for the 
expression of CXCR3 with the levels of CXCR3 being similar to controls in the IL-
12OVCAR stimulated population whereas 4-1BBLOVCAR clearly results in an increased 
expression of CXCR3, which is partially reversed by the addition of IL-12 as seen in 
the dual stimulated cultures. As can be seen in Figure 4-10 MFI was used to assess 
expression of CXCR3 while percentage of the NK population was used for CCR5, 
this was necessary as staining of CXCR3 did not generally produce a clear positive 
and negative population rather showing a shift of the population as a whole. 
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Figure 4-10 Expression of CCR5 and CXCR3 following short term culture. 
0.5x10
6
 Adherent cell depleted PBMC were stimulated with 1x10
5
 pre-infected 
OVCAR-3 cells (infected with adenoviral vectors expressing costimulation as 
indicated) for 7 days. Expression of CXCR3 was determined and presented as MFI of 
the NK population (CD3
-
CD56
+
) (A) which is normalised to the background staining 
of the 2
o
 antibody control. Expression of CCR5 (B) by the CD56
bright
 population was 
also determined by flow cytometry. Mean, SD, paired t-test. C shows a clear example 
of CXCR3 expression in response to stimulation, (gated on the NK population (CD3
-
CD56
+
)). D shows CCR5 staining of the CD56
bright
 population following culture, red 
indicates staining, black shows isotype control staining. 
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These data show that the majority of NK cells following stimulation with the active 
costimulatory molecules are of the CD56
bright
 subset. The lack of CD27 however is in 
contrast to other markers of the CD56
bright
 subset which were tested. As CD27 is a 
marker of effector function this may be reflective of the activation of these cells rather 
than as a subset marker (Appay et al., 2002; Hayakawa and Smyth, 2006; Tomiyama 
et al., 2004; Marzo et al., 2007). The expression of homing markers such as CCR7 
and CD62L is in accordance with the CD56
bright
 phenotype, and also suggests that in 
vivo cells stimulated with 4-1BBL and/or IL-12 may be able to home to secondary 
lymphoid tissue, where NK cells may have important roles in the activation of T cell 
based immune responses (Mailliard et al., 2003; Marcenaro et al., 2005; Garcia-Sastre 
and Biron, 2006). The expression of CXCR3 by 4-1BBL stimulated cultures and the 
ability of 4-1BBL to partially retain CXCR3 expression with IL-12 stimulation is a 
novel finding and as CXCR3 has also been implicated in homing to tumour (Wendel 
et al 2008), including renal cell carcinoma, potentially important to function (Cozar et 
al., 2005). 
4.1.7 Natural Killer cell proliferation characteristics 
4.1.7.1 Natural Killer Proliferation is delayed following stimulation 
The lack of CD16 expression by cultured cells and other markers, including the 
acquisition of a CD56
bright
 state, would suggest that CD56
bright
 NK cells are being 
produced in response to stimulation. There were therefore two possibilities; either 
these stimulatory conditions were selectively inducing proliferation of the CD56
bright
 
population or a transition of CD56
dim
 NK cell to a CD56
bright
 NK cell was taking 
place. 
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To try and identify the subset of NK cells in the original samples which were 
proliferating in response to 4-1BBL and IL-12, non-adherent PBMC were labelled 
with CFSE and cultured for 5 days. Cells were stained for CD56 and CFSE dilution 
analysed on day 1, 3 and 5 after stimulation. However, surprisingly the data did not 
show proliferation of a specific subset following stimulation. As Figure 4-11 shows, 
no proliferation took place by day 3 of stimulation rather proliferation was delayed 
until between day 3 and day 5 of stimulation. In the period between stimulation and 
proliferation the level of CD56 expression can be seen to be increasing in response to 
4-1BBL and IL-12, prior to the production of CD56
bright
 cells following proliferation. 
 
This suggests that a population of CD56
dim
 cells is able to transition to express similar 
levels of CD56 as CD56
bright
 NK cells. The subsequent proliferation of CD56
bright
 cells 
may suggest that a population of CD56
dim
 cells can become CD56
bright
 and proliferate. 
This is interesting as CD56
dim
 cells are suggested to be a mature subset derived from 
the CD56
bright
 subset which is regarded as immature (Cooper et al., 2001, Juelke et al., 
2010). Therefore the production of CD56
bright
 cells from CD56
dim
 required further 
investigation. 
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Figure 4-11 Time course of NK cell proliferation by CFSE. 0.5x10
6
 Adherent cell 
depleted PBMC isolated from a healthy lab donor were labelled with CFSE and 
stimulated with 1x10
5
 pre-infected OVCAR-3 cells (infected with adenoviral vectors 
expressing costimulation as indicated). Panel A provides explanation of CD56 
expression levels and changes which occur following culture. B shows expression of 
CD56 and CFSE dilution analysed on day 1 (red), 3 (green) and 5 (blue) of culture by 
flow cytometry. Shown is CFSE (X axis) and CD56 (Y axis), representative plots of 
at least 3 donors. 
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4.1.7.2 Acquisition of a CD56bright phenotype prior to proliferation 
In order to assess the phenotypic changes of stimulated NK cells further the dynamics 
of the NK cell population phenotype during the first five days of culture (i.e. up to the 
start of proliferation) expression of CD56 and CD16 was analyses at days 1, 3 and 5 
of culture. As shown in Figure 4-11A there is a population of cells appearing to 
transition to a CD56
bright
CD16
-
 phenotype, firstly by loss of CD16 then increased 
CD56 expression in response to stimulation with either IL-12±4-1BBL. A 
significantly increased population of CD56
bright
CD16
-
 is present following 
proliferation at day 5 of culture, again showing that the main subset of cells produced 
in response to 4-1BBL+IL-12 are of the CD56
bright
 subset. Note Mock stimulated 
cultures did not differ significantly from GFP stimulated cultures therefore are not 
shown for clarity.  
 
Examining expression of CD56 further reveals that NK cells stimulated with IL-
12OVCAR or 4-1BBL+IL-12OVCAR show as a population an increase in the expression 
of CD56 prior to proliferation of CD56
bright
 cells as seen in Figure 4-11. In contrast to 
this there appears to be a very modest increase in the levels of CD56 following 
stimulation with 4-1BBL OVCAR, prior to proliferation, but following proliferation, 
there is a notable increase in CD56 levels (Figure 4-12A and B). 
 
Analysis of the expression of CD16 during the same time period, as shown in Figure 
4-12C shows a steady lost of CD16 in response to stimulation with IL-12OVCAR alone 
or in combination with 4-1BBL, with a notable population of cells lacking CD16 prior 
to significant proliferation. However with 4-1BBLOVCAR stimulation there is again 
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little change in CD16 expression until after the onset of proliferation. This again 
suggests that a population of CD56
dim
 cells is able to transition to a CD56
bright
 NK cell 
and may proliferate. In order to investigate this further CD56
dim
 cells were separated 
and CD56 expression and proliferation analysed in subsequent experiments (4.1.7.5). 
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Figure 4-12 Time course of  CD56 increase and loss of CD16 by cultured NK 
cells. 0.5x10
6
 Adherent cell depleted PBMC were stimulated with 1x10
5
 pre-infected 
OVCAR-3 cells expressing costimulation as indicated. Expression of CD56 and 
CD16 was measured at day 0, 1, 3 and 5 of culture by flow cytometry (A), (gated on 
NK cells (CD3
-
CD56
+
)) upper right panel indicates gates shown. Expression levels of 
CD56 (B) were also measured as MFI of the NK population (CD3
-
CD56
+
) by flow 
cytometry and the fold change from the starting population (day 0) determined at day 
1, 3 and 5 of culture (N=6, SD). The loss of CD16 expression was also determined at 
days 1, 3, and 5 of culture (C) as a percentage of the NK population appearing CD16
-
  
by flow cytometry (N=3, SD). 
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4.1.7.3 Natural Killer cells are rapidly activated 
To test whether NK cells were firstly showing a delay in activation and secondly 
whether NK cells were able to respond to stimulation during the period prior to the 
proliferation, NK cells were stained for CD25 and 4-1BB expression, both of which 
are activation markers. 
 
As Figure 4-13A and B shows, CD25 is rapidly induced by 4-1BBL and IL-12 alone 
or in combination. The dual combination rapidly induces CD25 by day 1 to a level 
which is maintained on day 3 prior to proliferation, however the dynamics of 
expression appear to be slower in single stimulation, IL-12OVCAR begins to induce 
CD25 on day 1 which increases by day 3 to a level similar to the combination. A 
similar pattern is seen with 4-1BBLOVCAR stimulated cells albeit to a lower level. 
 
Figure 4-13A and C show the dynamics of 4-1BB expression to be similar to 
expression of CD25 across all stimulations, with induction by day 1 which is 
increased by day 3. IL-12 stimulation alone or in combination induces similar levels 
of 4-1BB expression. As with CD25, the percentage of 4-1BB
+
 cells induced by 
stimulation with 4-1BBLOVCAR is lower than that induced by IL-12OVCAR. 
 
Therefore while NK cells do not proliferate during the initial period of stimulation 
this is not due to an inability to respond to stimulation. This may suggest that the 
proliferation of NK cells is delayed due to a requirement to attain a ‘proliferative’ 
state rather than the primary effector function of NK cells. As a report has suggested 
NK cells degranulate prior to 4-1BB expression (Lin et al., 2008) and NK cells 24hrs 
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post-4-1BBL stimulation show reduced effector function (Baessler et al., 2010), the 
response to and effects of 4-1BB stimulation require further investigation. 
 
Figure 4-13 Time course of CD25 and 4-1BB expression by cultured NK cells. 
0.5x10
6
 Adherent cell depleted PBMC were stimulated with 1x10
5
 pre-infected 
OVCAR-3 cells (infected with adenoviral vectors expressing costimulation as 
indicated), Expression of CD25 and 4-1BB was then determined by flow cytometry at 
day 0 (black), 1 (blue), 3 (green) and 5 (red) of culture (A), plots are gated on NK 
cells (CD3
-
CD56
+
). The percentage of the NK cell population expressing CD25 (B) or 
4-1BB (C) in response to stimulation was also assessed for three healthy lab donors 
SD. 
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4.1.7.4 Natural Killer Cells require additional ‘Help’ in order to respond to 4-
1BBL 
It appeared paradoxical that 4-1BBL stimulation was able to induce phenotypic 
changes, including down regulation of CD16, and up regulation of CD56, CD25 and 
its own receptor 4-1BB, even though at the outset the proportion of cells expressing 4-
BB was negligible. Therefore I wondered whether NK cells may express undetectable 
levels of 4-1BB allowing them to respond to 4-1BBLOVCAR or whether there may be a 
role for an accessory cell, capable of responding to 4-1BBLOVCAR, stimulating the 
expression of 4-1BB by NK cells. 
 
In order to test this NK cells were separated from PBMC by negative isolation with a 
Miltenyi kit, purified NK cells or total PBMC were then stimulated with OVCAR-3 
infected with Ad-4-1BBL or Ad-IL-12 as a positive control for three days. As can be 
seen in Figure 4-14A, purified NK cells do not express 4-1BB to levels seen in PBMC 
cultures following stimulation with 4-1BBLOVCAR, and more closely resemble the 
control culture, suggesting the response of a secondary cell type is required for 4-1BB 
induction. 
 
As this suggested NK cells were inducing 4-1BB expression through a secondary cell 
type, possibly by the production of cytokine, I wished to assess whether NK cells 
were inducing 4-1BB in response to IL-12 stimulation through activation by IL-12 or 
whether IL-12 was allowing NK cells activated by targets to express 4-1BB. PBMC 
were therefore stimulated with either OVCAR-3, GFPOVCAR, or without additional 
targets in the presence or absence of 20ng/ml rhIL-12, or IL-12OVCAR as a positive 
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control. Cells stimulated in the absence of rhIL-12 do not express 4-1BB in response 
to OVCAR-3 with or without Ad-GFP (as was shown previously), nor is 4-1BB 
expression induced in the presence of rhIL-12 alone; however NK cells in the 
presence of both targets and rhIL-12 are able to express 4-1BB (Figure 4-14B). 
 
Figure 4-14 4-1BB expression by isolated NK cells requires help. 0.5x10
5
 
negatively isolated NK cells (NK) or 0.5x10
6
 adherent cell depleted PBMC (PBMC) 
were cultured with 1x10
5
 OVCAR-3 cells (pre-infected with the appropriate 
adenoviral vectors) for 3 days and percentage of the NK cell population (CD3
-
CD56
+
) 
expressing 4-1BB determined (A and B). Isolated NK cells were also cultured alone 
or in the presence or absence of recombinant human IL-12 (rhIL-12) or OVCAR-3 
cells without adenoviral vector infection (MockOVCAR) or with Ad-IL-12 (IL-12OVCAR) 
or Ad-GFP (Ad-GFPOVCAR) infection, for 3 days and expression of 4-1BB by the NK 
cell population analysed by flow cytometry (C). SD, paired t-test. 
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These data therefore show that in contrast to the induction of 4-1BB on T cells in 
response to strong TCR stimulation, NK cells require a combination of signals to 
promote 4-1BB expression. In this system target recognition, likely provided by the 
allogenic nature of OVCAR-3 cells or potentially ligation of activating receptors by 
ligands expressed by OVCAR-3, is likely to be providing a ‘first signal’. A secondary 
signal in the form of IL-12 or another cytokine produced by accessory PBMC 
(possibly IL-15 for example) is then required for full activation and responsiveness to 
4-1BBL stimulation as shown in Figure 4-15.  This could be an important 
consideration for the use of 4-1BB stimulation of NK cell for cancer immunotherapy. 
The actual activating signals which are required for NK cell 4-1BB responsiveness 
and the role and requirement for different cytokines in the activation of NK cells is an 
interesting point requiring further investigation. 
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Figure 4-15 Requirements for 4-1BB expression by NK cells. In the absence of 
sufficient activation signals (either activating ligands or missing self) tolerance is 
maintained. When sufficient activating signals are achieved NK cells perform effector 
functions, however further activation is not achieved. Through the recognition of 
target and provision of ‘help’ by an unknown accessory cell increased activating 
signals are achieved and 4-1BB is expressed allowing further activation. In the 
absence of accessory cells ‘help’ can be provided by IL-12. 
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4.1.7.5 Proliferation of CD56dim NK 
In order to evaluate the proliferation of the two subsets of NK cells (CD56
bright
 and 
CD56
dim
) a Miltenyi CD56
+
CD16
+
 NK Cell Isolation Kit was used to isolate cells 
which were classically CD56
dim
 (i.e. CD3
-
CD56
dim
CD16
+
) (Figure 4-16) and also 
allowed the enrichment of the CD56
bright
CD16
-
 population. The isolated cells were 
subsequently CFSE labelled and cultured with OVCAR-3 expressing 4-1BBL+IL-12 
or IL-12 alone. OVCAR-3 with 4-1BBL alone was not included as I have shown 
additional stimulation is required for isolated NK cells to be responsive to 4-1BBL. 
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Figure 4-16 Purification of CD56
dim
 NK cells. Using a Miltenyi CD56
+
CD16
+
 cell 
isolation kit NK cells were first enriched by negative isolation. Subsequently cells 
were positively selected by CD16 microbeads with a Miltenyi CD56
+
CD16
+
 cell 
isolation kit. Shown are CD3 and CD56 staining of the lymphocyte population and 
CD16 staining of the NK (CD3
-
CD56
+
) population following positive selection of 
CD16
+
 cells. 
 
I was first interested to assess whether CD56
dim
 cells were able to proliferate in 
response to IL-12OVCAR with or without 4-1BBL. When NK cells of the CD56
bright
 and 
CD56
dim
 subset are compared by CFSE the cells dividing in both groups appear to 
also undergo CFSE dilution (Figure 4-17A). Whether CD56
dim
 cells could transition 
to a CD56
bright
 state was also examined, as can be seen in Figure 4-17B there is a 
small minority of CD56
dim
 cells which appear to increase levels of CD56 expression 
following stimulation with IL-12OVCAR with or without 4-1BBL on the third day of 
stimulation. Subsequently the proportion of the CD56
bright
 cells increases by the 
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seventh day of culture with IL-12OVCAR and is markedly increased following 
stimulation with 4-1BBL+IL-12OVCAR.  
 
Figure 4-17 Analysis of CD56
dim
 NK cell proliferation and expression of CD56 in 
culture. NK cells were negatively isolated and further selected on the basis of CD16 
expression to provide CD56
bright
 (CD16
-
) and CD56
dim
 (CD16
+
) NK cell populations 
which were labelled with CFSE. 0.5x10
5
 NK cells were then cultured with 1x10
5
 
OVCAR-3 cells (pre-infected with adenoviral vectors) for 7 days. Dilution of CFSE 
by isolated CD56
bright
 (Black) and CD56
dim
 (red) NK cells was then analysed by flow 
cytometry (A). The expression of CD56 by isolated CD56
dim
 NK cells was analysed 
on days 0 (shaded grey), 3 (green), and 7 (red) of culture (B).  
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In order to validate the transition of a CD56
dim
CD16
+
 cell to a CD56
bright
 cell type, the 
presence of CD56
bright
CD16
-
 cells was assessed in cultures following 7 day 
stimulation. As can be seen in Figure 4-18 there is a notable population of CD56
bright
 
cells following stimulation with IL-12OVCAR, while stimulation with 4-1BBL+IL-
12OVCAR results in the majority of cells becoming CD56
bright
. The expression of CD16 
shows a similar pattern with the combination of 4-1BBL+IL-12OVCAR producing a 
large population of CD16
-
 cells, while IL-12OVCAR alone does not show such marked 
production of CD16
- 
cells. A similar pattern is also seen with expression of CD62L. 
Therefore these data suggest that 4-1BBL+IL-12OVCAR is facilitating a switch from a 
CD56
dim
 to a CD56
bright
 cell. The ability of 4-1BBLOVCAR alone or the requirement for 
IL-12 in this process however could not be assessed. 
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Figure 4-18 CD56
bright
 NK cells are produced in response to 4-1BBL and IL-12. 
NK cells were negatively isolated and CD56
dim
 (CD16
+
) NK cells positively selected 
on the basis of CD16 expression. 0.5x10
5
 CD56
dim
 NK cells were then cultured with 
1x10
5
 OVCAR-3 cell (pre-infected with adenoviral vectors) for 7 days. Expression of 
CD56, CD16 and CD62L were then determined by flow cytometry at day 7 of culture, 
expression by the starting population at day 0 is shown as shaded grey. 
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These data definitively show a population of CD56
dim
 NK cells can proliferate and 
become CD56
bright
. Therefore these data are important for the understanding of NK 
cell biology, showing that the differentiation of CD56
dim
 to CD56
bright
 is not a 
unidirectional process. Therefore the CD56
bright
 and CD56
dim
 NK cells cannot be 
regarded as immature and mature stages of the same cell population. 
4.2 Long Term Proliferation of Natural Killer Cells 
4.2.1 4-1BBL allows Long Term Proliferation of Natural Killer 
Cells 
As 4-1BBL is known to promote the long term survival and proliferation of T cells, it 
was of considerable interest to investigate whether the use of adenovirus directed 
‘costimulation’ with 4-1BBL alone or in combination with IL-12 would also permit 
the long term expansion of Natural Killer cells. Following the initial 7 day stimulation 
with Ad-infected OVCAR-3, the lymphocytes were counted and redistributed with the 
inclusion of 20U/ml IL-2. Following a further 7 days of culture populations were 
again counted and analysed, cultures were then re-stimulated with OVCAR-3 pre-
infected with appropriate adenovirus vectors for a further 7 days. This system of 
stimulation was settled on to give the best proliferation of NK cells while avoiding the 
use of excessive recombinant cytokines. IL-2 was found to improve proliferation; 
however the population was able to proliferate at a reduced level in the absence of IL-
2 (data not shown). As NK cells were by this stage beginning to dominate the 4-
1BBL+IL-12OVCAR cultures and as NK cells are incapable of producing IL-2, it 
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seemed reasonable to add exogenous cytokine as in vivo T cells would presumably be 
present in a true immune response to provide a source of IL-2.  
 
Figure 4-19 shows the proliferation of Natural Killer cells over a period of 3 weeks. 
IL-12OVCAR stimulated cultures were unable to continue to proliferate to a significant 
degree (mean 64 fold expansion) following the initial burst of proliferation in the first 
week. Cultures stimulated with 4-1BBLOVCAR proliferated to a similar level to IL-
12OVCAR stimulated cultures over the first 7 days however the 4-1BBLOVCAR 
stimulated cultures continued to proliferate (mean 259 fold expansion at day 21). As 
with short term cultures, the combination of 4-1BBL+IL-12OVCAR again showed a 
significant enhancement of proliferation in long term culture, compared with either 
alone (mean 1076 fold expansion at day 21). The control cultures generally 
diminished to untenable levels by day 14. These data clearly show 4-1BBL is required 
and capable of inducing the long term expansion of NK cells. This is the first clear 
demonstration of the ability of 4-1BBL alone to induce the long term expansion of 
NK cells, and the first demonstration of the long term expansion of NK cells in 
response to 4-1BBL+IL-12. 
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Figure 4-19 Long term proliferation of NK cells in response to costimulation. 
0.5x10
6
 non-adherent PBMC were cultured for 7 days, with 1x10
5
 OVCAR-3 cells 
(pre-infected with adenoviral vectors) and expansion of NK cells calculated by flow 
cytometry and haemocytometer. Cultures were then redistributed and IL-2 added to a 
final concentration of 20U/ml. Expansion was then determined again at day 14 of 
culture by haemocytometer count and flow cytometry. Cultures were then re-
stimulated with 1x10
5
 OVCAR-3 cells pre-infected with the appropriate adenoviral 
vectors in the continued presence of IL-2 and expansion determined again at day 21 of 
culture. N=5, SD, paired t-test. 
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4.2.2 Cytokine Production and Cytotoxicity of Long Term Cultures 
Following culture for 21 days the ability of the cultured cells (predominantly NK 
cells) to show effector functions was again characterised.  
 
Cultures were again adjusted to 0.5x10
6
cells/ml and cultured overnight. The 
production of IFNγ was then assessed by ELISA. As can be seen in Figure 4-20A 4-
1BBL stimulated cultures  continue to produce IFNγ although this is overshadowed 
by the amount of IFNγ produced by IL-12 stimulated cultures, as was seen in short 
term culture. As control cultures diminish by this time point no direct comparison can 
be made to these cultures, however the pattern for the stimulated cultures remains 
similar to that in short term culture. 
 
The cytotoxicity of cultures against K562 targets was also characterised by Cr release 
assay, as shown in Figure 4-20B the cultures continue to be cytotoxic with the 
presence of IL-12 in cultures allowing a higher degree of cytotoxicity to be attained. 
 
As mentioned in section 4.1.5 the assessment of the ability of 4-1BBL to support NK 
cell effector functions is highly pertinent. It is of interest and importance that 
stimulated cultures are able to maintain effector function during long term 
stimulation. 
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Figure 4-20 IFNγ production and cytotoxicity by long term cultured cells. PBMC 
(predominantly NK cells) cultured for 21days with stimulation with OVCAR-3 cells 
pre-infected with adenoviral vectors at day 0 and 14 were re-suspended in fresh 
media, cells were then cultured o/n at 0.5x10
6
 cells/ml and production of IFNγ 
determined by ELISA (N=5, SD), production of IFNγ by day 7 GFP stimulated 
cultures is also shown for comparison (A). Cytotoxic function of day 21 cultured cells 
was also tested in a standard 5hr chromium release assay against K562 targets (SD) 
(B). 
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4.2.3 4-1BBL does not enhance survival of Natural Killer cells 
As we have shown the ability of 4-1BBL to facilitate the long term proliferation of 
NK cells and given 4-1BBL is known to facilitate the long term expansion and 
maintenance of T cells by allowing increased survival I chose to examine whether 4-
1BBL was facilitating the long term expansion of NK cells through a reduction in cell 
death. 
 
To do this I examined the presence of live, apoptotic and necrotic NK cells within 
cultures at day 7, 10 and 14 with the use of Syto 16 and PI staining. The SYTO dyes 
are cell permeable but essentially non-fluorescent until bound to nucleic acids. Thus 
when combined with PI staining allows the identification of live cells which have a 
full DNA content and intact cell membranes, Syto 16
bright
PI
-
. While apoptotic cells 
have reduced or absent Syto 16 staining but retain membrane integrity excluding PI, 
and necrotic cells are Syto 16
-
PI
+
. The gating strategy used for Syto-16 staining is 
shown in Figure 4-21A. 
 
Initial staining at day 7 revealed a stark reduction in the survival of control cultures 
compared with those stimulated with 4-1BBL and/or IL-12 which were also actively 
proliferating at this stage (Figure 4-21B and Figure 4-21C). There is however no 
difference seen between the 4-1BBLOVCAR stimulated cultures and the IL-12OVCAR 
stimulated culture. Comparing 4-1BBLOVCAR stimulated cultures to IL-12OVCAR 
cultures at day 10 and 14 there is again no difference between these cultures (Figure 
4-21C). 
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Figure 4-21 Viability of cultured NK cells. 0.5x10
6
 adherent cell depleted PBMC 
were cultured with 1x10
5
 OVCAR-3 cells (pre-infected with the appropriate 
adenoviral vectors) for 7 days, after which time 20U/ml IL-2 was added to cultures. 
The viability of NK cells was determined by Syto-16 and PI staining flow cytometry 
assay, as shown in A. cells were first selected by forward scatter and CD56
+
 cells and 
subsequently gated on the CD3
-
 population. NK cells staining Syto-16
+
PI
-
 were 
termed live, double negative cells were proposed to be apoptotic and Syto-16
-
PI
+
 cells 
necrotic. An example of day 7 staining from one donor is shown in B.  Results from 
six healthy lab donors from day 7, 10 and 14 of culture are shown in C. Cultures were 
supplemented with 20U/ml at day 7-14 of culture. SD. 
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As these cultures had been cultured in accordance with the long term expansion 
model with the addition of 20U/ml IL-2 at day 7, I also tested whether the presence of 
IL-2 may be masking a protective effect for 4-1BBL in NK cell survival. However as 
shown in Figure 4-22, IL-2 improved the viability of the control cultures, but had no 
significant effect on the viability of cultures stimulated with IL-12 and 4-1BBL alone 
and in combination, therefore suggesting 4-1BBL does not increase the survival of 
NK cells in contrast to T cells. 
 
Figure 4-22 Viability of expanded NK cells in the presence or absence of IL-2. 
0.5x10
6
 adherent cell depleted PBMC were cultured with 1x10
5
 OVCAR-3 cells (pre-
infected with the appropriate adenoviral vectors) for 7 days, after which time cells 
were cultured in the presence or absence of 20U/ml IL-2. NK cells viability was then 
determined by Syto-16 and PI staining at day 14 of culture. N=2, SD. 
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This shows 4-1BBL does not provide a survival advantage to NK cells, allowing their 
continued expansion. This may suggest that in contrast to T cells, NK cell stimulation 
by 4-1BBL allows increased or continued proliferation. This would be in accordance 
with the data of Fujisaki et al. (2009) who showed 4-1BBL+IL-15 stimulation of NK 
cells does not increase Bcl-2 family members. However it should be noted that as 
cells are gated on CD56 it may be that a proportion of necrotic cells may be missed 
during gating, a purified NK cell population may allow a more accurate measurement 
of necrotic cells in culture to be obtained, i.e. remove the requirement to gate on an 
antibody stained NK cell population. 
4.3 Expansion of Natural Killer cells from Renal Cell 
Carcinoma patients  
4.3.1 Introduction 
We have shown the ability of 4-1BBL and IL-12 to activate and induce the short and 
long term proliferation of NK cells, and the beneficial effects of a combination of 
both 4-1BBL and IL-12. However this has been based on the responses of NK cells 
derived from healthy lab donors. I therefore wished to investigate the potential 
applicability of this finding for the stimulation of anti-tumour immune responses in 
cancer patients. 
 
Renal cancer is the seventh most common cancer diagnosis in men and the ninth most 
common in women, with the peak incidence between 60-70 years of age. The 
incidence of renal cancer has increased over the past 65 years by 2% per year with an 
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estimated 54,390 new cases and 13,010 deaths expected in 2008. Prognosis is poor, 
30% of patients present with metastatic disease, and 20 to 30% of patients with 
clinically localized disease will develop metastatic disease after nephrectomy, having 
a variable 5-year survival rate that is generally less than 2% and a median survival of 
less than 1 year. However, even with the licensing of small molecule drugs such as 
the tyrosine kinase inhibitor Sorafenib, and the use of targeted therapies such as 
Bevacizumab, the treatment choice is still limited. IL-2 therapy remains the first 
choice therapy for most patients following nephrectomy, producing response rates 
between 10 to 20%. Therefore new therapies for the treatment of renal cancer are 
important and desirable (Reeves and Liu 2009; Rini, 2009).  
 
NK cells are present in the majority of RCC tumours. Conversely tumour infiltrating 
NK cells lack cytotoxic function, however following in vitro stimulation with IL-2 
NK cells derived from tumour are capable of killing autologous tumour (Schleypen et 
al., 2003; Schleypen et al., 2006). Therefore there is rational for the activation of NK 
cells for immunotherapy of RCC. Additionally the use of adenoviral vector delivered 
costimulation may be particularly appropriate for RCC therapy as the majority of 
TAA epitopes identified are expressed uniquely by individual tumours (Geiger et al., 
2009). 
 
In order to test the ability of our system to produce an immune response from renal 
cell carcinoma patients, blood, tumour and normal kidney tissue was collected from 
such patients at the time of first treatment (i.e. nephrectomy). Non-adherent PBMC 
were isolated and stimulated with OVCAR-3 infected with adenoviral vectors as for 
health controls. 
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4.3.2 Short term expansion of Natural Killer Cells derived from 
RCC patients 
Examining the short term expansion of NK cells derived from RCC patients the 
pattern of proliferation seen in healthy lab donors is maintained as shown in Figure 
4-23, albeit to a lower level than seen in healthy donors, with 4-1BBLOVCAR and IL-
12OVCAR able to induce proliferation of NK cells (mean 4 and 5 fold respectively), 
while the combination 4-1BBL+IL-12OVCAR enhances this proliferation (mean 18 fold 
expansion). 
 
Figure 4-23 Short term proliferation of RCC patient NK cells in response to 
costimulation. 0.5x10
6
 adherent cell depleted PBMC from different RCC patients 
were cultured with 1x10
5
 OVCAR-3 cells (pre-infected with the appropriate 
adenoviral vectors) for 7 days. NK cell expansion was determined by haemocytometer 
count and flow cytometry and expressed as fold change compared to the starting 
population. SD, paired t-test. 
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4.3.2.1 Comparison of Healthy and RCC Patient Natural Killer Cell Responses 
Comparison of the proliferation of NK cells derived from healthy donors and RCC 
patients reveals a significant defect in the proliferation of NK cells derived from RCC 
patients compared to healthy donors in response to stimulation, as shown in Figure 
4-24.  
 
Figure 4-24 Comparison of RCC patient and healthy lab donor NK cell 
expansion in short term culture. Data from section 4.1.4 and section 4.3.2 are 
presented. SD, student t test. 
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4.3.3 Functionality of Short Term Culture 
Having shown that our system could expand NK cells from RCC patients we wished 
to determine whether these stimulated cultures were also capable of effector 
functions. To do this we again assessed the production of IFNγ by ELISA and 
cytotoxicity by killing of K562 targets in a standard five hour chromium release 
assay. 
 
As shown in Figure 4-25A cultures which had been stimulated for 7 days then re-
suspended at 0.5x10
6 
cells/ml and cultured overnight produced large amounts of IFNγ 
in response to stimulation with IL-12OVCAR or 4-1BBL+IL-12OVCAR, however 
stimulation with 4-1BBLOVCAR alone did not induce IFNγ production to levels which 
were significantly different to control cultures. This latter finding was in contrast to 
the production seen in healthy controls. 
 
In contrast to IFNγ production, stimulation with either 4-1BBL or IL-12 alone or in 
combination resulted in similar levels of killing of K562 targets, which were 
significantly greater than the control stimulated cultures (Figure 4-25). 
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Figure 4-25 IFNγ production and cytotoxicity by short term cultured RCC 
patient PBMC. 0.5x10
6
 adherent cell depleted PBMC derived from RCC patients 
were cultured with 1x10
5
 OVCAR-3 cells (pre-infected with the appropriate 
adenoviral vectors) for 7 days. Cells were re-suspended in fresh media, and tested for 
either overnight production of IFNγ at 0.5x106 cells/ml by ELISA (A) (N=5), or 
cytotoxicity in a standard 5hr chromium release assay against K562 targets (B). 
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4.3.4 Short term Expansion of Natural Killer Cells Derived from 
an Ovarian cancer patients 
As shown for one ovarian cancer patient in section 3.2 our model system allowed the 
expansion of TAL from the ascitic fluid of an ovarian cancer patient. I was also able 
to test the expansion of NK cells derived from there ovarian cancer patient, as shown 
in Figure 4-26, NK cells can be expanded from these donors in a pattern similar to the 
expansion seen in healthy and RCC donors.  
 
Another patient sample was also tested during the initial stages of the NK expansion 
work using autologous adherent cells isolated from ascitic fluid. An increase in the 
percentage of CD3
-
CD56
+
 cells was seen in agreement with later data, however the 
actual expansion of these cells could not be enumerated due to technical issues with 
the CD56 antibody used (data not show). 
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Figure 4-26 Expansion of tumour-associated T, NKT and NK cells isolated from 
ovarian cancer patients. 0.5x10
6
 TAL isolated from the ascitic fluid of three ovarian 
cancer patients were cultured with 1x10
5
 OVCAR-3 cells (pre-infected with 
appropriate adenoviral vectors), for 7 days. Expansion of T, NKT and NK cells was 
determined by haemocytometer cell count and flow cytometry at day 7 of culture, and 
expressed as a fold change compared to the starting population. 
4.3.5 Long Term Expansion of Natural Killer Cells from RCC 
Patients 
Having shown that our system could expand NK cells from RCC patients, albeit to a 
lower level than healthy donors, we wished to assess whether RCC patient NK cells 
could continue to expand in long term culture and whether there would also be a 
defect in long term proliferation. NK cells were therefore cultured as for healthy 
donor long term culture. As shown in Figure 4-27 the combination of 4-1BBL+IL-12 
was able to allow long term expansion of RCC patient NK cells (mean 431 fold 
expansion at 21 days), however in contrast to healthy donors 4-1BBL alone was 
unable to allow long term proliferation of RCC patient NK cells, expanding to levels 
not dissimilar to IL-12OVCAR stimulated cultures (33 fold and 15 fold expansion at 21 
days respectively). 
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Figure 4-27 Long term expansion of RCC patient derived NK cells. 0.5x10
6
 non-
adherent PBMC from six RCC patients were cultured for 7 days with 1x10
5
 OVCAR-
3 cells (pre-infected with appropriate adenoviral vectors), and expansion of NK cells 
calculated by flow cytometry and haemocytometer. Cultures were then redistributed 
and IL-2 added to a final concentration of 20U/ml. Expansion was then determined 
again at day 14 of culture by haemocytometer count and flow cytometry. Cultures 
were then re-stimulated with 1x10
5
 OVCAR-3 cells (pre-infected with the appropriate 
adenoviral vectors) in the continued presence of IL-2 and expansion determined again 
at day 21 of culture. N=6, SD. 
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4.3.5.1 Comparison of Healthy and RCC Patient Natural Killer Cell Responses 
Figure 4-28 compares the expansion of NK cells from healthy donors and RCC 
patients, in response to long term culture as previously described. Stimulation of RCC 
patient PBMC with 4-1BBLOVCAR gave only a mean ~33 fold expansion, almost 
~10% that seen in healthy donors, likewise IL-12OVCAR also gave very little 
expansion. The combination of 4-1BBL+IL-12 gave a mean expansion of ~430 fold 
of NK cells from RCC patients; this was ~40% that of the expansion achieved in 
healthy donors. The advantage of the combination of 4-1BBL+IL-12 for stimulation 
of NK cell proliferation was therefore greater in the RCC patients. 
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Figure 4-28 Comparison of RCC patient and healthy lab donor NK cell 
expansion in long term culture. Data from section 4.2.1 and section 4.3.5 are 
presented. SD, student t test. 
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4.3.6 RCC Patient NK can express 4-1BB 
As RCC patient NK cells show relatively poor responses to 4-1BBLOVCAR alone in 
short or long term culture we wished to determine whether RCC patient NK cells 
were capable of expressing 4-1BB in response to stimulation.  
 
RCC patient PBMC were cultured with OVCAR-3 as for standard short term culture, 
then analysed at day 3 for the expression of 4-1BB on NK cells in response to 
stimulation. As shown in Figure 4-29 NK cells are able to induce expression of 4-
1BB. Expression was induced to the greatest extent following stimulation with IL-
12OVCAR, while expression in response to 4-1BBL+IL-12OVCAR or 4-1BBLOVCAR 
showed variation between the donors tested, but overall showed a slightly reduced 
expression of 4-1BB, perhaps due to the ligation of the receptor in these cultures.. 
Therefore the reduced responsiveness of RCC patient NK cell to 4-1BBLOVCAR cannot 
be attributed to a lack of expression of 4-1BB. 
 220 
 
Figure 4-29 Expression of 4-1BB by RCC patient NK cells. 0.5x10
6
 adherent cell 
depleted PBMC isolated from RCC patients were stimulated with 1x10
5
 OVCAR-3 
cells (pre-infected with appropriate adenoviral vectors). Expression of 4-1BB was 
determined by flow cytometry as a percentage of the NK population (CD3
-
CD56
+
) 
after 3 days of culture (A), mean is shown. B shows plots of 4-1BB staining at day 3 
of culture, gated on NK cells (CD3
-
CD56
+
). 
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These data show that in a similar manner to healthy donors RCC patient NK cells are 
able to respond to 4-1BBL+IL-12 stimulation for short and long term expansion; 
although at a reduced level compared to healthy donors. Whether the reduction in 
expansion is due to the age of these donors or whether the immunosuppressed nature 
of cancer patients has reduced the responsiveness of these cells has not been 
determined. The requirement for 4-1BBL and IL-12 interestingly agrees with results 
from a murine model system using a poorly-immunogenic tumour model where only 
the combination of 4-1BBL+IL-12 could reject tumour, in an NK cell dependent 
manner (Xu et al., 2004). Therefore suggesting that 4-1BBL in combination with IL-
12 or another cytokine may be required for efficacy as an immunotherapy, and 
therefore warrants further investigation. 
4.3.7 Killing of autologous tumour cells 
As we have been able to show that the combination of 4-1BBL+IL-12 is able to 
induce the expansion of functional NK cells from RCC patients, assessing the ability 
of these NK cells to recognise and kill autologous tumour was of significant 
importance. 
 
At the time of blood collection tumour and normal margin was also collected from 
patients therefore it was possible to match patients to autologous tumour and a 
negative control, while K562 could provide a positive control. PBMC were cultured 
as before for 7 days, at which point tissue which had been dissociated and 
cryopreserved could be used in a standard five hour chromium release assay. 
Unfortunately due to the small number of tumour cells recovered, only an 
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effector:target ratio of 10:1 could be used for tumour and ‘normal’ margin, whereas 
the K562 control was performed at a 1:1 ratio to conserve effectors. 
 
As shown in Figure 4-30A, cells cultured with costimulation were able to efficiently 
kill K562 targets, while little cytotoxicity was seen with GFP and mock controls. 
Reassuringly no cultures showed detectable levels of killing of ‘normal’ cells. 
However due to wide variation in results the level of tumour cell killing could not be 
reliably determined.  
 
The assay involving tumour was confounded by a high background level of 
51
Cr 
release, resulting in a wide error margin in which low levels of killing could be 
masked. Also the population may contain cells which are not tumour cells, therefore 
reducing the number of valid targets. We therefore chose to attempt to grow out 
tumour cells in vitro. Following culture for 2-3 weeks, cells were used as targets for a 
five hour chromium release assay. Following culture we were able to detect 
cytotoxicity against cultured tumour cells by 7 day cultured PBMC, with cells 
cultured in the presence of 4-1BBL providing the highest level of killing, however 
following culture there was also a similar level of killing of ‘normal’ cells (Figure 
4-30B). 
 223 
 
Figure 4-30 Killing of autologous target cells by short term cultured RCC patient 
derived PBMC. 0.5x10
6
 adherent cell depleted PBMC isolated from RCC patients 
were stimulated with 1x10
5
 OVCAR-3 cells (pre-infected with appropriate adenoviral 
vectors). After 7 days cultures were used as effectors in standard chromium release 
assays against autologous cells isolated from normal and tumour tissue used as 
targets. Target cells were either cryopreserved (A) until the 7
th
 day of culture of 
PBMC or cultured alongside PBMC cultures (B). SD. 
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The ability of cultured NK cells in my experiments to retain self tolerance against 
‘freshly’ isolated normal tissue is encouraging, it is unfortunate that for technical 
reasons the ability of these cells to recognise ‘freshly’ isolated autologous tumour 
could not be reliably tested. Further experiments will be required to investigate this 
further. 
4.3.8 Discussion 
These experiments are the first to study the responses of NK cells to a combination of 
4-1BBL+IL-12 within a human system, and add to the limited data available 
regarding the response of human NK cells to 4-1BB stimulation. I have been able to 
show that 4-1BBL or IL-12 alone can induce the expansion of NK cells derived from 
healthy and RCC patients in short term culture, additionally 4-1BBL is able to 
promote long term expansion of healthy donor NK cells. The combination of 4-
1BBL+IL-12 however has been shown to be superior to either stimulation alone in 
short and long term culture in healthy lab donors and RCC patient samples. In 
contrast to healthy lab donors RCC patient NK cells were shown to require a 
combination of 4-1BBL+IL-12 to promote long term proliferation. Importantly the 
expanded NK cells have also been shown to be functional; the combination of 4-
1BBL+IL-12 stimulation resulting in superior cytokine production. 4-1BBL+IL-12 
stimulated NK cells also possessed potentially beneficial homing potential, i.e. the 
potential to home to tumour via CXCR3 and also secondary lymphoid tissue through 
expression of CCR7 and CD62L. These data highlight the requirement for a 
combination of stimuli for effective immunotherapy strategies. 
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I have also shown the favoured expansion of a CD56
bright
 NK cell population, 
including the differentiation of CD56
dim
 NK cells to CD56
bright
 NK cells. These data 
add to the knowledge of the complex relationship of the CD56
bright
 and CD56
dim
 
subsets. 
4.3.8.1 Proliferation and phenotype of NK cells 
From phenotyping data it has been shown that the majority of expanded NK cells are 
of the CD56
bright
 subset. These data are in contrast to those reported by the Campana 
group using a K562 model system stably expressing 4-1BBL and IL-15. No 
preference was shown in that system in terms of subset or receptor diversity, however 
CD56 levels were increased (Fujisaki et al., 2009b; Imai et al., 2005). In contrast to 
data from the Campana group Loza and Perussia (2004) showed IL-12 could induce 
the acquisition of a CD56
bright
 phenotype from NK cells cultured for 5 days; this 
phenotype was stable in the presence of IL-12. Therefore the use of IL-12 rather than 
IL-15 may explain the difference in reported phenotypes following culture. 
 
Of particular interest I have also provided data which show that a proportion of 
CD56
dim
 NK cells are able to transition to a CD56
bright
 phenotype. The derivation and 
relationship of these two subsets is an area which has yet to reach a consensus. 
Currently there are a number of studies showing, in different systems, the conversion 
of CD56
bright
 to CD56
dim
 and vice versa, such as the work mentioned by Loza and 
Perussia (2004), or work by Chan et al. (2007) showing differentiation to a CD56
dim
 
phenotype following culture with synovial fibroblasts. A number of markers have 
been suggested to identify different subsets of NK cells, such as the presence or 
absence of CD27. CD27 has been identified to be differentially expressed by human 
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NK cells with CD56
bright
 NK cells predominantly expressing CD27 while it is absent 
in most CD56
dim
 NK cells. CD27 was initially identified to subdivide murine NK cells 
into functional groups analogous to those of CD56
dim
 and CD56
bright
 cells in humans 
(Hayakawa and Smyth, 2006; Vossen et al., 2008). However I found the NK cells 
which were expanded to be predominantly CD27
-
 characteristic of the CD56
dim
 
phenotype, this is in contrast with other phenotypic makers tested. Loss of CD27 
however is also a marker for the acquisition of effector function in T cells (Appay et 
al., 2002; Tomiyama et al., 2004; Marzo et al., 2007). However study of CD27 
expression on NK cell subsets has been performed on resting NK cells; therefore as 
other markers are in accordance with the CD56
bright
 phenotype it may be possible that 
these cells are losing CD27 not as a marker of the CD56
dim
 subset but rather as a 
consequence of activation and cytotoxic potential. Indeed the absence of CD27 was 
shown in the previous study to be associated with increased cytolytic function 
(Hayakawa and Smyth, 2006). 
 
The expression of high or low density CD94 was recently shown to divide the 
CD56
dim
 subset into two distinct subsets, CD94
low
 possessing classical CD56
dim
 
properties of cytotoxicity and minimal cytokine production, whereas the CD94
high
 
population showed increased IFNγ production (albeit lower than CD56bright NK cells) 
while retaining cytotoxicity. The CD94
high
 CD56
dim
 subset of NK cells also 
differentially expressed other markers such as CD62L. These data were suggested to 
show an intermediary state during the transition of the CD56
bright
 cell to CD56
dim
. 
However there is no evidence to exclude the possibility of transition in the alternate 
direction. Likewise, these data do not show an actual change toward a CD56
dim
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phenotype, therefore the differential expression of CD94 may be marking further 
subdivisions in the NK cell population. 
 
More convincingly Chan et al. (2007) showed a proportion (~30%) of a population of 
sorted CD56
bright
 cells could become CD56
dim
, with associated changes in function, 
following culture with synovial fibroblasts. This process was contact dependent, and 
was not seen with other culture conditions including IL-2 and IL-15. Intriguingly 
differentiation was partially inhibited by a FGFR-I blocking antibody; FGFR-I is able 
to bind NCAM i.e. CD56. Surprisingly the acquisition of a CD56
dim
 phenotype was 
not associated with division. 
 
The CD56 dim and bright subset have also been found to possess differential lengths 
of telomeres with the CD56
dim
 population having shorter telomeres, which suggests a 
history of higher proliferation and given the lower proliferative potential ascribed to 
the CD56
dim
 population these data have suggested CD56
dim
 NK cells are a more 
mature form of NK cell than the CD56
bright
 subset (Ouyang et al., 2007). However, the 
differential telomere length of CD56
dim
 and CD56
bright
 NK cells is in contrast with the 
data of Chan et al. (2007) showing differentiation to a CD56
dim
 cell in the absence of 
proliferation, i.e. if CD56
bright
 NK cells are becoming CD56
dim
 without proliferation 
telomere length should be maintained. 
 
The observation of a population of CD56
dim
 NK cells which can transition to a 
CD56
bright
 phenotype and proliferate may suggest 4-1BBL+IL-12 is capable of 
‘rejuvenating’ CD56dim NK cells to allow further proliferation. This is particularly 
pertinent as 4-1BBL is capable of reactivating and inducing proliferation of 
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‘exhausted’ T cells (Bukczynski et al., 2003; Waller et al., 2007). 4-1BB signalling is 
able to induce the expression of telomerase by activated T cells, it would be 
interesting to determine if telomerase is expressed by NK cells in response to 4-1BBL 
stimulation; the expression of telomerase by NK cells could provide a mechanism by 
which 4-1BBL is able to promote expansion of NK cells in long term culture, with 
stimulation by IL-12 increasing the responsiveness of NK cells to 4-1BBL by 
increasing 4-1BB expression. 
 
These data and the literature suggest human NK cells are a complex heterogeneous 
population. Likewise it could be suggested all NK cells are derived from a single 
progenitor with not only divergent activating and inhibitory receptor expression but 
also variable functional abilities, dependent upon signals received during 
development. As I show given appropriate signals NK cells are able to alter subtypes. 
Perhaps these data and the literature suggest clonal NK cells can acquire both ‘helper’ 
and ‘effector’ status in a similar manner as is ascribed to CD4 and CD8 T cells, 
whether these NK cells can also ultimately form memory however is currently 
debated (Cooper and Yokoyama, 2010). A potential model for this is show in Figure 
4-31. The occurrence of subset transitions and the functional consequences during 
infection would be interesting to elucidate. 
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Figure 4-31 NK cell activation in an immune response. CD56
dim
 NK cells kill 
targets, and become activated, 4-1BB stimulation promotes a CD56
bright
 cell type 
transition. Following homing to lympnodes these NK cells could carry out 
immunoregulatory functions and proliferate, forming a population of NK cells with 
appropriate receptor diversity to recognise the current target. The expanded NK cells 
may persist and show enhanced secondary responses.  
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4.3.8.2 Expression of 4-1BB by NK cells 
While it has been shown previously that NK cells can induce the expression of 4-1BB 
following activation, the model systems used have relied upon culture with IL-2 (Imai 
et al., 2005; Lin et al., 2007). Interestingly 4-1BB was shown in a recent study to be 
expressed in response to IL-2 or IL-15 stimulation alone. However the NK cells used 
in this study were a polyclonal population cultured for 10 days with 50U/ml IL-2 
(Baessler et al., 2010). In my experiments the absence of exogenous cytokines during 
short term culture has allowed the identification of a requirement for ‘help’ from other 
PBMC (possibly T cells) in order for NK cells to express 4-1BB and therefore 
respond to 4-1BBL. Previously it has been documented that NK cells require CD8
+
 T 
cell help in a murine model system, for the rejection of P815 mastocytoma tumours 
(Shanker et al., 2007). These data therefore add further to the knowledge of the 
interactions of the immune system and the importance of a comprehensive activation 
of the immune system to generate an effective immune response. It would be of 
interest to investigate this area further. 
4.3.8.3 Long term expansion of NK cells 
Consistent with short term culture data I have shown that a combination of 4-
1BBL+IL-12 stimulates increased expansion of NK cells in long term culture (21 
days). Importantly I have also shown the ability of 4-1BBL alone to allow long term 
expansion of NK cells, which has not been shown before, previous data used IL-2 and 
IL-15. Therefore these data show that in parallel with other reports of 4-1BBL driving 
long term T cell proliferation 4-1BBL alone is also sufficient to sustain long term NK 
cell responses. 
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The long term expansion of NK cells in this model system with 4-1BBL+IL-12 
stimulation resulted in approximately 1000 fold expansion of the starting NK 
population, on average, during a 21 day culture, which is again in keeping with 
reports by Imai et al. (2005). Given that it is likely only a portion of NK cells were 
responding actual expansion of responding cells could be considerably higher. The 
ability of NK cells to continue to expand further than this may be limited due to 
telomere degradation. The Campana group studied the loss of telomeres during long 
term culture with stimulation using the K562-IL-15-4-1BBL expansion system. 
Cultures expanded to a similar level to those reported here, but subsequently 
proliferation waned. The ectopic expression of telomerase however was found to 
restore proliferation indefinitely (Fujisaki et al., 2009a). This would suggest if 
telomerase is induced by 4-1BBL stimulation of NK cells, that expression is transient. 
This may also suggest the effects or responsiveness of NK cells to 4-1BBL vary in a 
temporal manner determined by prior activation as subsequent 4-1BB stimulation 
does not allow further expansion, as shown by Fujisaki et al. (2009a). There are 
therefore many questions remaining regarding the function of 4-1BBL in NK cell 
activation. 
 
NK cells derived from older individuals are likely to have a lower replicative potential 
as they are likely to posses shorter telomeres (Ouyang et al., 2007). This could 
contribute significantly to the reduced proliferation seen in RCC patients. However, 
as there is a difference in proliferation at the 7
th
 day of culture, the impact of shorter 
telomeres in the NK population would be unlikely to provide a comprehensive 
explanation for the reduced level of proliferation. It would be informative to directly 
compare the proliferation of RCC patient NK cells and healthy age matched controls. 
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However due to the incidence of RCC being most prevalent between 60-70 years of 
age this was not done during this project. Likewise the attenuated response to single 
costimulation and long term response to 4-1BBL alone would suggest further 
deficiencies in RCC patient derived NK cells. Differences in the response of other 
‘helper’ cells in culture maybe responsible, however as NK cells induce similar levels 
of 4-1BB this is unlikely to be the sole cause. There is reported to be an increased 
level of Treg in RCC patient PBMC (Cesana et al., 2004; Griffiths et al., 2007), 
however as the NK cell population tends to dominate cultures in later stages this is 
again unlikely to be a sole cause. NK cells from cancer patients are know to show 
reduced responsiveness ex vivo, therefore the NK cells may not be able to or may 
show differing requirements for full activation. Further analysis of the signalling 
events following 4-1BB ligation may be warranted. While there are many potential 
contributing factor to the reduced response of RCC patient NK cells it is encouraging 
that 4-1BBL+IL-12 can continue to induce expansion and function of this cell 
population. 
4.3.8.4 Effector functions and homing potential 
I have also shown the cells expanded within this model system to be functional, (and 
retain function during culture), in terms of cytolytic activity towards K562 targets, 
and IFNγ and GM-CSF production. I have also shown differences in the expression of 
homing markers which may be important in the homing of NK cells to tumours.  
 
IL-12 has previously been shown to reduce the expression of CXCR3 (Hodge et al., 
2002), however I show 4-1BBL partially retained its ability to promote the expression 
of CXCR3 in the presence of IL-12. CXCR3 is also predominantly expressed by the 
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CD56
bright
 subset, which is consistent with my observation that the NK cells produced 
in response to 4-1BBL+IL-12 are predominantly of the CD56
bright
 subset. 
 
While levels of IFNγ production show little difference between cultures stimulated 
with IL-12 alone or in combination with 4-1BBL, cytolytic function against K562 
targets show some difference between IL-12 or 4-1BBL alone with the combination 
being superior. The fact that the combination of 4-1BBL+IL-12 also enhances the 
proliferation of NK cells should result in a qualitatively and quantitatively superior 
response in vivo. 
 
Recently Baessler et al. (2010) have reported a negative effect of stimulating NK cells 
derived from AML patients or healthy donors with 4-1BBL; in these experiments 4-
1BB stimulation was shown to reduce IFNγ production and cytotoxicity. Interestingly 
the NK cells used by Baessler et al. (2010) were polyclonaly activated with IL-2 for 
10 days prior to stimulation with 4-1BBL, therefore these cells were effectively 
experiencing 4-1BBL stimulation following initial culture. My data from long term 
cultures of NK cells from RCC patients and healthy lab donors showed significant 
cytotoxicity following long term culture with stimulation either alone or in 
combination in contrast to the results reported by Baessler et al.. These data therefore 
highlight the need for a full understanding of the effects of costimulation for cancer 
immunotherapy and the potential requirement for a combination of costimulation for 
efficacy. 
 
The results of adoptive transfer of NK cells (as discussed in section 1.2.6.3 and 
1.2.6.4) and the lysis of freshly isolated autologous tumour by NK cells (Alici et al., 
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2008) have been encouraging. These data firstly show the ability of NK cells to 
recognise and kill autologous tumour cells and secondly maintain tolerance to self, or 
tolerance for healthy tissue in the case of adoptive transfer of KIR mismatched NK 
cells. The ability of cultured NK cells in my experiments to retain self tolerance 
against ‘freshly’ isolated normal tissue is encouraging (Figure 4-30), it is unfortunate 
that for technical reasons the ability of these cells to recognise ‘freshly’ isolated 
autologous tumour could not be reliably tested. No real conclusions can be drawn 
from these data. It would be important and very interesting to study the killing of 
normal and tumour tissue further, including the direct isolation and potential culture 
of tumour cell lines, as at this point we cannot be certain the cells isolated or cultured 
as tumour are actually tumour cells. Unfortunately further investigation was not 
possible due to the time constraints of this project. 
4.3.8.5 NKT-like cells 
Alongside the short term expansion of NK cells I have also demonstrated the 
expansion of NKT-like cells (Figure 4-3). Further investigation of the expansion of 
NKT cells in response to 4-1BBL and IL-12 may be warranted. The activation of 
NKT cells by 4-1BBL has been previously shown in a murine model of airway hyper-
responsiveness (Kim et al., 2008), while 4-1BB deficient mice have been shown to 
have a reduced number of NKT cells (Vinay et al., 2004), however to my knowledge 
these are the first data showing the expansion and activation of human NKT cells in 
response to 4-1BBL. As discussed however some questions remain at this stage 
whether these represent true NKT cells.  Previously Loza et al. (2002) have shown the 
acquisition of CD56 is associated with maturation of NKT and T cells in response to 
IL-12, becoming polarised towards Th1 cytokine secretion. Interestingly the 
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expression of CD56 by NKT cells has also been shown to be a marker for the subset 
of NKT cells with variant TCR usage (Giroux and Denis, 2005). Whether these NKT-
like cells are true NKT cells is an interesting question to explore further. If these cells 
are true NKT cells, i.e. invariant NKT (1.1.3), these cells could be easily defined by 
assessing invariant TCR usage.  
4.3.8.6 Conclusion 
I have therefore shown that a combination of 4-1BBL+IL-12 is superior to individual 
ligands for the expansion of NK cells in short and long term culture, and NKT-like 
cells in short term culture. Furthermore I have shown that the combination of 4-
1BBL+IL-12 provides a beneficial effect in terms of effector functions and potential 
homing ability. I have also produced novel data showing the ability of CD56
dim
 NK 
cells to differentiate to CD56
bright
 phenotype. 
 
These data show that a combination of ‘costimulatory’ molecules is required to 
support optimal proliferation of NK cells, in particular from RCC patients, and 
therefore also highlight the importance, and add to the understanding of the effects of 
combinations of costimulation for optimal activation of an immune response for 
immunotherapy. These data also therefore provide evidence to suggest the 
combination of 4-1BBL+IL-12 warrants further study as a novel immunotherapy 
strategy. 
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5 General Discussion 
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The stimulation of T cells through costimulatory receptors has aimed to overcome the 
ineffective presentation of TAA, inducing an effective T cell response. The tumour 
specific T cells generated however may not overcome the immunosuppressive 
environment present within the tumour. Therefore strategies which overcome the 
immunosuppressive environment of the tumour may provide significant benefits 
(Choi et al., 2004; Kilinc et al., 2006; King and Seagal, 2005; Valzasina et al., 2005). 
As the non-specific activation of the immune system (such as Coleys toxin, BCG or 
IL-2) has provided significant efficacy, comprehensive activation of the immune 
system may be required to enable an effective anti-tumour response. While the use of 
costimulation as an immunotherapy is still in its infancy, as the understanding of the 
immune system increases and optimal combination of costimulation for the activation 
of not only T cell based immune response, but the immune system as a whole are 
elucidated the potential for significant benefit is increased. Here I have shown 4-
1BBL with the addition of IL-12 activates not only the adaptive T cell immune 
response but also the NK and NKT innate response possibly facilitating a 
comprehensive anti-tumour immune response. 
 
The serendipitous discovery of the stimulatory effect of the combination of 4-1BBL 
and IL-12 on the proliferation of NK cells in healthy donors during the investigation 
of T cell responses is novel and has highlighted an important and potentially 
beneficial effect for this combination if used as an immunotherapy. These data have 
highlighted the potential of 4-1BBL to induce the proliferation and sustained 
expansion of NK cells, although 4-1BBL was shown not to increase survival of NK 
cells compared to IL-12 stimulation. Further study of the mechanisms responsible for 
these effects of 4-1BBL on NK cells is required. It would also be interesting to further 
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examine the differentiation of CD56
dim
 NK cells to a CD56
bright
 state; it would be 
particularly prudent to determine whether this phenotype was maintained in extended 
culture or whether these cells revert to a CD56
dim
 state. Initial extended culture 
experiments suggested there may be a population of CD56
dim
 cell appearing after long 
term culture, unfortunately these are only preliminary data and therefore further work 
is needed to characterise and validate these observations. If this were the case it could 
be suggested that a population of CD56
dim
 cells cycle through a CD56
bright
 state then 
return to a CD56
dim
 phenotype, rather than being terminally differentiated.  
 
It would also be of great interest to further examine the responses of NK cells 
following culture, given the suggested role of 4-1BBL in the generation of memory T 
cells and the recent studies showing the generation of a ‘memory-like’ NK cell 
population following initial stimulation by cytokines ex vivo or interactions with DC 
in vivo (Cooper et al., 2009; Shimizu and Fujii, 2009; Sun et al., 2009). However a 
consensus of whether the NK cells characterised as memory cells represent a true 
memory population, as defined in T cell biology, has yet to be reached. Additionally 
these studies were performed in murine models rather than human systems; the ability 
of human NK cells to form a memory-like cell has not yet been reported. As the size 
of the initial immune response dictates the development of T cell memory (Prlic et al., 
2007; Seder and Ahmed, 2003) the ability of 4-1BBL to stimulate significant 
expansion of NK cells may facilitate the production of memory NK cell properties by 
expanding specific NK cell populations. It would be interesting to determine if the 
response of NK cells which received 4-1BBL costimulation during initial interaction 
with a target was either enhanced or skewed in any way following reencounter with a 
target cell.  
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In concert with the study of ‘memory’ responses it would also be interesting to study 
firstly the diversity of inhibitory and activating receptor repertoires which are 
expressed following expansion using this system and secondly test whether 4-
1BBL+IL-12 stimulation with the use of recombinant agonist antibodies to provide 
specific activating or inhibitory signals could be used to expand NK cells with 
specific inhibitory and activating receptor repertoires; if this were possible this could 
provide a novel technique for the ex vivo generation of NK cells with defined 
repertoires for adoptive transfer. 
 
Importantly I have also shown the adenoviral vector directed expression of 4-
1BBL+IL-12 is capable and sufficient to induce the short and long term expansion of 
functional NK cells derived from RCC patients. Significantly these data also highlight 
the benefit of a combination of costimulatory molecules for optimal efficacy. 
Interestingly as mentioned previously the synergy of 4-1BBL+IL-12 was shown by 
Xu et al. (2004) to promote the rejection in mice of poorly immunogenic melanoma 
tumours, which was not rejected by stimulation with 4-1BBL or IL-12 alone. These 
data encouragingly correspond to data from the in vitro RCC patient results. The 
validity and insight of further in vivo studies in mouse however may be of limited use 
given that mice do not possess CD56 bright and dim NK subsets and the combination 
of 4-1BB stimulation and IL-12 has been shown to be superior or required in tumour 
models and to be dependent on NK cells (Chen et al., 2000; Martinet et al., 2000; Xu 
et al., 2004). Therefore work moving towards clinical trial of adenoviral vector 
delivery of 4-1BBL+IL-12 maybe warranted. 
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As discussed the Campana group has developed a similar model system utilising IL-
15+4-1BBL expressed by K562 cells, allowing the ex vivo expansion of NK cells; the 
large scale expansion of clinical grade NK cells has been reported, as have in vivo 
mouse data (Fujisaki et al., 2009b). From these data I believe that a clinical trial 
utilising adoptive transfer of ex vivo expanded NK cells for the treatment of 
ALL/AML may soon be undertaken. Given the success of adoptive transfers of KIR 
mismatched NK cells for the treatment of AML the results of this trial will be of great 
interest. Further work to study the effects of 4-1BBL+IL-12 stimulation of NK cells 
for ex vivo expansion are therefore also warranted. Given the success of NK cell 
therapy for AML but relatively poor outcomes in ALL, it would also be of interest to 
examine the development of 4-1BBL+IL-12 stably transfected ‘off the shelf’ cell 
reagents or modified autologous tumour cells as a vaccine for lymphocytic 
leukaemia’s. Whereby following chemotherapy/conditioning 4-1BBL+IL-12 could be 
used to stimulate NK cell expansion and function in vivo, either of autologous NK 
cells or KIR mis-matched donor NK cells.  
 
It may also be warranted to explore methods to enhance the effect of 4-1BBL 
stimulation. 4-1BBL like other TNF superfamily ligands such as CD40L and FasL is 
subject to cleavage by metalloprotease (Elmetwali et al., 2009). Cleavage of 4-1BBL 
is believed to occur following interaction with 4-1BB (Salih et al., 2001). It is 
possible that soluble 4-1BBL is able to antagonise the function of 4-1BBL as cross-
linking of 4-1BB by 4-1BBL is required to stimulate T cell responses (Rabu et al., 
2005). The creation of a non-cleavable form of CD40L has increased its effect by 
retaining CD40L on the cell surface (Palmer et al., 2007). Therefore it maybe of 
interest to examine the effects of cleavage of 4-1BBL in this model system; the 
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production of a non-cleavable 4-1BBL may allow enhanced costimulation by 
prolonging the time 4-1BBL is available on the cell surface. However the cleavage of 
4-1BBL may be a mechanism by which the levels of stimulation can be controlled 
during activation; it may be that some of the deleterious effects attributed to anti-4-
1BB agonist antibodies are due to the quantitative and qualitatively differences in 
signals delivered by prolonged stimulation of 4-1BB by agonistic antibodies 
(Schabowsky et al., 2009). Initial studies I have performed did not show a significant 
difference in the levels of 4-1BBL expressed by adenoviral vector on OVCAR-3 and 
A549 with the addition of metalloprotease inhibitors; however this was done in 
isolation without the addition of PBMC (data not shown).  
 
Likewise it may also be interesting to examine the use of other cytokines alone or in 
combination with IL-12, in order to determine if alternative cytokines alter the 
outcome of stimulation, and the cytokine requirements for 4-1BBL responsiveness. 
This is especially pertinent given the differences in subset proliferation in this system 
and the K562-4-1BBL-IL-15 system utilised by Imai et al. (2005). Therefore there is 
further scope to enhance this system, and the understanding of NK cell biology. 
 
In conclusion I have developed a novel system for the activation and expansion of NK 
cells, with a preference for the expansion of the CD56
bright
 subset, these cells have 
been shown to be functional. Notably I have shown that a combination of 4-
1BBL+IL-12 is required to expand NK cells from RCC patients. Given the 
progression of 4-1BB stimulation into the clinic these data are of particular 
importance. The literature suggests there is a significant potential for the use of NK 
cells for the immunotherapy of cancer. Therefore these data are of value. 
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Consequently further study of the stimulation of NK cell responses and the ability to 
simultaneously enhance the innate and adaptive immune responses requires and 
warrants further investigation. 
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